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Introduction
Worldwide, breast cancer is diagnosed in approximately 1.15 million cases per 
year, resulting in an estimated 410,000 deaths annually.1 With the vast majority 
(99%) of patients being female, it is the most common cancer and the second 
most common cause of cancer-related death among women.2 As such, patients 
with a breast lesion experience high levels of anxiety when waiting for a 
diagnosis.3,4
Patients with breast lesions present to surgeons either with signs 
and/or symptoms (a palpable lump, pain, unilateral nipple discharge, skin 
dimpling, nipple retraction, or a combination) or following detection of a 
suspicious lesion on screening mammography (mass, microcalcifications, 
architectural distortion, or a combination). The general diagnostic work-up of 
patients presenting with a breast lesion (either symptomatic or detected during 
mammographic screening) is depicted in Figure 1. Of all solid breast lesions 
presenting to surgeons, grossly 20% will be malignant. The main aims of the 
non-operative assessment of breast lesions are to accurately prepare both the 
patient and the surgeon for definitive surgery in case of operable malignancy 
and to quickly reassure the patients and preclude an operation for patients 
with benign disease.5 Additionally, patients with lesions that convey an 
increased risk of associated or future breast cancer can be identified and 
patients with non-resectable carcinomas can be selected as candidates for 
primary systemic therapy.
Histologically, breast cancers can be divided grossly into invasive and 
non-invasive carcinoma. Invasive carcinomas largely comprise invasive ductal 
carcinoma, invasive lobular carcinoma, and tubular carcinoma. In contrast to 
invasive carcinomas, ductal carcinoma in situ (DCIS) is confined to the 
lactiferous duct as it does not invade its basal membrane. Yet, surgical 
treatment is indicated for DCIS as well since it carries a high risk of 
transformation to invasive carcinoma and since it may exhibit occult invasion.6
Present-day non-operative diagnosis of solid breast lesions comprises 
'triple assessment' by physical examination, imaging (mammography and/or 
ultrasound (US)), and pathology (fine needle aspiration (FNA) or core needle 
biopsy (CNB)).7, 8 This diagnostic work-up precludes diagnostic excisional biopsy 
when all three components of the triple assessment are conclusively positive 
(~100% probability of malignancy) or conclusively negative (~100% probability 
of a benign lesion).9-11 Additionally, patients presenting with nipple discharge
10
(ND), constituting the presenting symptom in 4-7% of cases,12-14 may have the 
discharge smeared for cytological examination.
F ig u r e  1 . D ia g n o s t ic  w o r k -u p  o f  p a t ie n t s  a t  a  b r e a s t  c l in ic
Concordantly conclusive physical examination, imaging and cytology (fine needle 
aspiration, core wash or touch imprint cytology) allow for a same-day diagnosis. A 
conclusive cytological diagnosis is defined as "benign" in truly benign lesions and 
"malignant" (C5) in truly malignant lesions.
US indicates ultrasound; FNA: fine needle aspiration; CNB: core needle biopsy; TI: 
touch imprint; CW: core wash.
Due to the introduction of biannual mammographic screening of 
women aged 50-75 years, however, the proportion of small, nonpalpable 
breast lesions presenting as microcalcifications on mammography has risen.15,16 
Additionally, the increasing use of magnetic resonance imaging (MRI) screening 
in high-risk women has further increased the number of small tumours in which 
malignancy can only be excluded or confirmed conclusively by image-guided-
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percutaneous needle biopsy.17 As such, the role of a cyto- or histopathological 
diagnosis in stratifying patients to surgery or clinical follow-up has increased 
and surgeons' confidence in such decisions depends upon the conclusiveness of 
non-operative pathological diagnoses.18
FNA involves aspiration of cells of the target lesion with a thin (20-25 
Gauge) needle connected to a syringe (Figure 2), making multiple passes 
through the lesion to ensure adequate sampling. Consequently, the aspirated 
fluid is either directly smeared onto a slide and air-dried, or it is added to a cell- 
preserving solution until final preparation takes place in the laboratory. 
Following simple Papanicolou or Giemsa staining, fine needle aspirates yield 
cytological specimens which can be examined by a pathologist within 30 
minutes after aspiration (Figure 3).
In contrast, CNB harvests larger tissue samples by using 7-18 Gauge 
needles (Figure 4). Vacuum-assisted biopsy (VAB) systems represent recent 
large-core CNB variants (7-14 Gauge as opposed to 14-18 Gauge for 
conventional CNB) and use a vacuum to the biopsy needle, allowing more 
tissue to be included in the biopsy. As for FNA, multiple biopsies are taken per 
lesion to yield optimally representative material. Initially fixated in formalin, 
CNB samples undergo microsection and hematoxylin-eosin staining in the 
laboratory which usually takes more than one day to complete. This process 
yields a histological image allowing for interpretation of the arrangement of 
cells in relation to the surrounding tissue (Figure 5).
12
F ig u r e  2. FN A  e q u ip m e n t
A: 21-Gauge needle remotely connected to a 10-mL syringe, allowing for easy 
multidirectional biopsying (needle inner diameter: 0.5 mm);
B: 21-Gauge needle and 10-mL syringe mounted on a manual biopsy gun (needle 
inner diameter: 0.5 mm).
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F ig u r e  3 . M ic r o s c o p ic  im a g e  o f  a  c y t o l o g ic a l  s p e c im e n  d e r iv e d  f r o m  a n
INVASIVE DUCTAL CARCINOMA THROUGH F N A
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Papanicolaou-stained, magnification x200
F ig u r e  4 . CN B  e q u ip m e n t
A: 9-Gauge vacuum-assisted biopsy instrumentation 
(needle inner diameter: 2.8 mm);
B: 18-Gauge conventional core needle biopsy device 
(needle inner diameter: 0.8 mm).
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F ig u r e  5. M ic r o s c o p ic  im a g e  o f  a  h is t o l o g ic a l  s p e c im e n  d e r iv e d  f r o m  a n
INVASIVE DUCTAL CARCINOMA THROUGH C N B
Haematoxylin-eosin-stained, magnification x200
Cytological specimens are conventionally diagnosed as C ('cytology') 1­
5, whereas CNB specimens are categorised into B ('biopsy') 1-5 (Table 1). 
Cytological or histological diagnoses are useful when conclusive, as the surgeon 
will be more confident in denying operative procedures to patients with a 
benign diagnosis and in operating on patients with a malignant diagnosis. As an 
inconclusive diagnosis neither confirms nor excludes malignancy, repeated 
biopsies should be taken to allow for a conclusive diagnosis.19,20 Eventually, in 
case repeated attempts are unsuccessful, diagnostic excisions are necessary to 
obtain a clear diagnosis.
A conclusive diagnosis by cytology or CNB is defined as a 'benign' 
diagnosis (C2/B2) in a truly benign lesion and a 'malignant' diagnosis (C5/B5) in 
truly malignant lesions. Consequently, we will refer to diagnostic 
'conclusiveness' as the proportion of C2/B2 diagnoses in benign lesions 
(specificity) and as the proportion of C5/B5 diagnoses in malignant lesions 
(absolute sensitivity). This includes inadequate specimens (C1/B1) as this 
reflects daily practice most.21
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Ta b l e  1 . D e f in it io n  o f  c o n c lu s iv e  a n d  in c o n c lu s iv e  d ia g n o s e s  
B Y FN A  AND CNB
Modality Conclusive?
Preoperative
diagnosis
FNA CNB Benign follow-
upa
Malignant
follow-upa
Inadequate C1 B1 No No
Benign C2 B2 Yes No
Atypical C3 B3 No No
Suspicious C4 B4 No No
Malignant C5 B5 No Yes
a Either surgical of clinical/radiographic
First described in 1930,22 FNA has been used for several decades as a 
rapid and safe tool for distinguishing benign from malignant breast lesions. Yet, 
the increasing need for preoperative knowledge of a histological diagnosis and 
prognostic factors has prompted the introduction of CNB in the 1980's,23 with 
VAB systems representing a recent large-core variant.
With cytology and CNB both having unique advantages, there is an 
increasing acceptance of CNB for evaluating breast lesions.18,24 This chapter 
aims to outline the scientific basis of this trend, focussing on diagnostic 
accuracy, impact on surgical management, assessment of prognosis and 
complications of these modalities. Finally, we will discuss novel needle biopsy 
techniques that combine cytology and histology.
Diagnostic accuracy
Com parative accuracies
The histological sample collected by the large-calibre needles used for CNB 
allow for a tissue diagnosis and could rationally be expected to yield more 
representative and more readily interpretable material than the smaller FNA 
needles that only allow for cytological examination. Many authors have claimed 
CNB to have superior diagnostic accuracy based on solely historical 
comparisons of CNB and FNA series.25-27
16
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F ig u re  6. C o n c lu s iv e n e ss  r a te s  o f  FNA a n d  CNB in  p ro sp ective , d ir e c t ly  co m p a ra tiv e  stu d ie s
Study N Modality Benign lesions Malignant lesions
* P<.05; 7 P<.005; * P<.001
Conclusiveness is defined as the proportion o fC 2/B 2 ("benign") diagnoses in benign lesions and as the propotion of  
C5/B 5 ("m alignant") diagnoses in malignant lesions.
Light dots delineate estimates o f  FNA conclusiveness, whereas dark dots delineate estimates o f  CNB conclusiveness. 
Horizontal lines correspond to 95% confidence intervals.
FNA indicates fin e  needle aspiration; CNB, core needle biopsy; 95% Cl, 95% confidence interval.
Ch
ap
te
r 
1
In fact, few studies have directly compared FNA and CNB regarding 
their diagnostic accuracies that is, they prospectively investigated the same 
patients with both modalities (Figure 6).28-34 In these studies CNB has 
repeatedly, but not invariably, been shown to yield more conclusive diagnoses 
than FNA in both malignant and benign lesions. This implies that CNB is 
imperative to the treatment planning of all breast lesions.
However, this does not exclude FNA from the preoperative pathology 
work-up. In fact, combining both modalities may result in an even higher 
conclusiveness. Specifically, using FNA in conjunction with CNB may increase 
conclusiveness rates with 5%-16% in malignant lesions and with 0%-2% in 
benign lesions.30,32,34 As such, it has been suggested that the role of FNA is 
complementary to CNB, facilitating definitive exclusion or confirmation of 
malignancy in case of an indeterminate CNB.28 Yet, indeterminate primary FNA 
invariably mandate a CNB.20
Nipple discharge (ND) cytology has not been compared to 
percutaneous needle biopsy since patients presenting with ND often do not 
have an identifiable breast lesion.35 Reported overall conclusiveness rates range 
from 51-85%.35-39 While some centres still perform ND smears because they 
may incidentally reveal a carcinoma,40-42 a recent report on 163 histologically 
confirmed ND patients found that only 1 breast cancer and 2 benign lesions 
were diagnosed conclusively by ND cytology alone.38 This implies that, on 
average, it may confuse diagnostic work-up, as supported by a study 
demonstrating only mammography and US findings to be independently 
predictive of malignancy.36 In another comparative study, ND cytology had the 
lowest overall accuracy among palpation, mammography, US and 
galactography.43
Factors affecting conclusiveness
Generally, diagnostic modalities that yield consistently conclusive results 
irrespective of the operator and interpreter involved are most useful to breast 
pathology patients. Specimen adequacy is considered to be less operator- 
dependent for CNB than for FNA.44 Operator experience, however, has been 
identified to impact on CNB success. This factor has never been studied for 
FNA.45,46 As for microscopic assessment, CNB has been shown to produce highly 
reliable and reproducible results in a study of more than 2400 biopsies, with a 
chance-corrected interobserver agreement (k ) of 0.90.47 In contrast, FNA
18
conclusiveness varies significantly among pathologists, but seems to be 
independent of the experience in cytopathology.48 Currently however, it cannot 
be estimated which modality yields the most consistent results as no directly 
comparative studies exist.
Irrespective of these parameters, relatively simple clinical and 
radiologic lesion characteristics can predict whether an FNA or CNB will be 
informative. For FNA, small (<1 cm) and large (>4 cm) tumours, freehand 
aspiration (i.e., without ultrasound guidance) and lesions appearing as 
microcalcifications on mammogram have been associated with inconclusive 
diagnoses.49-52 In contrast, for CNB, especially VAB which samples a greater 
tissue volume, conclusiveness rates are similar between microcalcifications and 
masses.46,53
Even after aspiration, FNA conclusiveness can be increased by having 
an on-site cytopathologist assessing specimen adequacy54 and by processing 
the aspirate to create a monolayer preparation (versus directly smearing it) in 
the laboratory.55
IMPACT ON SURGICAL MANAGEMENT
Obviously, conclusively benign FNA or CNB diagnoses obviate the need for a 
diagnostic excisional biopsy, provided that imaging and clinical examination are 
concordantly benign.10,56,57 Avoiding redundant surgeries is one of the major 
goals in breast care.5 Similarly, a conclusive FNA or CNB decrease the number of 
surgical procedures in malignant lesions.56,58 Accordingly, both FNA and CNB 
are cost-effective modalities.59,60
Yet, important differences between FNA and CNB exist (Table 2). FNA 
allows for a rapid diagnosis within 30 minutes, providing immediate 
reassurance to the majority of patients with benign disease and minimizing the 
psychologically stressful period of waiting for a malignant diagnosis.3,4 A recent 
prospective cohort study of 528 patients found that patients with a benign 
diagnosis reported substantially less psychological symptoms directly following 
the diagnosis when the diagnosis was achieved within 1 day.4
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Ta b l e  2. D if f e r e n c e s  b e t w e e n  FN A  a n d  C N B  r e g a r d in g  t h e ir  im p a c t
ON THE SURGICAL MANAGEMENT OF BREAST LESIONS
Influence FNA CNB
Same-day decision making and patient counselling + +/-
Preclude excision of benign lesions + +
Preclude excisional biopsy of malignant lesions + +
Differentiation of in situ vs. invasive carcinoma - +
Differentiation of lobular vs. ductal carcinoma +/- +
Accurate identification of high-risk lesions3 - +
Complete lesion removal - +/-
a Such as atypical ductal hyperplasia, atypical papillomatosis, atypical 
lobular hyperplasia, lobular carcinoma in situ and flat epithelial atypia 
FNA indicates fine needle aspiration; CNB, core needle biopsy
Although patients with a malignant diagnosis exhibited similar 
psychological distress regardless of timing of diagnosis, they in retrospect 
regarded the period directly before the diagnosis as more stressful than the 
period following the diagnosis. Moreover, emotional complaints decreased 
following surgery, indicating that efficient preoperative work-up reduces the 
total psychological burden of breast cancer patients. The authors concluded 
that a rapid diagnosis programme is useful for routinely diagnosing patients 
with breast lesions.4
In addition, in a 670-patient randomized controlled trial, patients 
attending a one-stop breast clinic were less anxious on the short term than 
those randomized to delayed discussion of diagnostic results.61 Additionally, 
direct conclusive diagnoses obviate further review appointments in patients 
with benign lesions and facilitate the surgical scheduling in breast cancer
patients.61
However, FNA cannot accurately assess histological information 
necessary for adequate surgical treatment planning for malignancies. Here lies 
the main advantage of CNB.
First, CNB can differentiate between DCIS and invasive ductal 
carcinoma. This conveys important information since pure DCIS lesions often 
require larger tissue removal and only necessitate sentinel node biopsy in 
selected cases.62-64 However, due to selective sampling, invasion is 
underestimated in 9%-38% of cases showing DCIS on CNB.46,58,64-66
20
Consequently, these patients will require a second operative procedure for 
axillary staging. As for FNA, having similar sampling problems for DCIS, 
specimens lack sufficiently specific cytomorphological aspects to predict 
invasion or absence thereof.67,68
Patients with only DCIS on CNB and a high risk of missed invasion (e.g. 
lesions >5cm) should receive standard sentinel node biopsy. However, the 
predictive values of preoperative criteria, such as young age, a palpable 
tumour, high-grade DCIS, greater extent of mammographic disease and 
mammographic mass are inconsistent across different validation studies.64,66
Second, CNB can better distinguish invasive lobular from invasive ductal 
carcinoma than FNA as the infiltrating pattern is characteristic on histology and 
epithelial markers can confirm the diagnosis.69,70 Preoperative knowledge of 
specific tumour histology is fundamental to planning the extent of surgery since 
lobular carcinoma carries an increased risk of positive lumpectomy margins and 
synchronous contralateral disease.71,72
Nevertheless, the more specific nature of histological diagnoses 
provided by CNB also poses therapeutic dilemmas when B3, 'high-risk' lesions 
are found on CNB. These include atypical ductal hyperplasia (ADH), lobular 
carcinoma in situ (LCIS), atypical papillomatosis, flat epithelial atypia and radial 
scars/complex sclerosing lesions. As these lesions can both mimic and, if 
diagnosed correctly, are associated with malignancy,73,74 possible 
underestimations of surrounding DCIS and invasive cancer should be kept in 
mind. As such, surgical excision is warranted in lesions with high 
underestimation risks, such as ADH.74 Although the increasing use of large-bore 
VAB reduced the risk of missing adjacent cancer by sampling more breast 
tissue, more patients with benign disease will accidentally be found to have 
precursor lesions and may have redundant excisions or follow-up.
Assessment of prognostic and predictive factors by percutaneous needle biopsy
The increasing use of neoadjuvant chemotherapy has resulted in a more 
frequent need for knowledge of prognostic and predictive tumour 
characteristics. These include histological grade and subtype, estrogen receptor 
(ER), progesterone receptor (PR) and HER2-neu status, and are key to planning 
both neoadjuvant and adjuvant treatment. Additionally, the type of systemic 
therapy is partly determined by receptor expressions in patients unfit for 
excision or in patients who present with metastatic disease. CNB is considered
21
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to provide reliable assessments of prognostic and predictive factors, exhibiting 
high concordance rates with surgical specimens for tumour grade (59%-91%), 
ER status (78%-100%), PR status (71%-91%) and HER2-neu status (60%- 
100%).(reviewed in75)
There have been successful attempts to assess receptor expression on 
FNA specimens,76,77 however, accurate assessment of histological grade is only 
possible on CNB. Yet, grade may still be underestimated by CNB due to regional 
differences in primary tumour differentiation.78 Although cytological grading on 
FNA specimens has been shown to correlate with histological grade,79 its 
relation with histological grade on the surgical specimen, response to 
chemotherapy and prognosis is unknown. Also, as FNA cannot discriminate 
between DCIS and invasive carcinoma, the meaning of a given cytological grade 
for malignant FNA remains unknown.
Complications
The main complication of both FNA and CNB is pain during the biopsy 
procedure. It seems obvious that larger needles would cause more biopsy- 
related pain, as measured by a validated visual analogue scale.80 This has 
indeed been demonstrated in a randomized controlled trial on 104 patients 
comparing 23-gauge and 21-gauge FNA and in a prospective cohort study 
comparing 21-gauge FNA and 14-gauge CNB.81,82 Contrarily, in a recent 
prospective cohort study of 220 biopsies, patients undergoing 21-gauge FNA 
had significantly more pain than those having 14-gauge CNB or 11-gauge VAB.83 
However, this study did not adjust for patient-related factors that may 
influence pain perception, such as psychological distress.
By directing FNA and CNB needles towards the chest wall, 
pneumothorax may occasionally result, especially in the tail of the breast. 
However, larger series have reported pneumothorax rates of only 1 and 5 in 10 
000 cases for FNA and CNB, respectively.84,85
Additionally, malignant cells may be displaced along the needle tract in 
up to 50% of breast cancers sampled by CNB,86-88 while for FNA no recent data 
are available. However, it is unlikely that malignant cell seeding impacts 
recurrence and survival.89,90
22
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Table 3. Overview of conclusiveness rates of preliminary diagnoses
by touch imprint and core wash cytology
Author [reference] Modality Design N Conclusiveness (%) 
Benign Malignant
Concordance 
with CNB (%)
W auters 200991 Tl Prospective 30 67 75 70
Kulkarni 200992 Tl Retrospective 813 84 87 96
Oikonomou 200893 Tl Retrospective 72 93 90 90
Foutou 200794 Tl Retrospective 93 85 100 -
Farshid 200695 Tl Retrospective 567 56 42 47
Klevesath 200596 Tl Retrospective 128 63 85 91
Jones 200497 Tl Prospective 111 76 81 80
Kass 200398 Tl Retrospective 199 62 58 62
Green 200199 Tl Retrospective 100 - - 84
Sneige 2000100 Tl Retrospective 172 44 62 58
W auters 200991 CW Prospective 30 89 75 73
Uematsu 2008101 CW Prospective 458 32 38 33
Lankford 1998102 CW Retrospective 211 85 39 83
CNB indicates core needle biopsy; Tl, touch imprint cytology; CW, core wash cytology
Empty cells indicate that calculation of the respective parameter was impossible because of insufficient data presentation 
in the published paper
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Combining cytology and histology in preoperative work-up
In an attempt to combine the unique benefits of a same-day diagnosis, 
enhanced diagnostic accuracy and histological information in a single 
percutaneous needle biopsy, laboratory techniques that derive cytological 
specimens from CNBs have been investigated recently. Touch imprint (TI) 
cytology involves smearing the CNB specimen onto a microscopic slide prior to 
final formalin fixation. Alternatively, core wash (CW) cytology specimens are 
prepared by washing the tissue contained in the needle notch in a saline or cell- 
preserving solution. For CW, either a smear, involving air drying of the cell- 
containing solution, or a liquid-based preparation, using a cytocentrifuge, is 
then created.
Similar to FNA, the success of TI and CW cytology depends on the 
conclusiveness with which a preliminary diagnosis can be given to the patient. 
The results of studies focussing on the conclusiveness of these modalities are 
summarized in Table 3.
Studies on TI cytology have found conclusiveness rates ranging from 44­
93% in benign lesions and from 42%-100% in malignant lesions.91-100 
Unfortunately, only 2 studies used the final diagnosis by surgical or clinical 
follow-up as the gold standard.91,97 Conversely, the other studies only 
correlated TI cytology diagnoses to the later CNB diagnoses (a surrogate gold 
standard assessment). As CNB can miss cancers and falsely diagnose non- 
malignant lesions as malignant (Figure 6), the true conclusiveness of TI cytology 
may have been under- or overestimated in these studies.
The use of CW cytology has been questioned due to conclusiveness
101 102rates in both benign and malignant lesions being lower than 40%. , In a 
prospective study of 236 benign and 210 malignant cases, Uematsu and Kasami 
found 42% of CW samples to be inadequate (C1). Therefore, they concluded 
that CW is not useful for same-day diagnosis of breast lesions.101 Contrarily, in a 
small prospective laboratory study using a modified CW procedure on 30 breast 
lesions only 1 specimen was found to be inadequate.91 This resulted in higher 
conclusiveness rates than those previously found.
The same study explored whether CW and TI cytology had different 
conclusiveness rates in the same patient population. Conclusiveness was 
demonstrated to be identical in malignant lesions (both 75%), but slightly 
higher for CW cytology in benign lesions (89% vs. 67%, respectively, P=.26).91
24
Yet, the true comparative conclusiveness rates are currently unknown as larger 
studies are lacking.
From the results of the above studies, it is apparent that TI and CW 
cytology are promising new techniques that frequently enable a same-day 
diagnosis of benign or malignant breast lesions.
A ims of this thesis
The feasibility of a same-day diagnosis work-up for breast pathology 
patients by cytology (FNA, ND, TI, and CW cytology) is still subject to
18 91 101 103 104debate.18,91,101,103,104 This is mainly due to varying conclusiveness rates of these
modalities found in different series, an overview of which is given above. As the 
clinic of current research had overall good experiences with FNA for lesions 
visible on US, while more and more breast clinics are switching to CNB for 
primary assessment,7,18,24 the studies of the current thesis were primarily 
designed to learn from daily cytological practice. As such, the future use of 
cytological modalities in the study clinic and other breast clinics may be altered 
and refined to optimize the accuracy and efficiency and lower the psychological 
burden of breast pathology diagnosis.
Specifically, the studies undertaken for this thesis were designed to 
answer the following questions:
1. Does a conclusive preoperative diagnosis by FNA reduce the number of 
operative procedures needed for complete breast conserving therapy? How 
does this compare to a conclusive CNB diagnosis? (Chapter 2)
2. How often does FNA yield a conclusive diagnosis and can FNA conclusiveness 
be predicted from simple clinical and radiologic parameters? (Chapter 3)
3. Does laboratory preparation of a monolayer preparation result in more 
conclusive FNA diagnosis than conventionally smearing the aspirate?
(chapter 4)
4. Should an inconclusive FNA diagnosis be followed by a repeated FNA or by a 
CNB in order to obtain a conclusive non-operative diagnosis? (Chapter 5)
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5. How often is ND cytology helpful in diagnosing patients presenting with
unilateral ND? (Chapter 6)
6. What is the accuracy of FNA in male patients with breast pathology?
(Chapter 7)
7. Are CW and TI cytology of CNB specimens accurate means of providing a
preliminary, same-day diagnosis of breast pathology? (Chapter 8)
8. Lastly, this thesis aimed to critically consider the methodological strengths
and limitations of retrospective designs, as used in most studies of this thesis.
An overview on this matter is presented in Chapter 9.
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A bstract
A ims
Surgeons rely on preoperative diagnoses by fine needle aspiration (FNA) or core 
needle biopsy (CNB) for planning the extent of breast surgery. The present 
study aimed to estimate the impact of (1) the grade of suspicion (conclusively 
malignant vs. less severe) and (2) the type (FNA vs. CNB) of preoperative 
pathology diagnoses on margin involvement of the initial excision and re­
excision rates in breast cancer patients treated by lumpectomy.
METHODS
We identified all breast cancer patients with FNA and/or CNB treated by 
lumpectomy within 90 days presenting from 1999-2008. FNA and CNB were 
diagnosed as C1-5 and B1-5, respectively: C1/B1, inadequate; C2/B2, benign; 
C3/B3, atypical; C4/B4, suspicious; or C5/B5, malignant. We defined a 
conclusive diagnosis as C5/B5. The primary endpoint was a positive margin of 
the initial excision (defined as tumour cells transecting the inked margin), the 
secondary endpoint was re-excision.
Results
In 1066 eligible patients, conclusively malignant preoperative diagnoses were 
associated with lower rates of initial positive margins (20.9% vs. 45.9%, P<.001) 
and re-excisions (22.9% vs. 47.6%, P<.001). These effects remained significant 
on multivariate analysis (P=.004 and P=.001, respectively) adjusting for several 
clinicopathologic variables and were similar for the FNA and CNB groups. FNA 
(n=866) and CNB (n=200) had similar rates of positive margins (P=.816) and re­
excisions (P=.812).
CONCLUSION
Obtaining a conclusive diagnosis of malignancy by either FNA or CNB is key to 
effective and complete breast conservation therapy for breast cancer. Hence, 
breast centres may lower re-excision rates by optimizing preoperative 
pathology work-up.
34
Introduction
Percutaneous needle biopsy o f  breast lesions
There is general agreement on the necessity of a preoperative pathology 
diagnosis for planning surgical treatment of breast pathology.1,2 Apart from 
providing a relatively quick diagnosis, a main aim of a preoperative pathology 
diagnosis is to reduce the number of surgical interventions required for local 
control of early-stage breast cancer.1 Preoperative knowledge of 
clinicopathologic properties of the tumour assists the surgeon in completely 
excising breast malignancy.3
Excision margins
Percutaneous needle biopsy provides an important part of this information, as 
it predicts the histological nature of breast lesions more accurately and 
specifically than physical examination or imaging.4,5 Indeed, when compared to 
direct excisional biopsy, diagnoses obtained through both core needle biopsy 
(CNB) and fine needle aspiration (FNA) have impact on margin status of the 
initial excision and thereby on re-excision rates in breast cancer patients 
treated by lumpectomy.6-10
Surprisingly however, the importance of preoperatively obtaining an 
unequivocal diagnosis of malignancy in relation to the adequate local excision 
of breast cancer is unknown and remains to be quantified. False-negative or 
equivocal preoperative diagnoses may motivate surgeons to conservative initial 
excision, whereas conclusively malignant diagnoses (C5 or B5) may incite them 
to relatively wider excisions.
Additionally, little research has yet focussed on the comparative roles 
of these preoperative biopsy modalities in directing surgeons to complete 
excision. Univariate comparisons of FNA and CNB have yielded conflicting 
results regarding which yields lower positive margin rates.11,12
Study aim
The present study aimed to estimate the impact of (1) the grade of suspicion 
(conclusively malignant vs. less severe) and (2) the type (FNA vs. CNB) of 
preoperative pathology diagnoses on rates of margin involvement of the initial 
excision and re-excision rates in breast cancer patients treated by lumpectomy. 
We hypothesized that, independent of each other and of other clinical and 
histopathological variables, CNB and a definitive diagnosis (C5 or B5) would
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lower the chance of involved margins on initial excision and of a subsequent re­
excision.
METHODS
Study design and population
This was a retrospective cohort study. We identified all breast cancer patients 
treated by lumpectomy in our regional teaching hospital from 1999-2008. This 
hospital serves both symptomatic and screen-detected breast patients. We 
identified patients through the Dutch nationwide pathology database called 
PALGA. Eligible patients had a preoperative diagnosis established either (1) by 
FNA alone (the FNA group) or (2) by CNB with or without FNA (the CNB group), 
followed by lumpectomy within 90 days.
Preoperative data
For each patient we recorded age, tumour palpability, appearance on 
mammography, the type of needle percutaneous biopsy, the diagnosis 
obtained by needle biopsy, and the number of days between preoperative 
diagnosis and the first excision. We categorized the appearance on 
mammography as mass, microcalcifications, architectural distortion, or normal 
mammogram.13
FNA was performed using a 21- or 23-gauge needle. Aspirates were 
rinsed, fixed in an ethanol 50%, polyethylene glycol 2% solution and 
centrifuged, creating a monolayer preparation, and were Papanicolaou- 
stained.14 CNB was performed with an 18-gauge needle mounted on an 
automated device (Bard® MAGNUM®, C.R. Bard, Inc., Covington, GA) for lesions 
appearing as masses on ultrasound. For lesions invisible on ultrasound, 
stereotactic vacuum-assisted CNB (VACORA®, Bard Peripheral Vascular, Inc., 
Tempe, AZ) were performed using a 14-gauge needle. CNB specimens were 
fixed in formalin and haematoxylin- and eosin-stained.
Pathologists diagnosed both FNA and CNB as C1/B1, inadequate; C2/B2, 
benign; C3/B3, atypical; C4/B4, suspicious; or C5/B5, malignant.15,16 We defined 
a conclusive diagnosis as C5/B5 and an inconclusive diagnosis as C1-4/B1-4. All 
cytological and histological specimens were examined by eight pathologists 
with 6-20 years of experience.
We handled patients diagnosed by both FNA and CNB as follows. If FNA 
had yielded a greater degree of suspicion, we classified the patient to the FNA
36
group. Alternatively, if CNB had yielded a greater degree of suspicion, we 
classified the patient to the CNB group. The rationale for this was that it is likely 
that surgeons' operative approaches were mainly directed by the preoperative 
diagnosis with the greater level of suspicion. We excluded patients with similar 
diagnoses by FNA and CNB.
Operative param eters
The primary outcome measure was margin status of the initial excision. We 
defined a positive margin as tumour cells (either invasive carcinoma or DCIS) 
invading the inked margin or a non-representative excision.6,13,17-19 We did not 
consider the presence of lobular carcinoma in situ or atypical ductal hyperplasia 
as a positive margin. Additional histopathological variables collected included 
histological grade,20 lymphovascular invasion (LVI), multifocality, and 
extratumoural ductal carcinoma in situ (DCIS). The secondary outcome 
constituted whether one or more re-excisions were performed to obtain clear 
margins.
Statistical analysis
We used the Chi-square test for univariate comparisons of proportions. 
Furthermore, we constructed forced-entry logistic regression models with 
lumpectomy margin status (involved vs. not involved) as the outcome variable, 
and all other abovementioned variables as predictors. We used a similar 
approach with re-excision as the outcome variable. We expressed independent 
associations between predictors and outcomes as odds ratios (ORs), using a 
threshold of P<.05 for statistical significance. We used SPSS 14.0 software (SPSS 
Inc., Chicago, IL) for calculations.
Results
Study population
From 1999-2008, 1102 patients were diagnosed by FNA, CNB, or both, and had 
a lumpectomy for breast cancer. Of these, we excluded 36 patients who had 
both FNA and CNB yielding similar diagnoses. The subsequent 1066 patients 
formed the basis of the presented analyses. Of these, 866 were in the FNA 
group and 200 were in the CNB group. In the FNA group, there were 26 patients 
who also had a (less suspicious) diagnosis by CNB. In the CNB group, there were 
12 patients who also had a (less suspicious) diagnosis by FNA.
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Mean patient age was 57.9 (SD, 11.7) years. The most frequent final 
histopathological diagnoses were invasive ductal carcinoma (n=767), invasive 
lobular carcinoma (n=138), and DCIS (n=86). The FNA or CNB was conclusive in 
896 cases. Lesions in the FNA group had a conclusive diagnosis slightly more 
frequently than those in the CNB group (P=.022, Table 1). The lesions with an 
inconclusive preoperative diagnosis included invasive ductal carcinoma (n=98), 
invasive lobular carcinoma (n=32), DCIS (n=28), tubular carcinoma (n=9), and 
medullary carcinoma (n=3).
Ta b l e  1 . P r e o p e r a t iv e  p a t h o l o g y  d ia g n o s e s  o f  
1 0 6 6  b r e a s t  c a n c er s  t r e a t e d  b y  l u m p e c t o m y
Number of cases (n)
Diagnosis FNA CNB
B1/C1 16 10
B2/C2 15 8
B3/C3 31 8
B4/C4 69 13
B5/C5 735 161*
* P=.022.
FNA indicates fine needle aspiration; 
CNB, core needle biopsy.
Margin status o f  the initial excision
Two hundred and sixty-five patients (24.9%) had at least one positive margin on 
the initial excision. There was no difference in margin involvement between the 
FNA and CNB groups (24.7% vs. 25.5%, respectively, P=.816, Figure 1). Margins 
were involved significantly less frequently in patients with conclusive 
preoperative diagnoses (20.9% vs. 45.9%, P<.001, Figure 1). This association 
remained significant on multivariate analysis (0R=0.19; 95% confidence interval 
(95% CI), 0.06-0.59; P=.004; Table 2). Other variables significantly associated 
with a positive margin were LVI (P=.004), multifocality (P=.001), and tumour 
histology (P=.040).
38
Ta b l e  2. L o g is t ic  r e g r e s s io n  a n a l y s is  o f  f a c t o r s  p r e d ic t in g
POSITIVE MARGINS OF THE INITIAL EXCISION
Factor Odds ratio (95% CI) P-value
Age (years) 1.0 (0.98-1.01) .509
Palpable (vs. nonpalpable) 0.77 (0.54-1.09) .135
Mammographic aspect 
Microcalcifications vs. mass 
Architectural distortion vs. mass 
Negative mammogram vs. mass
1.03 (0.66-1.64) 
1.02 (0.43-2.42) 
0.92 (0.55-1.71)
.997
.889
.974
.920
FNA (vs. CNB) 0.94 (0.33-1.60) .724
Conclusive (vs. inconclusive) 0.19 (0.06-0.59) .004
preoperative pathology diagnosis*
Delay between preoperative diagnosis 1.01 (1.00-1.03) .083
and lumpectomy (days)
Tumour size (cm) 1.22 (1.04-1.43) .013
Tumour grade 
Grade 1 vs. 2 
Grade 1 vs. 3
1.19 (0.95-1.47) 
1.15 (0.91-1.47)
.092
.125
.248
Extratumoural DCIS+ 0.98 (0.71-1.35) .875
LVI+ 1.87 (1.22-2.87) .004
Multifocality+ 2.15 (1.38-3.34) .001
Tumour histology 
Lobular carcinoma (vs. other) 
DCIS (vs. other)
1.32 (0.94-1.85) 
1.00 (0.66-1.51)
.040
.105
.996
*A conclusive preoperative diagnosis is defined as C5 or B5.
t  Defined as negative in pure DCIS lesions
Margin involvement was defined as tumour cells transecting one or more 
microscopic surgical margins, or a non-representative lumpectomy.
An odds ratio >1 indicates an increased probability of a positive initial margin 
when a certain factor is present or when a continuous variable changes one unit. 
The association between margins and severity of a preoperative pathology 
diagnosis was not significantly different between the 
FNA and CNB groups (P=.451)
95% CI indicates 95% confidence interval; FNA, fine needle aspiration; 
CNB, core needle biopsy; DCIS, ductal carcinoma in situ; LVI, lymphovascular 
invasion.
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F ig u r e  1 . U n iv a r ia t e  a s s o c ia t io n s  b e t w e e n  th e  m o d a l it y  a n d
SEVERITY OF PREOPERA TIVE PATHOLOGY DIAGNOSES 
AND MARGIN INVOLVEMENT OF THE INITIAL EXCISION.
* + +
P<.05;f P<.005; * P<.001 
Light dots delineate estimates of FNA conclusiveness, whereas dark dots 
delineate estimates of CNB conclusiveness. Horizontal lines correspond to 
95% confidence intervals.
FNA indicates fine needle aspiration; CNB, core needle biopsy;
95% CI, 95% confidence interval.
Re-excision
Two hundred and seventy-five patients (25.8%) had one re-excision and 11 
patients (1.0%) had two. Patients with conclusive preoperative pathology 
diagnoses were at significantly lower risk of undergoing one or more re­
excisions (22.9% vs. 47.6%, P<.001, Figure 2), whereas the diagnostic modality 
did not influence this risk (26.7% for FNA vs. 27.5% for CNB, P=.812). In
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multivariate analysis, the association between inconclusive preoperative 
diagnoses and re-excisions remained significant (OR=0.15; 95% CI, 0.05-0.47; 
P=.001; Table 3). Other variables significantly associated with re-excision were 
younger age (P=.001), more days from preoperative diagnosis until the first 
excision (P=.006), and multifocality (P=.001).
Ta b l e  3 . L o g is t ic  r e g r e s s io n  a n a l y s is  o f  f a c t o r s  p r e d ic t in g  r e - e x c is io n
Factor Odds ratio (95% CI) P-value
Age (years) 0.98 (0.96-1.00) .001
Palpable (vs. nonpalpable) 0.90 (0.63-1.28) .551
Mammographic aspect 
Microcalcifications vs. mass 
Architectural distortion vs. mass 
Negative mammogram vs. mass
1.22 (0.76-1.96) 
0.76 (0.30-1.91) 
1.02 (0.57-1.84)
.873
.413
.553
.929
FNA (vs. CNB) 0.56 (0.25-1.29) .174
Conclusive (vs. inconclusive) 0.15 (0.05-0.47) .001
preoperative pathology diagnosis*
Delay between preoperative 1.02 (1.00-1.03) .049
diagnosis and lumpectomy (days)
Tumour size (cm) 1.10 (0.94-1.29) .253
Tumour grade 
Grade 1 vs. 2 
Grade 1 vs. 3
1.08 (0.87-1.35) 
1.43 (1.13-1.83)
.006
.486
.003
Extratumoural DCIS+ 0.92 (0.66-1.27) .808
LVI+ 1.42 (0.92 -2.21) .117
Multifocality+ 6.78 (4.30-10.70) <.001
Tumour histology 
Lobular carcinoma (vs. other) 
DCIS (vs. other)
1.13 (0.79-1.59) 
1.23 (0.82-1.85)
.052
.508
.310
*A conclusive preoperative diagnosis is defined as C5 or B5. t  Defined as negative 
in pure DCIS lesions
An odds ratio >1 indicates an increased probability of a re-excision when a 
certain factor is present or when a continuous variable changes one unit.
The association between more severe preoperative pathology diagnoses and re­
excisions was not different between the FNA and CNB groups (P=.213).
95% CI indicates 95% confidence interval; FNA, fine needle aspiration; CNB, core 
needle biopsy; DCIS, ductal carcinoma in situ; LVI, lymphovascular invasion.
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F ig u r e  2 . U n iv a r ia t e  a s s o c ia t io n s  b e t w e e n  th e  m o d a l it y  a n d  s e v e r it y  o f
PREOPERATIVE PATHOLOGY DIAGNOSES AND RE-EXCISION RATES.
Re-excisions were significantly associated with inconclusive preoperative 
pathology diagnoses (P<.001), but not with the modality used to obtain the 
diagnosis (P=.812).
Discussion
Main findings
Preoperative cytological or histological diagnosis is a necessary step in the work 
up of patients with a suspicious breast lesion.1 It gives the patient as well as the 
surgeon the opportunity to reflect on the diagnosis and to plan the definitive 
form of treatment. We identified the conclusiveness of percutaneous needle 
biopsy (i.e., FNA or CNB) as the strongest preoperative predictor of margin 
involvement of the initial excision of locally resectable breast cancer.
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Consequently, conclusive FNA or CNB decrease the number of surgeries 
required for complete breast conservation therapy in these patients. This 
stresses the importance of obtaining conclusive breast biopsies prior to local 
excision, not only in the light of accurate preoperative work-up, but also with 
respect to efficient surgical management of malignant lesions amenable to 
breast conservation.
Study lim itations
The current study has some limitations. Although we are aware that only a 
minority of the included patients had a CNB, we found that FNA and CNB yield 
statistically similar rates of positive margins and re-excisions, and that the 
lowering effect of conclusively malignant diagnoses (B5 and C5) on these rates 
is similar for FNA and CNB. Consequently, we can be confident that the current 
results are well applicable to centres adhering to CNB only.
Interpretation
In an attempt to select patients who are likely to have complete excisions in the 
first instance, several authors have studied clinicopathologic factors affecting 
lumpectomy margins, including mammographic aspect, 6,13,17 palpability,7,11,21 
tumour size,6,8 histological grade,5,8 lymphovascular invasion,9,21,22 and 
multifocality.12,22,23 Although some of these characteristics are sensible guides 
to the intended size of the excision, none can be influenced.
The present study is the first to directly focus on the effect of 
conclusiveness of preoperative diagnoses by FNA and CNB on completeness of 
local excision in a comprehensive population of breast cancer patients. In a 
series of 100 DCIS patients, no significant association between FNA 
conclusiveness (i.e., C5 diagnoses) and margin status was found. However, 
when C1-3 and C5 diagnoses were compared, there was a significant 
association of C5 diagnoses with clear margins.5
The current study suggests that, irrespective of the modality used, a 
conclusive preoperative pathology diagnosis can improve the efficiency of 
breast conservation therapy substantially. This may reflect surgeons' tendency 
to more adequately plan the excision volume when 'alarmed' by conclusively 
malignant preoperative pathology diagnoses.
Our findings also imply that breast centres should optimize technical 
prerequisites for a decisive FNA or CNB diagnosis. Strategies to maximize the
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likelihood of a conclusive diagnosis include ultrasound guidance of the biopsy 
procedure,24,25 using a monolayer laboratory technique for preparing 
aspirates14 and using larger-core needles for CNB.26 Also, it is of utmost 
importance to obtain a conclusive diagnosis in cases of an inconclusive primary 
diagnosis. Lesions with an inconclusive FNA diagnosis should be re-biopsied by 
CNB,27 whereas inconclusive CNB should be followed by repeated CNB.28
Additionally, does the modality by which the preoperative diagnosis is 
obtained influence completeness of excision? Until now, two large series have 
yielded conflicting results, with one suggesting more positive margins for FNA 
when compared to CNB11 and the other finding no difference.12 We found 
similar rates of compromised margins and re-excisions for the FNA and CNB 
groups. Thus, as far as the effect on margins of the initial excision is concerned, 
preferring one modality over another seems irrational.
Conclusion
Obtaining a conclusive preoperative diagnosis by either FNA or CNB is key to 
effective and complete breast conservation therapy. Hence, breast centres may 
lower re-excision rates by optimizing preoperative pathology work-up.
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A b s t r a c t
A ims
To (1) to assess the conclusiveness of fine needle aspiration (FNA) in a 
histologically confirmed population of more than 2400 breast lesions, and to (2) 
evaluate whether FNA conclusiveness can be predicted from baseline clinical 
and radiologic parameters.
Methods
We retrospectively collected data on all histologically confirmed breast lesions 
presenting from 1999-2007. Aspirates were diagnosed as inadequate, benign, 
atypical, suspicious or malignant. We defined a conclusive FNA diagnosis as 
'benign' in histologically benign lesions and as 'malignant' in histologically 
malignant lesions.
Results
In 2419 breast lesions, the proportion of conclusive diagnoses was 46.1% (95% 
confidence interval, 42.0%-50.2%) in histologically benign lesions (n=571) and 
81.6% (95% confidence interval, 79.8%-83.4%) in histologically malignant 
lesions (n=1848). On multivariate analysis, factors associated with a conclusive 
preoperative diagnosis included tumour diameter of 2-2.9cm (P<.001), 
malignant histology (P<.001) and the pathologist examining the aspirate 
(P=.02).
Conclusion
Breast FNA has to be utilized selectively in the routine work-up of breast 
lesions. In suspicious lesions of large size, FNA may be used to obtain a quick 
confirmation of malignancy, which will have to be followed by a CNB for 
determination of further tumour characteristics. However, FNA should not be 
used in the work-up of breast lesions with low clinical and radiologic grade of 
suspicion.
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Introduction
N on-operative pathology diagnosis o f  b reast lesions
Percutaneous needle biopsy is fundamental to stratify patients presenting with 
breast lesions to conservative or surgical treatment, and, if surgery is indicated, 
to different surgical strategies.1-3 The ability of core needle biopsy (CNB) to 
differentiate between invasive and in situ carcinoma, to allow for 
immunohistochemical staining of breast tissue, and to yield high rates of 
conclusive diagnoses (i.e., a 'benign' diagnosis in a histologically benign lesion 
and a 'malignant' diagnosis in histologically malignant lesions) has increased its 
use as compared to fine needle aspiration (FNA).1,4
Yet, FNA may still have value in the work-up of some patients by 
providing an additional opportunity of a conclusive diagnosis.5-7 Specifically, this 
may prevent redundant surgeries in patients with benign breast pathology and 
can spare diagnostic excisions for malignant lesions.1,8 Additionally, a decisive 
same-day diagnosis reduces short-term anxiety in patient with benign 
pathology and shortens the psychologically stressful waiting period in breast
9 10cancer patients.
Therefore, predicting whether or not a certain patient will have a 
conclusive breast FNA can be useful for selecting patients who would benefit 
from FNA. This has been the subject of a recent report which, unfortunately, 
only included histologically malignant lesions.11 This limits its generalizability as 
the true nature of a lesion (benign vs. malignant) is a post-hoc variable in that it 
is only known after excision.
Study aim
The current study aimed to assess the conclusiveness of FNA in a histologically 
confirmed population of more than 2400 benign and malignant breast lesions. 
Furthermore, we created a multivariate model to predict which patients are 
more likely to have a conclusive FNA diagnosis.
Materials and methods
Study population
We retrospectively identified all patients who had a breast FNA with 
histological confirmation in our regional teaching hospital from January 1st, 
1999, until December 13th, 2007. In this clinic, all patients with clinically or
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screen-detected breast lesions that are visible on ultrasound (US) as a solid 
lesion are punctured by FNA.
Clinical and radiologic data
We obtained clinical and radiologic data from medical records and radiologic 
hospital registries. Recorded data included age, palpability, and whether the 
FNA was performed freehanded or US-guided. Further, the mammographic 
appearance of each lesion was categorized into 'mass', 'microcalcifications', 
'architectural disturbance' and 'negative mammogram'.
Pathology data
Aspirates were taken by making 2-4 passes through the lesion and were 
processed by a liquid-based preparation technique.12 We retrieved cytological 
and histological data from the Dutch national pathology database (PALGA). 
According to international guidelines,13 aspirates were diagnosed as 
inadequate, benign, atypical, suspicious or malignant. The end point of the 
present study constitutes a conclusive and correct FNA diagnosis, defined as 
'malignant' in histologically malignant lesions and as 'benign' in histologically 
benign lesions. We considered all other diagnoses as inconclusive.
We collected histological data regarding tumour size, histological 
grade14 and subtype. We considered invasive carcinoma and ductal carcinoma 
in situ (DCIS) as malignant. Histology was obtained by excisional biopsy 
(n=1439), mastectomy (n=782), core needle biopsy (n=192), or 
microdochectomy (n=6).
The cytological and histological samples were examined by nine 
pathologists with formal training and 6-20 years of experience in 
cytopathology. In the seven years prior to the study period, they each 
examined averages of 25-106 breast FNA per year.
Statistical analysis
We calculated proportions of conclusive FNA diagnoses in histologically benign 
and malignant lesions, with their respective 95% confidence intervals (95% CIs).
We employed a forced entry logistic regression model that relates 
clinical, radiologic and histopathological factors to the probability of obtaining a 
conclusive FNA diagnosis. We entered patient age, palpability, mammographic 
appearance, aspiration mode (US-guided vs. freehand), tumour size, histology
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(benign vs. malignant) and the pathologist examining the aspirate as 
independent variables. We estimated adjusted odds ratios (OR) from the 
logistic regression model.
We set the significance level at a=0.05.
REsuLTs
Patients' characteristics
A total of 2419 patients matched our inclusion criteria. Mean patient age was 
56.8 years (SD, 14.7). The mean time between FNA and histology was 16.0 days 
(SD, 9.0 days). Of all histological diagnoses, 1848 were malignant and 571 were 
benign. The most frequent diagnoses included invasive ductal carcinoma 
(n=1385), 'benign not otherwise specified' (n=262), invasive lobular carcinoma 
(n=247), and fibroadenoma (n=159).
FNA conclusiveness
The proportion of conclusive diagnoses was 46.1% (95% CI, 42.0%-50.2%) in 
histologically benign lesions and 81.6% (95% CI, 79.8%-83.4%) in histologically 
malignant lesions (Table 1). In benign lesions, the rate of false-positives was 
2.1% (95% CI, 0.9%-3.3%). In malignant lesions, the rate of false-negatives was 
2.4% (95% CI, 1.7%-3.1%).
Ta b l e  1. D is t r ib u t io n  o f  p r e o p e r a t iv e  FN A d ia g n o s e s
IN 2 4 1 9  BENIGN AND MALIGNANT BREAST LESIONS
FNA diagnosis Count (n), proportion (%)
Benign lesions 
(n=571)
Malignant
lesions(n=1848)
Inadequate 101 (17.7) 67 (3.6)
Benign 263 (46.1) 44 (2.4)
Atypical 158 (27.7) 81 (4.4)
Suspicious 37 (6.5) 148 (8.0)
Malignant 12 (2.1) 1508 (81.6)
On multivariate analysis, factors associated with a conclusive 
preoperative diagnosis included tumour size (P<.001), malignant histology 
(P<.001) and the pathologist examining the aspirate (P=.02, Table 2).
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Specifically, lesions with diameters of 2.0-2.9 cm were independently 
more prone to yield a conclusive FNA, when compared with lesions of <1 cm in 
diameter. However, lesions of larger sizes were equally likely to yield conclusive 
diagnoses when compared with lesions of <1 cm in diameter. Additionally, 
independent of age, palpability, mammographic aspect, tumour size, 
histological diagnosis and aspiration mode, there was significant heterogeneity 
regarding conclusiveness rates among the nine pathologists.
Ta b l e  2 . L o g is t ic  r e g r e s s io n  a n a l y s is  o f  f a c t o r s
INFLUENCING THE CONCLUSIVENESS OF PREOPERATIVE FN A DIAGNOSIS 
IN 2 3 4 9  BENIGN AND MALIGNANT BREAST LESIONS
Factor Odds ratio (95% CI) P-value
Age (years) 1.00 (0.99-1.01) .78
Palpable (vs. nonpalpable) 1.21 (0.95-1.53) .13
Mammographic aspect 
Microcalcifications vs. mass 
Architectural distortion vs. mass 
Negative mammogram vs. mass 
Tumour size
1-1.9 cm vs. <1 cm
2-2.9 cm vs. <1 cm
3-3.9 cm vs. <1 cm
4-4.9 cm vs. <1 cm 
>5 cm vs. <1
1.06 (0.78-1.45) 
0.75 (0.48-1.18) 
1.08 (0.80-1.44)
0.96 (0.80-1.15) 
1.82 (1.45-2.28) 
1.28 (0.95-1.71) 
0.96 (0.64-1.43) 
0.92 (0.64-1.31)
.49
.71
.21
.63
<.001
.66
<.001
.10
.83
.62
Malignant histology (vs. benign) 4.81 (3.80-6.10) <.001
US-guidance (vs. freehand) 1.33 (0.95-1.86) .10
Pathologist - .02
There were 70 cases with missing data on >1 independent variables, and were 
thus excluded from multivariate analysis 
An odds ratio > 1 indicates an increased probability 
of obtaining a conclusive FNA
FNA indicates fine needle aspiration; 95% CI, 95% confidence interval;
US, ultrasound
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Discussion
M ain findings
We found that a conclusive preoperative diagnosis by FNA is feasible in less 
than half of patients with benign breast pathology and in around 80% of breast 
cancer patients. Furthermore, selecting patients for whom FNA will provide a 
conclusive diagnosis proves difficult when employing preoperative clinical and 
radiologic criteria.
Fine needle aspiration in relation to core needle biopsy
Breast FNA has considerably been criticized because of its inability to 
distinguish between histological subtypes of breast lesions that require 
different surgical treatment approaches.15 For example, it cannot reliably 
distinguish in situ from invasive carcinoma, while the former does not 
necessitate sentinel node biopsy in all cases and often requires a more 
extensive surgical approach.15,16 Additionally, FNA is unreliable in distinguishing 
lobular from ductal carcinomas and in assessing tumour grade and Her-2-neu 
status.17,18 As CNB does provide such information critical to adequate surgical 
and neoadjuvant treatment planning,19 this modality is generally preferred over 
FNA.2,3
Still, a sensible use of FNA may exist in avoiding unnecessary excisions 
of benign breast lesions.4,8 However, we found that only 46% of these lesions 
can be conclusively diagnosed preoperatively by FNA. Other authors have 
found FNA conclusiveness rates of 54%-98% in benign breast lesions.4,20,21 
While, compared to CNB, FNA is a less painful procedure and allows for a same- 
day diagnosis,22 CNB has been shown to have a far higher conclusive diagnostic 
yield in benign breast lesions, ranging from 80%-99%.1,4,6,23,24
Acknowledging the inferiority of FNA in diagnosing breast cancer, its 
role as an adjunct to CNB has been demonstrated in some studies in which 
combining the two modalities resulted in the highest diagnostic yield.5-7 More 
importantly, a same-day diagnosis of malignancy minimizes the psychologically 
stressful period of waiting for a malignant diagnosis.9,25 As a decisive malignant 
diagnosis was possible in more than 80% of breast cancer patients in our study, 
we believe that FNA is still useful in diagnosing suspicious lesions. Yet, when 
forced to choose between FNA and CNB, the latter will be the preferred 
modality because of its higher conclusiveness in breast cancers, which ranges
from 75%-95%.4, 7, 22-24
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Selective use of fine needle aspiration
Unfortunately, selecting patients for whom FNA will still favourably impact 
preoperative work-up (i.e., by providing a valid and conclusive diagnosis) is 
difficult on the basis of simple preoperative characteristics. Benign histology 
(vs. malignant) had the strongest association with an inconclusive diagnosis. As 
such, FNA has limited value in the work-up of lesions with low clinical and 
radiologic grade of suspicion.
A preoperative variable independently associated with a conclusive 
FNA diagnosis was increasing tumour size, with lesions of 2-2.9 cm in diameter 
being most likely to be diagnosed conclusively. The fact that lesions larger than
3.0 cm were as likely to be diagnosed conclusively as lesions <1 cm seems 
surprising. Yet, a similar relationship has been found in a 689-patient breast 
cancer series, with FNA conclusiveness dropping again in lesions >4 cm.26 This 
threshold for optimal FNA yield has been attributed to aspiration of necrotic 
debris or desmoplastic tissue which are often present in such large lesions.26,27
A recent analysis of 418 screen-detected breast cancers demonstrated 
that tumour size <1cm (vs. >1cm) was an independent predictor of inconclusive 
FNA.11 Consequently, as the introduction of mammography screening 
programmes has lowered the mean size of breast lesions presenting to breast 
clinics,28,29 the role of FNA is diminishing ever more.
Our finding that FNA conclusiveness also depends on the pathologist 
examining the aspirate is detrimental to centres without dedicated 
cytopathologists. Indeed, training in breast cytopathology increases the 
diagnostic yield of breast FNA and this argues for dedicated pathologists in 
breast clinics adhering to a rapid diagnosis.30
Surprisingly, US guidance did not increase the probability of obtaining a 
conclusive diagnosis in the current dataset. This is in contrast to a recent study, 
confined to breast cancer patients, that found significantly more conclusive 
diagnosis in patients that had a US-guided FNA.31
Study limitations
Including only patients that had subsequent histology limits the generalizability 
of our findings, mostly for patients with benign lesions, which were likely to be 
excised only when diagnosed inconclusively by FNA. Further, histologically 
benign lesions are only aspirated when palpation and/or radiographic findings
54
are equivocal. Therefore, the true value of FNA in the triple diagnosis of benign 
lesions cannot be accurately estimated from this study. Lastly, using different 
histological gold standards (ranging from CNB to mastectomy) has possibly 
influenced the cyto-histological correlation in this study.
However, we think that the large size of the present cohort enables us 
to draw valid conclusions on the utility of breast FNA. This is demonstrated by 
the narrow 95% CIs of the point estimates of FNA conclusiveness. Moreover, 
including only patients with surgical confirmation will have increased the 
internal validity of our study.
Conclusions
In conclusion, breast FNA has to be utilized selectively in the routine work-up of 
breast lesions. In suspicious lesions of large size, FNA may be used to obtain a 
quick confirmation of malignancy, which will have to be followed by a CNB for 
determination of further tumour characteristics. However, FNA should not be 
employed in the work-up of breast lesions with low clinical and radiologic grade 
of suspicion.
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A b s t r a c t
A im
To compare breast fine needle aspiration (FNA) specimens prepared by 
conventional smearing (CS) versus monolayer preparation (MP), with respect to 
the conclusiveness of the cytopathological diagnosis.
Methods
From 1992 to 1996, physicians/surgeons prepared aspirates themselves by 
direct smearing onto 2-4 slides. Aspirates obtained between 1996 and 1999 
were either CS or MP; all were excluded in order to avoid the effect of a 
"learning curve" concerning the latter. From 1999 to 2003, aspirate preparation 
was performed in the laboratory, creating a MP, using a Hettich cytocentrifuge. 
FNA diagnoses were categorised into inadequate (C1), benign (C2), atypical 
(C3), suspicious for malignancy (C4) and malignant (C5). The reference standard 
constituted histological follow-up. A conclusive FNA diagnosis was defined as 
C2 in lesions benign on follow-up and C5 in lesions malignant on histology.
Results
From 1992 to 1996, 692 aspirates were processed by CS, whereas from 1999 to 
2003, 1301 aspirates were processed by MP. More FNA were ultrasound- 
guided in the MP group (85.6% versus 21.5%, P<0.001). When compared with 
CS, MP-prepared FNA had conclusive diagnoses significantly more often (72.8% 
versus 58.5%, P<0.001). This effect remained significant when corrected for the 
difference in ultrasound guidance (adjusted odds ratio 1.7, 95% confidence 
interval 1.3 to 2.2, P<0.001), and was larger for malignant lesions than for 
benign lesions (P<0.001).
Conclusion
Patients presenting with breast lesions can more often be offered a same-day, 
conclusive cytopathological diagnosis when FNA are prepared by a manual MP 
processing technique.
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Introduction
The primary aim in same-day breast cancer diagnosis is integration of imaging, 
clinical investigation and cytological confirmation within 1 day. Consequently, it 
is important to minimize the number of inconclusive fine-needle aspiration 
(FNA) results. Liquid-based preparation of aspirates has been gaining popularity 
since its launch in the early 1990s. It has proven cost effective and time saving 
when compared with conventional smear (CS) preparation in gynaecological1,2 
and non-gynaecological3 cytology. More important, it offers uniform aspirate 
processing, possibly decreasing the number of inadequate FNA, and thus 
precluding expansion of the diagnostic investigation.4
Technically, a liquid-based preparation differs from a CS in that the 
aspirate is immediately fixed and centrifuged and that cells end up on a limited 
area on a single slide. This implies a shorter screening time,5 and also a change 
in cytological interpretation. Compared with CS, liquid-based preparations 
increase cellularity6 and enhance cellular morphology.5
While automated devices, such as the ThinPrep processor, are readily 
available, manual liquid-based techniques are less costly and might therefore 
prove a sensible alternative.7 In this paper, we report on our diagnostic 
experience with a manual monolayer preparation (MP) of breast FNA, 
employing the Hettich cytocentrifuge.
The present study aimed to evaluate the rates of conclusive diagnoses 
established by FNAs prepared by MP as compared with CS. Using retrospective 
data on 1993 cases, we hypothesised that breast FNA would be diagnosed 
conclusively more frequently when the aspirate was prepared by MP.
Methods
Data collection
This retrospective study was performed on FNAs taken from palpable and non- 
palpable breast lesions in a regional teaching hospital, followed by a 
histological diagnosis. Data were extracted from the prospective national 
pathology database of The Netherlands.
Cytology specimens were obtained by radiologists using ultrasound 
guidance, and by surgeons using freehand aspiration. Either a 21 gauge or a 23 
gauge needle was used for aspiration, and this was random for both CS- 
prepared and MP-prepared aspirates. No data on the skill of the physician 
performing the aspiration and on on-site assessment of specimen adequacy
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were available. Following excisional biopsy, tumour size was measured by 
pathologists, and the histological grade of malignant lesions according to the 
modified Bloom-Richardson classification8 was determined.
Laboratory processing
CS and MP samples were processed in the same laboratory. CS preparation was 
routinely used from 1992 to 1996. From then, it was gradually replaced by MP, 
giving cytotechnologists and pathologists time to gain experience. From mid- 
1998, MP became the only method used. Therefore FNAs taken in 1997 and 
1998 were excluded from this study, thereby skipping the learning curve.
Conventionally prepared specimens included direct smears for solid 
masses and cytospins (ThermoFisher Scientific, Waltham, Massachusetts, USA) 
for fluids. For CS, the aspirate was smeared by the aspirator onto as many slides 
as were needed to allow a complete image of the specimen (i.e., 2-4 slides) and 
instantly fixated in 95% ethanol. This allowed for immediate cytological 
examination when the slides arrived in the laboratory.
In case of MP, the aspirator had no role in the cytological preparation. 
Once arrived in the laboratory, cells were rinsed from the needle and syringe 
into a vial and directly fixed in a 50% ethanol, 2% polyethylene glycol solution. 
The mixture was centrifuged for 10 min at 688 rpm in a Hettich Rotina 48S or 
Hettich Rotanta 46S cytocentrifuge (Andreas Hettich, Tuttlingen, Germany).9,10 
The supernatant was discarded. Depending on the estimated density of the 
sediment, one or two drops of the 50% ethanol, 2% polyethylene glycol 
solution was added. The resultant mixture was dripped into a bucket that was 
clasped on a poly-l-lysine slide (Menzel, Braunschweig, Germany). By 
centrifuging for 5 min at 688 rpm, the sediment was pressed onto the slide, 
creating a monolayer arrangement of all cells within a 12 mm diameter area. 
Only one MP slide per aspirate was prepared.4 In case of a haemorrhagic 
aspirate, an additional slide was prepared by lysing erythrocytes with 2.5% 
acetic acid. CS and MP slides were stained with Papanicolaou stain.
FNA examination and histology
Slides were screened by cytotechnologists and examined by 10 staff 
cytopathologists with 6-20 years of experience in cytopathology. Using simple 
and well-defined criteria,11 they classified each aspirate into one of five 
diagnostic categories: inadequate (C1), benign (C2), atypical (C3), suspicious for
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malignancy (C4) and malignant (C5).12 A conclusive FNA diagnosis was defined 
as a benign diagnosis (C2) in lesions that were benign on follow-up and as a 
malignant diagnosis (C5) in lesions that were malignant on follow-up. On 
occasion, clinical information regarding the breast lesion was available to the 
pathologists at the time of cytopathological examination.
Each aspirate was related to its eventual histological diagnosis. Invasive 
carcinoma and ductal carcinoma in situ (DCIS) were considered malignant. All 
other diagnoses were considered benign.
Statistics
The relationship between the method of preparation (CS versus MP) and 
diagnostic conclusiveness was described with an odds ratio (OR) and was 
corrected for the effect of possible confounders by logistic regression. We used 
the chi-square test for testing differences between proportions of FNA 
diagnostic categories in the CS and MP groups.
We a priori planned one subgroup analysis. Since the elimination of 
disturbing background material is an important feature of MP,13 we 
hypothesized that the effect of MP on diagnostic conclusiveness would be 
larger in malignant lesions. We tested this with a formal test of interaction, 
using logistic regression.14
All tests were two-sided. Values of P<0.05 were considered significant. 
When separately testing proportions of FNA diagnostic categories, we adjusted 
the significance threshold to P<0.01 for multiple testing.15
REsuLTs
Study population
From 1 January 1992 to 31 December 1996, 692 FNA were performed and 
subsequently prepared by CS. From 1 January 1999 to 31 December 2003, 1301 
FNA were performed and prepared by MP. Of this subsequent total of 1993 
lesions aspirated, 516 (25.9%) were benign and 1477 (74.1%) were malignant. 
The most frequent histological diagnoses included invasive ductal carcinoma 
(n = 1073), aspecific benign tissue (n = 241), invasive lobular carcinoma (n = 223) 
and fibroadenoma (n = 141).
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Table 1 shows comparative clinical and pathological characteristics of 
the studied subjects. The only marked difference between the groups was that 
breast lesions in the CS group were significantly less likely to be aspirated under 
ultrasound guidance than those in the MP group.
Ta b l e  1. Ke y  p a tien t  ch aracteristics
Characteristic Preparation
CS (n=692) MP (n=1301)
Mean age (SD) (yr) 55.9 (14.8) 55.9 (15.0)
Malignant (%) 72.7 74.9*
Mean tumour size 2.4 (1.7) 2.2 (1.3)*
(SD) (cm)
Tumour grade (%)f
Grade 1 16.2 14.8
Grade 2 44.6 44.9
Grade 3 
Unknown
38.8
0.4
40.0
0.3
US-guided FNA (%) 21.5 85.6*
*  P<.05
In malignant tumours only
* P<.001
CS indicates conventional smear; MP, monolayer preparation; FNA, 
fine needle aspiration
Diagnostic conclusiveness
MP-prepared aspirates were conclusive significantly more frequently than 
aspirates prepared by CS (72.8% versus 58.5%, respectively, OR 1.9, 95% 
confidence interval (CI) 1.6 to 2.3), P<0.001; Table 2). When corrected for the 
effect of ultrasound guidance, a slightly weaker, but still highly significant, 
association remained (adjusted OR 1.7, 95% CI, 1.3 to 2.2, P<0.001). This 
corrected beneficial effect of MP on conclusiveness was significantly more 
pronounced in malignant lesions than in benign lesions (P<0.001, Table 3).
Specifically, MP-prepared aspirates of benign lesions were significantly 
less often inadequate than were CS-prepared aspirates (18.0% versus 32.8%,
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respectively, P<0.001; Figure 1). Malignant lesions had significantly less 
inadequate (4.8% versus 17.7%, respectively, P<0.001), less suspicious (7.2% 
versus 11.7%, respectively, P = 0.005), and more malignant FNA diagnoses 
(79.9% versus 63.4%, respectively, P<0.001) when the aspirate was prepared by 
MP.
Ta b l e  2 . A s s o c ia t io n  b e t w e e n  t h e  m e t h o d  o f  p r e p a r a t io n  a n d
DIAGNOSTIC CONCLUSIVENESS
Conclusiveness
Conclusive* (%) Inconclusive (%)
CS 58.5 41.5
MP 72.8 27.2f
* Defined as a C2 diagnosis in benign lesions and a C5 diagnosis in 
malignant lesions 
f OR=1.9 (95% CI, 1.6-2.3), P<.001
CS indicates conventional smear; MP, monolayer preparation
Ta b l e  3 . S u b g r o u p  a n a l y s is  o f  t h e  e f f e c t  o f  t h e  p r e p a r a t io n  m e t h o d  o n
t h e  DIAGNOSTIC CONCLUSIVENESS OF FN A IN MALIGNANT AND BENIGN LESIONS
Histology
Preparation
Benign
(conclusiveness, %)
Malignant 
(conclusiveness, %)
CS 45.5 63.4
MP 51.7 79.9*
* P<.001 for the effect of the interaction between preparation method and
histology on diagnostic conclusiveness
CS indicates conventional smear; MP, monolayer preparation
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F ig u r e  1. F r e q u e n c ie s  o f  FN A d ia g n o s e s  o f  a s p ir a t e s  p r e p a r e d  b y  c o n v e n t io n a l  s m e a r in g  a n d  b y  a  m o n o l a y e r  p r e p a r a t io n ,  in
BENIGN AND MALIGNANT BREAST LESIONS.
Benign lesions M alignant lesions
80° o
60% -
40°o—i
20°o
o%-
Tnadequate Benign Atypical Suspicious Malignant
FNA diagnosis
Preparatior
M C S
□ M P  so%
Inadequate Benign Atypical Suspicious Malignant
FNA diagnosis
Data are presented in proportions and 95% confidence intervals. O f paired bars, the left bars correspond to conventional smears, 
whereas the right bars correspond to m onolayer preparations
* P<.01 fo r  the difference in the proportions o f a diagnosis betw een conventional smearing and m onolayer preparation 
FNA indicates fine needle aspiration; CS, conventional sm ear; MP, m onolayer preparation.
Discussion
Key findings and limitations
The current study demonstrates that (1) breast FNAs are more conclusively 
diagnosed when processed by MP compared with CS, and (2) this benefit is 
most pronounced in malignant breast lesions. Our data show a 14.3% absolute 
reduction of inconclusive FNAs following MP adoption. This indicates that for 
one additional FNA to be diagnosed conclusively, seven aspirates should be 
processed by MP instead of CS (1/0.143).
The major limitation of this study lies in its retrospective nature. Certain 
confounding factors, such as differences among aspirators and variable 
cytopathologist experience, cannot be controlled for. Hence, a direct and 
completely fair comparison between CS and MP is impossible. However, we 
accounted for key patient and tumour characteristics affecting conclusiveness; 
these characteristics included ultrasound guidance, tumour size and tumour 
grade.16,17
Inconclusive cytological diagnoses
Inconclusive FNA diagnoses (i.e., diagnoses other than "benign (C2)" in benign 
lesions, and other than "malignant (C5)" in malignant lesions) are of clinical 
concern. These provide no information, delay diagnostic investigation, and 
require further investigations, such as core needle biopsies, to provide a 
conclusive diagnosis.18-20 Low-grade tumours and increased medicolegal claims 
are acknowledged as causes of the increased reporting of indeterminate 
diagnoses.11 Several studies have demonstrated variable conclusiveness rates 
for CS, ranging from 54% to 87%.21-24 As for MP, conclusiveness rates of 73-77% 
have been reported for breast FNAs processed by MP.7,25 Our results 
correspond well with these findings (Table 2).
Liquid-based preparation techniques, such as ThinPrep, have received 
considerable attention because of their favourable results with respect to 
cytomorphology and diagnostic conclusiveness.5,13,24 In direct comparisons with 
CS, ThinPrep has been shown to yield superior conclusiveness in 
gynaecological,3,26 general non-gynaecological3 and breast lesions.24 However, 
no direct comparisons of CS and MP preparations with regard to validity have 
been performed. In a paired comparison of 44 breast lesions, Florentine et al 
found CS and MP to yield similar cytological diagnoses, correlating in 41 cases.25 
However, FNA results were not correlated with histology.
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Obviously, the laboratory preparation method is not the only 
determinant of whether an aspirate will yield a conclusive, valid diagnosis. 
Substantially more aspirations were ultrasound-guided in the MP group. 
Therefore, lesions in this group may have been aspirated more accurately.16,27 
Yet, conclusiveness of MP-processed aspirates remained significantly higher 
following statistical correction for the effect of ultrasound guidance. This 
implies a genuine effect of MP on conclusiveness. Moreover, the finding of a 
smaller mean tumour size in the MP group, possibly caused by the 
implementation of the Dutch nationwide breast cancer screening programme,28 
may partly counterbalance the relative beneficial effect of ultrasound on 
conclusiveness. Detection of smaller tumours may have contributed to 
increased difficulty in obtaining diagnostic aspirations in the MP group.17
Differences in preparation and cytom orphology
During MP processing, aspirated cells are centrifuged and are concentrated 
upon a single 12 mm slide. This results in a higher observed cellularity, whereas 
in CS cells are dispersed over multiple slides.25,29 Additionally, liquid-based 
preparation comprises direct rinsing of cells in fixation fluid, preventing air 
drying artefacts and removing disturbing background material, both of which 
are frequently present in CS-prepared aspirates.30 Finally, conventionally 
smeared cells may be destroyed in the smearing process. These CS drawbacks 
are probably crucial in cases of borderline adequacy. For example, liquid-based 
preparations, including MP, remove the majority of disturbing background 
material such as necrotic debris.6,13,29 As the latter is relatively frequently 
present in aspirates of malignant lesions,31 the effect of MP may be more 
pronounced here. Indeed, we found that FNA conclusiveness increased more 
substantially in malignant lesions than in benign lesions following the 
implementation of MP.
Despite the potential advantages as described above, MP has potential 
limitations. First, MP of breast aspirates requires laboratory processing and 
therefore more time than CS. Yet, this difference is in the order of 20 min and 
should therefore not compromise the ability to provide a same-day diagnosis 
by FNA. A second potential limitation of MP is that is does not allow for an on­
site assessment of aspirate adequacy by methods such as Diff-Quik.32 In 
contrast, this is possible for smears. Thus, FNA in the CS group may have been 
conclusive more often had every aspirate been pre-assessed for adequacy.
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However, routinely performing these assessments is costly and time 
consuming,33 resulting in few centres adhering to this protocol.
Conclusion
In conclusion, patients presenting with palpable and non-palpable breast 
lesions can more often be offered a same-day diagnosis when FNA are 
prepared by a manual MP processing technique. Consequently, breast clinics 
adhering to conventionally smeared FNA as a means of providing a same-day, 
preliminary diagnosis of breast lesions may benefit from switching to MP 
processing.
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A b s t r a c t
Fine-needle aspiration (FNA) of breast lesions provides indeterminate (C1, C3, 
and C4) diagnoses in a high proportion of cases. The aim of the present study 
was to retrospectively determine whether repeat FNA or core needle biopsy 
(CNB) most frequently provides a correct and more conclusive diagnosis. All 
patients who had an indeterminate primary FNA followed by repeat FNA or 
CNB within 1 month from 1992 to 2007 were included. FNA was diagnosed as 
C1-C5; CNB was diagnosed as B1-B5. Improvement in preoperative diagnosis 
by repeat FNA or CNB was defined as C2/B2 in benign lesions, C3/B3 in 
premalignant lesions, C4/B4 or C5/B5 in malignant lesions where primary FNA 
was C1, and C5/B5 in malignant lesions where primary FNA was C3 or C4. 
Among 255 eligible cases, CNB improved the preoperative diagnosis more often 
than did repeat FNA (78.0% vs. 54.8%, odds ratio = 2.9, P<.001). When 
corrected for patient age, appearance on mammogram (mass or not), clinical 
findings (palpable or not), tumor size, and aspiration mode (freehand vs. image 
guided), this difference slightly increased (odds ratio = 3.0, P = .001). CNB 
should be performed after an indeterminate FNA of a breast lesion to obtain a 
reliable and clear preoperative diagnosis.
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Introduction
Fine-needle aspiration (FNA) has proven to be a reliable asset in same-day 
diagnosis of breast malignancies.1-3 Given the relative increase in nonpalpable 
breast lesions as a result of nationwide breast cancer screening, FNA carries 
more consequences in treatment planning than it did formerly. However, no 
definitive diagnosis can be established on the basis of cytology in 7% to 32% of 
cases.4-6 This group comprises lesions with inadequate (C1), atypical (C3), and 
suspicious (C4) FNA. Routinely, either a repeat FNA or a core needle biopsy 
(CNB) is performed to obtain a more definite preoperative diagnosis.5-7
The objective of the current study was to compare repeat FNA and CNB 
with regard to their ability to provide a clinically more useful diagnosis after an 
indeterminate primary breast FNA.
The hypothesis was that when corrected for potential confounding 
variables, CNB allows for a true and conclusive preoperative diagnosis more 
often than repeat FNA. This was tested by multivariate logistic regression 
analysis of 255 cases.
Materials and methods
Study Population and Data Acquisition
Data on all patients visiting the one-stop breast clinic in a regional teaching 
setting between 1992 and 2007 were retrospectively collected from the Dutch 
national pathology database PALGA. Patients that had an indeterminate FNA 
diagnosis (C1, C3, or C4) followed by a repeat FNA or a CNB of the same breast 
lesion within 1 month were analyzed.8 The PALGA database and patient files 
were reviewed for data on patient age, aspiration mode (freehand vs. image 
guided for both FNA and CNB), tumour size, clinical findings (palpable or 
nonpalpable), type of dominant lesion on mammography (mass or not), and 
signs of ipsilateral breast cancer developing if the patient was not operated on. 
Non-mass mammographic lesions included microcalcifications and architectural 
distortions. Tumour size was measured on the surgical specimen or on 
ultrasound in cases where the patient was not operated on.9
Follow-Up
The reference standard constituted surgical specimens or 2-year clinical follow- 
up when no surgical outcome was available. Premalignant surgical lesions
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included atypical ductal hyperplasia, lobular carcinoma-in situ, and atypical 
papillomatosis.
Repeat FNA and CNB
Cytological (FNA) and histological (CNB) material was obtained by freehand or 
image-guided needle handling. For FNA, a 21- to 23-gauge needle attached to a 
20-mL syringe was used. FNA were diagnosed as C1, inadequate; C2, benign; 
C3, atypical; C4, suspicious; or C5, malignant.8,10 An indeterminate FNA 
diagnosis was defined as C1, C3, or C4. Aspirates were either smeared and fixed 
in ethanol 95% or rinsed, fixed in an ethanol 50%-polyethylene glycol 2% 
solution, and centrifuged, creating a monolayer preparation. Both smears and 
monolayer slides were Papanicolaou stained.
CNB were performed with an 18-gauge needle mounted on an 
automated device (Bard M agnum , C. R. Bard, Covington, GA ) for lesions 
appearing as masses on ultrasound. For lesions invisible on ultrasound, 
stereotactic vacuum-assisted CNB (Vacora, Bard Peripheral Vascular, Tempe, 
AZ) were performed with a 14-gauge needle. CNB specimens were fixed in 
formalin and stained with hematoxylin and eosin. CNB diagnostic categories 
included B1, normal tissue or unsatisfactory; B2, benign; B3, uncertain 
malignant potential; B4 suspicious of malignancy; and B5, malignant.8 B3 
lesions included atypical ductal hyperplasia, lobular carcinoma-in-situ, and 
atypical papillomatosis. FNA and CNB were examined by 12 pathologists with 
11 to 20 years of experience at the beginning of the study period. Limited 
clinical information was available to pathologists when examining the slides.
A preoperative improvement of an indeterminate FNA diagnosis was 
noted when repeat FNA or CNB yielded a true and more conclusive diagnosis. In 
exceptional cases, lesions diagnosed as premalignant on the surgical specimen 
with inadequate and suspicious diagnoses on primary FNA and atypical 
diagnoses on repeat FNA or CNB were considered to have had an improvement 
in preoperative diagnosis (Table 1).
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Ta b l e  1. Cr it e r ia  f o r  a s s ig n in g  im p r o v e m e n t  in  p r e o p e r a t iv e  d ia g n o s is ,
ACCORDING TO THE HISTOLOGICAL NATURE OF THE SURGICAL SPECIMEN.
Indeterminate Improved preoperative diagnosis
diagnosis
Follow-up 1st FNA 2nd FNA CNB
Benign C1, C3, C4 C2 B2
Premalignant* C1, C4 C3
C3
3B
Malignant C1 C4, C5 B4, B5
C3, C4 C5 B5
* Includes atypical ductal hyperplasia, lobular carcinoma in situ and atypical 
papillomatosis
FNA indicates fine needle aspiration; CNB, core needle biopsy.
Statistical Analysis
The x2 test was used for comparing proportions of diagnostic improvement 
between repeat FNA and CNB. A forced-entry logistic regression model was 
used for correcting this difference for patient age, tumour size, aspiration 
mode, and lesion type as assessed by mammogram, as well as whether or not 
the lesion was palpable. Differences and odds ratios (OR) were considered to 
be statistically significant at P<.05. SPSS version 15.0 (SPSS, Chicago, IL) was 
used for statistical analysis.
Results
Patient characteristics
From January 1, 1992, until December 14, 2007, a total of 255 FNA in 242 
patients met the inclusion criteria. No patient received neoadjuvant therapy. 
Mean patient age was 55.6 years (standard deviation, 13.0). Follow-up was 
derived from the surgical specimen in 198 cases (median time to surgery, 5 
days; range, 0-122 days) and from clinical follow-up in 57 cases (median 
duration, 43 months; range, 7-137 months). Of these latter patients, 12 had 
malignant disease, but they were not operated on because they had distant 
metastases (n = 3), refused (n = 2), or were deemed unfit for surgery (n = 5), or
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because the aspirated lesion was a metastasis from a nonmammary primary 
tumour (n = 2).
After the primary indeterminate FNA, 73 patients had repeat FNA and 
182 patients had CNB. At follow-up, 87 lesions turned out to be benign, 10 
were premalignant, and 158 were malignant.
Diagnostic improvement
CNB improved the preoperative diagnosis more often than did repeat FNA 
(78.0% vs. 54.8%, OR = 2.9, x2 = 13.6, P<.001, Table 2). When adjusted for 
patient age, tumour size, and appearance on mammogram, as well as whether 
or not the lesion was palpable and the aspiration mode of the first and second 
diagnostic procedures, CNB still performed better compared with repeat FNA 
(OR = 3.0, P = .001, Table 3). Logistic regression revealed no significant effect of 
any of the above parameters on improving preoperative diagnosis. There were 
no significant correlations between tumour size and clinical findings (P = .23) 
and between appearance on mammogram and clinical findings (P = .16).
Ta b l e  2 . U n iv a r ia t e  d if f e r e n c e s  in  a l l o w a n c e  f o r  d ia g n o s t ic  
im p r o v e m e n t  b y  r e p e a t  FN A v s . CN B a f t e r  a n  in d e t e r m in a t e  p r im a r y  FN A
Diagnostic improvement (%)
No Yes
Second-line FNA 45.2 54.8
diagnostic modality CNB 22.0 78.0*
*  X2=13.6, P<.001
FNA, Fine needle aspiration; CNB, Core needle biopsy
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Ta b l e  3 . M u l t iv a r ia t e  l o g is t ic  r e g r e s s io n  a n a l y s is  o f  f a c t o r s  a f f e c t in g  
d ia g n o s t ic  im p r o v e m e n t
Odds ratio* P-value
Repeat FNA vs. CNB 3.0 .001
Patient age 1.0 .17
Palpable vs. non-palpable 0.8 .70
Mass vs. no mass on mammography 0.7 .36
Tumour size 1.0 .90
Primary FNA: freehand vs. image-guided 1.3 .54
Repeat FNA/CNB: freehand vs. image-guided 1.6 .38
* An odds ratio >1 means an increased corrected chance of improving the 
preoperative diagnosis when the covariate increases with one unit (i.e. 
switches from the first to the second category in case of a dichotomous 
covariate)
FNA, fine needle aspiration; CNB, core needle biopsy.
Discussion
The current study evaluated the optimal preoperative workup after an 
indeterminate (C1, C3, or C4) breast FNA. In patients who subsequently had 
CNB, preoperative diagnosis improved in 78.0%, compared with 54.8% for 
patients with repeat FNA (Table 2). This difference was not affected by clinical, 
radiologic, and histopathologic differences between these groups (Table 3).
In general, CNB is preferred over FNA as the first-line diagnostic 
modality because it more often provides a conclusive and adequate diagnosis 
than FNA.4,11-13 However, other centers continue to use primary FNA because 
the predictive value of malignant FNA diagnoses approaches 100%, allowing for 
a same-day diagnosis in 49% to 90% of breast cancers.1,2,6,14 Patients are served 
well when quickly informed about their diagnosis and treatment opportunities, 
but this is only possible when an unequivocal diagnosis is available 
preoperatively. Indeterminate FNA diagnoses result from sampling errors, 
interpretation errors, and possibly adverse histopathological tumour 
characteristics such as a fibrous consistency and lobular histology.15,16
In these instances, either a repeat FNA or a CNB is routinely performed,
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probably varying with specific center protocols or radiologist preference.6,7 
However, the validity of this choice has only been defined in small patient 
groups. CNB has been reported to provide clinically useful information in 76% 
to 90%, compared with 41% to 45% for repeat FNA.5,6,17 The present study 
indicates that this difference is somewhat smaller, but still evident. Compared 
with FNA, CNB needles are larger and sampling is less operator dependent.18 
Deep, desmoplastic lesions would therefore be unlikely to be aspirated 
successfully by repeating the same FNA procedure. Because most failed FNAs 
are the result of sampling error, this is probably the most important 
explanation of the observed difference in improvement of preoperative
diagnosis.6,19
It is of note that CNB yielded clinically useful information in only 78%, 
while reported sensitivities and specificities are generally higher, ranging from 
88% to 100% and 68% to 96%, respectively.12,13,20,21 This is probably the result of 
a selection bias created by the study inclusion criteria, leaving only those 
lesions that are hard to aspirate or whose tissue is hard to examine by the 
pathologist. This might prompt some clinicians to directly move on to excisional 
biopsy after an indeterminate FNA. Although the current study did not 
investigate this scenario, it would not be advisable. A malignant CNB may result 
in wider margins at initial excision, possibly decreasing the chance of positive 
resection margins, and signs of histopathological invasion on CNB may 
preliminarily determine axillary workup (i.e., sentinel node biopsy or not).22,23 
Furthermore, a negative CNB spares the patient unnecessary surgery, making it 
a cost-effective modality.24
However, indeterminate diagnoses remain after CNB. An atypical CNB 
diagnosis (B3) would still seem more valuable clinically than an atypical FNA 
diagnosis (C3) because B3 lesions on CNB carry highly variable risks of 
malignancy on subsequent excision.25 As a consequence, treatment of 
indeterminate lesions can be more reliably tailored to the patient compared 
with situations where repeat FNA was atypical.
The present study has several limitations. Its retrospective design may 
not have allowed for a fair comparison between the repeat FNA and CNB 
groups. Because the study spans a long period of time, factors that have 
changed in time may have influenced diagnostic performance in these groups 
unequally. Multivariate analysis was used to minimize this potential bias. Yet 
the difference in diagnostic improvement between repeat FNA and CNB
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remained grossly unchanged between univariate and multivariate analyzes (OR 
= 2.9 to OR = 3.0, respectively; Tables 2, 3). This is rational to some extent. For 
instance, tumour size does not change from the first to the second diagnostic 
procedure and should therefore not affect better performance of one modality 
over the other.
In summary, this study indicates that a CNB should be performed after 
an indeterminate (C1, C3, or C4) FNA of a breast lesion to obtain a reliable and 
clear preoperative diagnosis. For breast clinics more heavily adhering to a 
same-day diagnosis, a repeat FNA may be feasible, but one should consider that 
obtaining a more conclusive diagnosis is only possible in half of these cases.
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A b s t r a c t
A im
Preoperative stratification of patients presenting with nipple discharge (ND) 
according to malignancy risk has proven difficult. Nevertheless, cytological 
examination is considered to be a diagnostic aid. The aim of this study was to 
determine its complementary value in clinical decision-making in patients 
presenting with ND.
METHODS
We retrospectively collected data on macroscopic ND colour, ND cytology, 
physical examination, mammography, ultrasound and fine-needle aspiration 
cytology results. On ND cytology, benign diagnoses were considered negative, 
whereas suspicious and malignant diagnoses were considered positive for 
malignancy.
Results
From 1992 to 2006, 618 patients had an ND smear, of those 163 patients had a 
biopsy. Sensitivity and specificity were 16.7% and 66.1%, respectively. These 
values were lower when ND was bloody than when ND was non-bloody (P=0.66 
and P<0.05 for sensitivity and specificity, respectively). When macroscopically 
defining bloody ND as positive and non-bloody ND as negative, macroscopic ND 
colour examination had a remarkably higher sensitivity (60.6 vs. 18.2%, 
P<0.001) and only a slightly lower specificity (53.6 vs. 65.0%, P=0.07) when 
compared to cytological ND examination. Only 1 malignant lesion (2.8% (95% 
CI, 0.0%-8.4%)) was designated positive solely by ND cytology and 3 lesions 
(1.6% (95% CI, 0.0-3.7%)) were correctly classified as negative by ND cytology.
Conclusion
Nipple discharge cytology has little complementary diagnostic value. Therefore, 
its routine use for detection of ND-related breast pathology should be 
reconsidered carefully. Nipple discharge cytology may redirect patient 
management well in some cases, but it may confuse work-up in the majority.
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Introduction
Nipple discharge (ND) is the third most frequent complaint of patients visiting a 
breast clinic, being the presenting symptom in 4-7% of cases.1-3 Additionally, it 
accounts for 6-7% of all indications for breast surgery, ranking only second to a 
lump.4,5 To the public the occurrence of ND has been ringing an alarm bell 
announcing breast cancer. However, preoperative risk stratification by a 
minimally invasive diagnostic work-up has proven difficult.3,6 In the past 
decades the concept of pathologic ND has been introduced for this purpose.
Yet, controversy remains concerning the criteria of pathologic ND. 
Several studies regard unilateral, single-duct, spontaneous and persistent 
discharge as pathologic.6-11 As others include expressible1,5,12,13 and bilateral 
ND4,14 as well, reported malignancy rates in pathological discharges range from 
6-29%.
In addition, it has been questioned whether discharge colour correlates 
to histological diagnosis. Some authors reported higher malignancy rates in 
bloody ND,6,13 whereas others found no association.8,11,14
Traditionally, pathologic ND is evaluated by cytological examination of 
fluid smears. Although there are additional diagnostic clues in a majority of 
cases,4,15 ND smears may detect malignancy reliably when other clues are 
absent. It is questionable however, how often this is the case.
The unique contribution of cytology to diagnosing pathologic ND has 
never been investigated. The present study aimed to retrospectively evaluate 
the diagnostic accuracy of ND cytology by means of correlation with 
unequivocal positive or negative signs found by other diagnostic modalities. A 
further hypothesis was that solely examining macroscopic ND colour would at 
least be as accurate as the cytological examination of an ND smear.
Materials and methods
Study population
We included all patients presenting with unilateral spontaneous and 
expressible ND from whom material for cytology was obtained. As spontaneous 
ND may be temporarily absent at clinical presentation, we also included 
expressible ND. The patients were seen in a regional teaching and a regional 
non-teaching hospital. Following exclusion of patients that were pregnant (n = 
9), lactating (n = 3) or had bilateral discharge (n = 98), a 618-patient series 
remained eligible for analysis. We did not include patients with bilateral ND
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since this does not usually raise clinical suspicion of focal breast pathology. We 
included only patients who had ND smears until August 1, 2006, allowing for a 
minimal follow-up of 2 years. We chose this time interval because more than 
40% of ND-secreting breast cancers in our group were excised more than 1 year 
following the ND smear.
Data collection
We searched patient files for clinical and radiological findings. We extracted 
pathology data from the Dutch nationwide pathology data network and archive 
(PALGA).
We noted the macroscopic colour of the discharge. For purposes of 
comparing diagnostic accuracies, we considered bloody ND as suspect for 
malignancy. A positive physical examination was defined as either a palpable 
mass, nipple retraction or pagetoid nipple aspect. Mammographic criteria for 
malignancy included irregular microcalcifications or a spiculated or irregular 
mass, whereas well-demarcated masses, polycystic architectural disturbance 
and gross microcalcifications were considered benign lesions. Ultrasound 
malignancy criteria were echogenic lesion within a dilated duct or a mottled 
hypoechoic architectural disturbance. We considered duct dilatation without a 
mass as benign.
ND acquisition and interpretation
Surgeons obtained ND by gently pressing the areola. ND was directly smeared 
onto a specimen slide and either fixated in ethanol 95% and Papanicolaou- 
stained, or air-dried and Giemsa-stained.
Pathologists assigned each smear one of the National Cancer Institute- 
recommended diagnostic categories: benign, atypical, suspicious or 
malignant.16 A specimen was diagnosed 'benign' if no or few epithelial cells 
were present. Specimens diagnosed 'malignant' contained several dyscohesive 
clusters of anaplastic cells and, optionally, a necrotic background. For accuracy 
calculation, benign ND was considered negative for malignancy, while both 
suspicious and malignant ND were considered positive. Although not 
conclusive, suspicious cytology leads to further diagnostic evaluation, in fact 
bearing the same consequence as a malignant diagnosis.
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Histology
We correlated smears to their later histological diagnosis if established within 5 
years following cytology. Ductal carcinoma in situ (DCIS) and invasive ductal and 
lobular carcinoma (IDC and ILC, respectively) were considered malignant. In 
spite of carrying increased risks of malignant degeneration,17-19 we designated 
atypical ductal hyperplasia (ADH) and papillomas as benign.
Twelve staff pathologists with 6-20 years of cytopathological 
experience examined both cytological and histological specimens. Clinical 
information or a prior cytological diagnosis was available to the pathologists.
Statistical analysis
We calculated sensitivity and specificity of ND cytology, as well as unique 
sensitivity and specificity. We defined unique sensitivity as the proportion of 
malignancies that was detected solely by cytology and unique specificity as the 
proportion of benign breast lesions that was designated malignant by 
examination, mammography and ultrasound, but benign by cytology.
We ran Chi-square and Fisher's exact tests for comparing proportions, 
whereas 95% confidence intervals (95% CI) for proportions were calculated by 
the Clopper-Pearson method.20 We used SPSS 14.0 software for calculations.
Results
Patients' characteristics and histology
From January 1, 1992 to August 1, 2006, approximately 24,000 new patients 
had visited the study centres. During this period 618 eligible ND smears were 
made (2.6%).
In this group median age was 50 years (range, 20-86) and 614 patients 
were women. Of these, 163 had histological follow-up, which we further 
analysed. Histology comprised excision or mastectomy in 160 cases and core 
needle biopsy in 3 cases. Median time between cytology and histology was 50 
days (range, 0-1627). Overall, solitary papilloma was the most frequent surgical 
finding (n=51). Malignancy was identified in 36 cases in this group, of which 19 
tumours were DCIS, 2 were pT1a, 3 were pT1c, 7 were pT2, 3 were pT3 and 2 
were pT4b. Five tumours were grade 1, 12 were grade 2 and 19 were grade 3.
89
Chapter 6
Ch
ap
te
r 
6
No previous diagnoses of breast cancer had been established in these women.
Ta b l e  1. S m e a r  d ia g n o s e s  in  m a l ig n a n t  a n d  b e n ig n  b r e a s t  l e s io n s
PRESENTING WITH NIPPLE DISCHARGE (N=163)
Histology
Cytological diagnosis Benign Malignant
Benign 66,1% 50,0%
Atypical 27,6% 33,3%
Positive 6.3% 16.7%
Overall diagnostic accuracy
Measures of cytological diagnostic accuracy are noted in Table 1. ND smears 
detected 5 of 36 malignancies and 84 of 127 benign lesions (Table 1). Malignant 
lesions showed somewhat higher rates of positive and atypical cytological 
diagnoses. Nevertheless, ND smear diagnosis did not significantly predict the 
histological nature of the ND-causing breast lesion (x2=5.0, P=0.082).
ND colour
In smears with available ND colour and histology data (n=156), cytological 
analysis of bloody ND had similar sensitivity (Fisher's exact P=0.66) and lower 
specificity (x2=7.2, P=0.007) when compared to otherwise coloured ND (Table 
2).
Table 3 shows comparative sensitivities and specificities of macroscopic 
examination of ND colour alone and ND cytology in the same group as was 
analyzed in Table 2. The sensitivity of colour examination was higher than the 
sensitivity of cytological examination (x2=12.4, P<0.001). For specificity, no 
significant difference was found (x2=3.3, P=0.069).
Ta b l e  2 . S m e a r  a c c u r a c y  in  c a s e s  o f  b l o o d y
AND NON-BLOODY DISCHARGE (N=156) *
Bloody Non-bloody
Sensitivity 15.0% 23.1%
Specificity 52.6% 75.8%f
* For cases with available colour data only
f P<.01 for smear specificity in bloody vs. non-bloody discharge
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Ta b l e  3 . D ia g n o s t ic  a c c u r a c y  o f  m a c r o s c o p ic  d is c h a r g e  c o l o u r  
a n d  c y t o l o g y  (n = 156) *
ND color1" Cytology
Sensitivity (95% CI) 60.6% (43.0-78.2%) 18.2% (4.3-32.1%)*
Specificity (95% CI) 53.6% (44.7-62.6%) 65.0% (56.5-73.6%)
* For cases with available colour data only
f When regarding red discharge as positive and non-red discharge as negative
* P=.001
Com plem entary diagnostic value
In the histology group data on clinical examination were available for all 163 
cases. Mammography, ultrasound and FNA were performed in 155, 106 and 10 
cases, respectively.
Sixty-one patients had a lump on clinical examination. No breast lesion 
was detected by physical examination and imaging in 50 cases. Of these 
patients, 8 (16%) turned out to have breast cancer. Of all malignant lesions, 8 
were designated benign by each of these diagnostic modalities, if performed 
(Table 4). Of these, 1 ND smear was still able to detect malignancy, thus 
carrying a unique sensitivity (95% CI) of 2.8% (0.0-8.4%). In addition, 4 smears 
were diagnosed as atypical, apparently necessitating histological biopsy in 
these cases. In 2 benign lesions the ND smear was the only negative diagnostic 
finding, indicating a unique specificity (95% CI) of 1.6% (0.0-3.7%). Yet, no 
mammography was performed in 1 of these cases.
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Ta b l e  4 . D ia g n o s e s  o f  n ip p l e  d is c h a r g e  s m e a r s  in  c a s e s  w it h  c o n c o r d a n t  
f in d in g s  o n  p h y s ic a l  e x a m in a t io n ,  m a m m o g r a p h y ,  
u l t r a s o u n d  a n d  f in e  n e e d l e  a s p ir a t io n
Histology
Benign (n=127) Malignant (n=36)
All other modalities* positive 2 2
- negative cytology 2 2
- atypical cytology 0 0
- positive cytology 0 0
All other modalities* negative 76 8
- negative cytology 48 3
- atypical cytology 25 4
- positive cytology 3 1
* Examination, mammography, ultrasound and fine needle aspiration (if 
performed)
Discussion
The present series shows that ND smears had a very low complementary 
diagnostic value in both benign and malignant breast lesions that cause 
pathologic ND. Still, smears of ND are performed in many centres because they
o a/  21 23
may incidentally detect a carcinoma.9,11,14,21-23 The rationale for this is that 
although cytology carries a low sensitivity, a positive finding is alarming all the 
same because of its acceptable specificity. Furthermore, the ease of obtaining 
ND and preparing a smear has led to its common use for cytological 
examination.
Potential advantages of ND cytology
The group where the potential advantage of cytology lies is small but 
interesting for it includes those patients with discharging lesions that lie too 
deep for detection by palpation or too well hidden in a dense breast for 
conventional imaging.2,24,25 Early cytological detection of breast cancers in this 
group may limit the extent of surgical and adjuvant therapy and improve 
prognosis. Nevertheless, relatively low malignancy rates are found in these 
patients in the present (16%) and other studies (0-13%),6,9,11,26,27 which partly
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explains the low unique sensitivity of cytology. Over a 14.5-year period, with an 
estimated total of 1450 breast cancers being treated in the two study centres, 
only one patient with breast cancer received timely surgery solely due to 
positive cytology (2.8% of all breast malignancies presenting with ND). In other 
studies on ND cytology unique sensitivities of 5-7% were found.12,14 Cytology 
yielded the only negative finding in 2 out of 127 benign lesions, but these 
patients were still operated on. This indicates ignorance of negative cytology 
findings if they are not concordant with other diagnostic findings, as has been 
advocated before.23,28,29
O ther diagnostic m odalities
Actually, addressing ND with cytology may prove to be a futile adjunct to simple 
and more accurate diagnostic aids. Of patients with unilateral ND there is no 
clinical and radiological evidence of a breast lesion in only 25%. Reported 
sensitivities of physical examination, mammography and ultrasound range from 
5-94%, 10-91% and 36-83%, respectively, whereas specificities of 50-93%, 38­
99% and 12-68% have been reported, respectively.1,4,5,7,8,10,11,24,26,30 Although
mammography and ultrasound are independent predictors of malignancy,11 
cytology is not (Table 1), as emphasized by its low unique sensitivity and 
specificity (Table 4).
When disregarding other diagnostic modalities, cytology has an 
extremely low sensitivity (16.7%) and a low specificity (66.1%, Table 1). 
Reported sensitivities and specificities range from 11% to 82% and 81% to 
100%, respectively.4,5,7,9,11-14,30,31 The fairly large differences with the present 
findings may in part be explained by the defined length of histological follow- 
up. Other studies may have adhered to a shorter maximum time interval of 
cytology to histology, thereby selecting those patients with advanced disease 
where cytological diagnosis may be easier. Determining if a late histological 
diagnosis explains the ND is hard and arbitrary. However, cancers can grow 
slowly over years and may still be identified after more than 10 years after 
clinical presentation.32 The high number of false-negative diagnoses may be the 
result of (1) only 1-5% of breast cancers producing ND 26,28 and (2) cancer cells 
not always being present in ND.33 Further complicating the matter, the odds of 
malignancy cannot be reliably estimated on the basis of the degree of atypia, 
since discharged cells degenerate in the secreting duct.12 False-positive results
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are less frequent and may in part result from discharged atypical papilloma
cells.14
M a croscop ic ND examination
In fact, even the examination of macroscopic ND colour alone may be a 
valuable alternative to ND cytology (Table 3). When bloody ND is considered 
positive for malignancy, ND colour examination has a remarkably higher 
sensitivity (60.6% vs. 18.2%, respectively) and only a slightly lower specificity 
(53.6% vs. 65.0%, respectively) when compared to ND cytology. In the presence 
of a test that could replace cytology for its specificity, such as physical 
examination, no single adjunctive benefit of cytology would remain.
Yet, in order to maximize their diagnostic yield, ND colour and cytology 
are used in conjunction with each other. Although most of the research on the 
two subjects has considered them separately, one study states that cytology is 
only useful in the diagnosis of bloody ND.22 Surprisingly, in the present study 
cytological examination of bloody ND has a lower specificity than otherwise 
coloured ND (Table 2). Cytology sensitivity was also lower for bloody ND, but 
this difference was not significant. This indicates a low relevance of cytology for 
clinically high-risk ND, mainly complicating diagnostic decision-making in these 
cases.
Study properties and im plications
An acknowledged limitation of this study is its retrospective nature. ND 
characteristics, such as colour, bilaterality and spontaneity were obviously 
subjective. Moreover, these and other variables vary greatly in time in a 
substantial portion of ND patients. This may also clarify the many contradicting 
results in this field of research.
Regardless of its retrospectively established (unique) diagnostic 
accuracy, the role of ND cytology in clinical decision- making is questionable. Of 
course, clinicians should not rely on cytology alone. However, many authors 
still regard it as 'useful' in cancer detection. This notion is reflected by the 
current data as well. Suspect cytological diagnoses tend to be quickly followed 
by surgery, implying the clinician's urge to obey cytological warnings. However, 
cytology does not predict surgical outcome (Table 1).
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Conclusion
In conclusion, nipple discharge smearing and its cytological examination have 
little complementary diagnostic value. Therefore, its routine use for detection 
of ND-related breast pathology should be reconsidered carefully. Nipple 
discharge cytology may usefully redirect patient management in some cases, 
but it may confuse work-up in the majority.
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A b s t r a c t
Objective
To determine the value of cytology in the workup of male breast lesions, 
important for the management in a same-day breast clinic
Study Design
A total of 146 fine needle aspirations (FNAs) from the male breast were 
classified in the categories malignant, suspicious, atypical, benign and 
inadequate. Cytohistologic correlation was done.
Results
Histologic correlation was available in 85 cases. On FNA the 15 malignant cases 
were classified as malignant (n=11), suspicious for malignancy (n=2) or atypical 
(n=2). Of the 35 benign lesions on histology 3 cases were classified as atypia 
and 1 as suspicious for malignancy on FNA. In the inadequate FNAs (n=45), the 
corresponding histologic specimens were benign, no carcinomas were 
diagnosed. The sensitivity and specificity of the FNA compared to the definite 
resection diagnosis were 100% and 90.2%, respectively. The results were 
comparable with the outcomes of the reviewed studies on male breast lesions 
in the recent literature.
Conclusions
Based on the nature of the benign breast lesions in man, a substantial number 
of inadequate FNAs were obtained. However, due to the good cytohistologic 
correlations in the group of malignant lesions, we can conclude that cytology 
remains an important diagnostic tool in the initial workup of male breast 
carcinomas.
100
Introduction
Fine needle aspiration (FNA) cytology has proven to be a quick, accurate and 
cost-effective method in the work-up of all sorts of tumours from a variety of 
body sites.1 Despite the emerging role of the core needle biopsy (CNB), the 
FNA continues to be a useful tool in the initial evaluation of breast masses.2 
However, the core wash or core imprint technique is gaining in popularity since 
these techniques generate a quick preliminary cytological diagnosis, which is 
important for same-day patient counselling, while the histological diagnosis 
follows within 24 hours.
Tumours of the male breast, especially carcinomas, are rare as 
compared to breast cancer in women. In the Netherlands, the incidence of 
breast carcinoma in men is 0,9 per 100.000 men compared with 126,7 per
100.000 women (data from the Dutch Cancer Registry 2006). The initial work­
up of a suspicious breast lesion in men is the same as is used for the female 
breast. In case of asymmetry or a suspicious mass FNA cytology is performed.
A limited number of studies have addressed the problems and pitfalls 
associated with male breast cytology.3-9 In this study we looked at the possible 
diagnostic problems which cytology can yield in the male breast lesions and 
how to deal with them. In this regard, we focussed on the proportion of non­
diagnostic and atypical FNAs as both items preclude proper decision making. 
Does the moderate to severe atypia often seen in gynecomastia, lead to false 
positive results in the FNA diagnosis?
The results of FNA male breast cytology over the past 16 years in our 
institute are used in addition to a critical review the literature from 2001.6,7,9
Materials and methods
All male breast FNAs, available CNBs and surgical specimens at our laboratory 
from January, 1993 to January, 2009 were identified through the national 
pathology database of the Netherlands (PALGA). The analyses of the current 
retrospective study were based on specimens of patients visiting a regional 
teaching hospital and a regional non-teaching hospital. In both hospitals breast 
patient care is managed according to national guidelines. Cytological 
specimens were obtained by surgeons and radiologists. Either a 21- or a 23- 
gauge needle was used for aspiration. Before 1997 the aspirate was smeared 
onto a slide and instantly fixated in ethanol 95% to a conventional smear. After 
1997, most FNAs were liquid based preparations (LBP). In this cytospin
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technique the cells were rinsed from the needle and syringe into a vial and 
directly fixated in an ethanol 50%, polyethylene glycol 2% solution. A 
cytocentrifuge procedure was applied, creating a monolayer arrangement of 
all cells within a 0.12 cm diameter area.8 Both smears and LBP slides were 
Papanicolaou-stained.
The slides were screened by cytotechnologists and examined by 10 
staff cytopathologists with 6-20 years of experience in cytopathology. Using 
simple and well-defined criteria, they classified each aspirate into one of the 5 
diagnostic categories as proposed by the 1996 National Cancer Institute- 
sponsored conference approach: malignant, suspicious for malignancy, 
atypical, benign and inadequate.10 We calculated the complete sensitivity as 
positive cases on FNA (atypia, suspicious for malignancy and malignant) 
divided by positive cases on histology (carcinoma or DCIS), the absolute 
sensitivity as the malignant cases on FNA divided by the malignant cases on the 
final histology and specificity as negative cases on FNA (benign) divided by 
non-malignant cases on histology. Inadequate specimens were left out of 
accuracy calculation.
The gender was always known to the pathologist at the time of the 
cytopathological examination. Further information regarding the clinical 
presentation of the breast lesion was mostly available to the pathologist. The 
cytological diagnoses were correlated with the available histological findings. 
The inadequate cases were reviewed independently by two pathologists and 
scored in four groups: no material, only blood, only some stromal elements and 
less than 6 epithelial cell clusters. These outcomes were correlated with the 
available clinical information.
In order to put our figures in perspective, we compared our study with 
three recent published male studies. We performed some recalculations in the 
quoted 3 studies for valid comparison and we only included the cases with 
available histology, the metastatic lesions were left out.6,7,9
RESULTS
From January 1993 to January 2009, a total of 8,483 FNAs of the breast were 
examined. One hundred forty seven FNAs (1.7%) were from 146 male breasts. 
They all underwent a unilateral FNA cytology. The median age was 53 years 
(range, 15-95). The median time interval between FNA and histology was 21 
days.
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Satisfactory aspirates were obtained in 101 of the 146 cases. These 
were categorized as benign in 78 cases, atypical in 9 cases, suspicious for 
malignancy in 3 cases and malignant in 11 cases. Forty-five of the 146 cases had 
unsatisfactory aspirates, which were not useful for cytological examination. 
Histological examination on excisions, biopsy or mastectomy specimens were 
available in 85 of the 147 FNA cases (Table 1).
Ta b l e  1. C o r r e l a t io n  o f  85 f in e  n e e d l e  a s p ir a t io n  c y t o l o g y  d ia g n o s e s  w it h
THE CORRESPONDING HISTOLOGICAL DIAGNOSES
Histological FNA diagnoses
diagnoses
Malignant Suspicious Atypical Benign Inadequate
Primary breast 
carcinoma
11 2 2
Metastasis 1
Gynecomastia 1 3 25 15
Infection 8 3
Lipoma or fatty 2 3
tissue
Fibrosis 4
Others 2 3
Total 12 3 5 37 28
Fifteen of the 16 histologically documented malignant cases were 
primary male breast carcinomas, including 14 infiltrating ductal carcinomas and 
one apocrine carcinoma. One malignant tumour was a metastatic 
neuroendocrine lung tumour. The clinical presentation of the primary breast 
carcinomas suggested in 11 cases a palpable tumour, suspect for carcinoma, in 
one case a palpable tumour probably benign, 2 cases with a palpable tumour 
not otherwise specified and one case a lesion suspect for a cyst. The 
corresponding FNA diagnosis was malignant in 11 cases, suspicious for 
carcinoma in 2 cases and atypical in 2 cases. One FNA diagnosis suspicious for 
carcinoma showed on slide only a few atypical cells, the other showed
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proliferating duct epithelium with atypia. In the 2 atypical cases on FNA, once a 
tumour of the cutaneous appendages was suggested on cytology, the other 
atypical case was the only apocrine carcinoma on histology.
Of the 78 cases reported cytologically as benign, histology was available 
in 37 cases. All 37 cases were benign lesions, with 25 cases reported as 
gynecomastia, 8 cases as infections, 2 cases as lipoma or fatty tissue, one case 
as syringomatous adenoma of the nipple and one case showed normal tissue 
on histology.
The 29 cases of gynecomastia on histology had an adequate FNA. The 
clinical information with the FNA suggested in 4 cases a malignant tumour, in 3 
cases a benign tumour, in 16 cases gynecomastia and in one case a lipoma. In 5 
cases no clinical information was available. The case suspicious for malignancy 
on FNA and gynecomastia in the final histological diagnosis, had no clinical 
data. The clinical information of the 3 atypical cases on FNA suggested in two 
cases a gynecomastia and in one case the clinician suspected a malignancy.
Of 45 cases diagnosed unsatisfactory or inadequate on FNA, 28 cases 
had histological follow-up. The 28 specimen revealed 15 gynecomastia cases, 3 
infection cases, 3 lipoma cases or fatty tissue, 4 fibrotic tissue cases, one 
haemangioma, one benign cyst and one biopsy was not representative. For the 
17 cases without follow-up we checked the national pathology databank, no 
carcinomas were seen.
The inadequate specimens were reviewed. In 14 cases no cell material 
was seen, in 15 cases only blood, in 5 cases only some stromal elements and in 
3 cases less than 6 epithelial cell clusters. Two cases were not available in the 
archive. The clinical information suggested a malignancy in 7 cases, a benign 
tumour in 12 cases, in 11 cases there was no clinical judgement about the 
palpable lesion, a gynecomastia was suspected in 9 cases, an infection in 4 
cases, a lipoma in one case and a cyst in one case (Table 2).
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Ta b l e  2. Th e  r e v ie w e d  4 5  in a d e q u a t e  f in e  n e e d l e  a s p ir a t io n s : c o r r e l a t io n  b e t w e e n
THE CLINICAL INFORMATION (VERTICAL) AND THE DEFINED CYTOLOGICAL CATEGORIES (HORIZONTAL) 
WITH THE AVAILABLE HISTOLOGICAL FOLLOW-UP
Clinical information Cytological score
No material Blood Stroma < 6 epithial No slides
cell clusters
N Histology N Histology N Histology N Histology N Histology
Malignant tumour 3 i  gyn 2 i  gyn 1 1 infect 1 1 gyn -
(n=7) 1 liooma
Benign tumour 3 2 gyn 5 i  gyn 2 i  gyn 2 1 gyn -
(n=12) 1 cvst 1 haem 1 not reor
Tumour n.o.s. 2 2 gyn 3 2 fibrosis 1 1 infect 3 1 gyn 2 1 lipoma
1 n=-m
Gynecomastia 4 2 gyn 5 i  gyn - - -
(n=9) 1 liDoma
Infection 2 i  gyn - 1 1 fibrosis 1 1 fibrosis -
(n=4) 1 infect
Cyst/lipoma - - - 2 -
(n=2)
Total 1 1 5 9 2
N indicates the number of cases in the cytological categories; n.o.s., not otherwise specified; gyn, 
gynecomastia; infect, infection; haem, haemangioma; not repr, not representative
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The diagnosis atypia was reported 9 times on FNA. Five cases had 
histological follow-up. Three cases eventually proved to be gynecomastia. In 2 
cases a diagnostic CNB revealed breast cancer, followed by a mastectomy.
The absolute sensitivity was 71.4 %, the complete sensitivity was 100%. 
The specificity was 90.2%.
Review o f the recent literature
Westenend et al. included 153 FNAs of the male breast out of a group of 'more 
than 10,000 FNAs' during a period of 15 years (approximately: 1.5%).9 One 
hundred forty one samples were from unilateral lesions. Of all male breast 
FNAs 9.8% were primary malignant breast tumours. In the unsatisfactory FNAs 
(18, 11.7%) no carcinoma or DCIS was found. The amount of atypical or 
suspicious for malignancy cases on FNA with related histology were not 
mentioned, however the sensitivity was 100% and the specificity was 89% 
when the inadequate FNAs were excluded (Table 3).
Siddiqui et al. reported 520 diagnostic aspirates from a palpable lump 
in a male breast out of a total group of 14,026 breast FNAs (male and female, 
3.7%) in a period of 10 years.7 All aspirates of the male breast were from 
unilateral lesions. The FNAs revealed malignancy in 32 cases. Fifteen cases were 
breast carcinomas, however only 14 were primary breast carcinomas (ductal 
carcinoma not otherwise specified) with corresponding histology. In 170 cases 
histology was available. Of all male FNAs 6.1% were malignancies, only 2.8% 
were primary male breast carcinomas. On FNA atypia or suspicious for 
malignancy was diagnosed in 61 cases. The corresponding histology was 
available in 57 cases and revealed 7 carcinomas and 2 DCIS cases. Ninety four 
(15.4%) cases were unsatisfactory on FNA, the corresponding tissue diagnosis, 
available in 21cases showed one DCIS and one carcinoma. Considering 
malignant, suspicious for malignancy and atypia on FNA as positive the 
calculated sensitivity was 95.3% and the specificity was 100%.
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Ta b l e  3. R e s u l  t s  o f  t h is  s t u d y  in  c o m p a r is o n  w it h  t h e  s t u d ie s  o f  
W e s t e n e n d  e t a l . ,9 S id d iq u i  e t a l . ,7a n d  M a c in t o s h  e t a l .6
2002
Westenend9
2002
Siddiqui7
2008
Macintosh6
2009 
This study
Male FNAs (n , % of
153 (1.5) 614 (4.3) 138 (3.2) 147 (1.7)
all breast FNAs)
Histological follow-up 
(n, %)
72 (47.0) 170 (27.7) 23 (16.7) 85 (57.8)
Malignant FNA 
(n, % of primary 
breast carcinomas)
15 (9.8) 26 (2.8)* 11 (7.9) 15 (10.2)*
Unsatisfactory FNA 
(n, %)
18 (11.7) 94 (15.4) 46 (33.3) 45 (30.6)
Unsatisfactory FNA 
with histological 
follow-up (n)
10f 21 f * 28
Sensitivity (%) 100 95.3 95.5 100
Specificity (%) 89 100 100 90.2
* The metastases were excluded in the calculations.
f In both studies the inadequate FNAs revealed 2 carcinomas in the follow-up. 
*Jhe unsatisfactory or inadequate cases were not discussed in this study.
Macintosh et al. studied with 2 groups of observers the accuracy and 
reproducibility of the FNA on the male breast and is the third large study on 
male breast carcinomas since 2001 we compared.6 They reported on 138 
breast FNAs performed on 123 male patients. One third, 46 FNAs (33.3%) were 
unsatisfactory. Histological correlation was available for 23 satisfactory FNAs. 
Eleven cases were primary breast carcinomas on histology. The corresponding 
FNAs were malignant in 7 cases and suspicious for malignancy in 4 cases. The 
12 benign cases showed on FNA unremarkable or proliferative in 11 cases and 
atypical in 1 case by one group of observers, the other group considered all 
corresponding FNAs unremarkable or proliferative. The sensitivity was 95.5% 
and the specificity was 100%.
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The sensitivity calculated in the three studies was only the complete 
sensitivity, the absolute sensitivity was not available.
DISCUSSION
In this study, 1.7% of all breast FNAs were from the male breast. Of all large 
cytology studies of breast lesions, FNA on the male breast constitute 1.5 to 
4.3% of the total cases.3-9 The majority of male breast lesions turned out to be 
benign. Although the incidence of male breast carcinomas is increasing, it still 
remains a very rare condition as compared to the incidence in females.3-9,11 In 
our study 10.2% of all male breast FNAs were primary malignant tumours, one 
lesion was metastatic. The complete sensitivity and the specificity of the FNA 
compared to the definite resection diagnosis were 100% and 90,2%, 
respectively.
Because the last review of the literature on male breast lesions dates 
from 2001, we compared our results with those of three large studies since 
2002 (Table 2).6,7,9 In line with these studies we considered atypia, suspicious 
for malignancy and malignant as a positive result and benign as a negative 
result. In order to compare the data, it was necessary to draw one line, 
although, we were aware that the further work-up of the breast lesion is 
different for atypia and suspicious for malignancy than for the FNA diagnosis 
malignant. After all, the latter result does not need a complementary core 
needle biopsy.
Our study and the study of Westenend et al. showed the highest 
percentage of primary breast carcinomas diagnosed on FNA cytology, 10.2 and 
9.8% respectively. Siddiqui et al. had only a percentage of 2.8%. As shown in 
Table 2, the sensitivity ranged from 89.7 to 100%. The specificity of 90,2% in 
our study was due to 4 false positive FNA diagnoses on gynecomastia. 
Gynecomastia is the most common cause of masses in the male breast, which 
is defined as the enlargement of the male breast due to proliferation of both 
glandular and stromal elements.12 According to the literature and the 
cytological textbooks, gynecomastia may present on FNA with dyshesive 
groups and sheets of ductular cells with moderate to severe nuclear atypia.3,8 
Because of these cytological criteria, one should expect many cases of atypia 
on FNA.
Westenend et al. mentioned less than 1% atypia and the other two 
studies did not report the frequency of atypia as a diagnostic diagnosis group.
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In our study, atypia was diagnosed in 11 cases on FNA. Five cases had 
histological follow-up. Two cases were carcinomas on histology and 3 were 
gynecomastias. Our study showed 44 cases of gynecomastia. One case was 
diagnosed as suspicious for malignancy and in 3 cases the diagnosis atypia was 
reported on FNA. Malignant was never the FNA diagnosis in cases of 
gynecomastia. So, in contrast to what was expected, we can conclude that in 
practice the diagnosis gynecomastia did not give much challenge on FNA. 
However, gynecomastias render a substantial number of unsatisfactory or 
inadequate cases on FNA. As showed, 15 of the 44 cases were inadequate 
(Table 2). In line with the other authors who also had this high percentage of 
unsatisfactory cases, we think it is due to the nature of the lesion 
gynecomastia and not to the FNA technique itself.
All studies showed many unsatisfactory cases, ranging from 11.7% to 
33.3%.6,7,9 In our study we had 45 (30,6%) unsatisfactory cases on FNA. 
However, in the clinical presentation only seven times a malignant lesion was 
suspected. Twenty-eight cases had a histological follow-up and no carcinomas 
were observed. The unsatisfactory cases in the studies of Westenend et al. and 
Siddiqui et al. had both 2 carcinomas on histology. MacIntosh et al. did not 
discuss the unsatisfactory or inadequate samples.
Since the last decade, the CNB has been introduced and for several 
reasons is preferred in the work-up of breast lesions. However, in order to 
obtain a quick preliminary diagnosis, essential for the management of the one- 
day breast clinic, core wash or touch imprint cytology of the core needle 
biopsy can be done, for it can provide a diagnosis within half an hour. 
However, the interpretation of the slides obtained by the wash or imprint 
techniques are still based on the cytological criteria of the FNA. In this respect, 
we can combine the benefits of both modalities in the future.
In conclusion, despite not yielding a conclusive diagnosis in a 
substantial number of cases, the high sensitivity and specificity justifies 
primarily opting for cytology in the initial diagnostic work-up of male breast 
lesions.
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A b str a c t
Background
Core wash or touch imprint cytology is often used to obtain a quick, preliminary 
diagnosis on a core needle biopsy (CNB) of breast lesions, essential for the 
management of a one-day breast clinic. Contradictory results of both 
techniques in the literature led to this preclinical study investigating an 
alternative method of touch imprint and core wash cytology.
Methods
Thirty breast lesions were biopsied by a core needle in a laboratory setting. The 
CNBs were collected in RPMI fluid (Roswell Park Memorial Institute fluid). The 
touch imprint cytology was performed taking the biopsy out of the fluid and 
smearing it on a microscopic slide and May-Grunwald Giemsa stained. The core 
wash cytology specimen was made by fixating the remaining cells in Fixcyt and 
prepared with a liquid-based preparation method and Papanicolaou stained. 
The cytological findings were categorized into benign, atypical favouring 
benign, atypical, suspicious, and malignant and were compared with the 
histological CNB results.
RESULTS
The CNBs showed 20 of 30 samples to be malignant, 2 to be phylloides 
tumours, 7 to be benign, and 1 to be unsatisfactory. Both techniques showed a 
sensitivity of 95% and specificity of 100%. Touch imprint yielded more 
insufficient diagnoses (13.3%), compared with core wash (6.6%). Of the core 
wash cases, 86% showed a good quality versus 30% of the touch imprint cases.
Conclusions
This preclinical study on modified touch imprint and core wash techniques led 
to results that were comparable to or better than those in the literature. The 
core wash cytology is preferred to touch imprint because of the better 
morphology.
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Introduction
Fine-needle aspiration (FNA) cytology is frequently used in the instant diagnosis 
of breast lesions. The histological diagnosis, however, gains importance in the 
initial diagnostic workup. A core needle biopsy (CNB) is often preferred to 
cytology because it can provide more information about the tumour 
characteristics, precise type of carcinoma, and hormonal and other receptor 
status.
However, CNB diagnosis requires 24 hours of processing whereas 
cytology can allow diagnosis within 1 hour. A quick, reliable preliminary 
diagnosis is very important for same-day patient counselling and expedites the 
planning of further surgical or neoadjuvant management. Immediate diagnosis 
of breast lesions is also useful for alleviating patient anxiety. Most patients 
prefer to receive their results on the same day as their tests.2-6
Core wash in a saline solution or touch imprint cytology could be an 
answer to this problem. There are several studies about touch imprint cytology 
derived from CNBs in breast lesions. The sensitivity and specificity vary from 
74%-100% and 83.7%-100%, respectively.1-4,7-9 The described procedures, 
however, result in a substantial proportion of unsatisfactory samples.
It was recently stated that core wash cytology was not useful at all for 
the immediate diagnosis of breast lesions by ultrasound-guided CNB.6 A 
sensitivity and specificity of 89% and 75%, respectively, was shown, with a 42% 
unsatisfactory rate.
In trying to integrate a rapid preliminary diagnosis with CNB, both core 
wash and touch imprint techniques were modified. The touch imprint 
procedure and a modified core wash procedure were tested in an in vitro 
laboratory setting. The cytological results were correlated to the CNB histology.
Materials and methods
In a laboratory setting, 30 lesions in 27 surgical resected breast specimens 
(lumps, mastectomies) were biopsied before fixation by 1 cytological technician 
or 1 pathologist. Two to 3 CNBs per lesion were obtained in 18 in vivo palpable 
and 12 nonpalpable breast lesions with an 18-gauge needle (Bard Needle 
Monopty, eGeneral Medical Inc., Murray Hill, NJ) and biopsy gun. No ultrasound 
guidance or other imaging techniques were used.
Uniquely and in contrast to other preparation manuals, the biopsies 
were collected in 6 mL RPMI medium (Roswell Park Memorial Institute,
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Invitrogen, Breda, the Netherlands). To each 500 mL, 0.5 grams of Natrium­
azide (Sigma-Aldrich Chemie B.V., Zwijndrecht, the Netherlands) and 5 grams of 
bovine serum albumin was added. The biopsies stayed in this mixture for 5-10 
minutes. The needle tip was rinsed in the medium.
The touch imprint cytology preparations included carefully taking the 
biopsy out of the medium and smearing it on a microscopic slide. The touch 
imprint slides were air dried and May-Grunwald Giemsa stained.
After this, the biopsy was fixated in formalin, paraffin embedded, and 
H&E stained.
The core wash cytology preparations included fixing the remaining cells 
in the medium in 2 mL Fixcyt (50% ethanol and 2% polyethylene glycol solution) 
for 10 minutes. According to the operator manuals, this mixture was 
centrifuged for 10 minutes at 688 rpm in a Hettich Rotina 48S or Hettich 
Rotanta 46S centrifuge (Andreas Hettich GmbH & Co.KG, Tuttlingen, Germany). 
Supernatant was discarded. Depending on the estimated density of the 
sediment, 1 or 2 drops of the ethanol 50% and polyethylene glycol 2% solution 
were added. The resultant mixture was dripped into a bucket that was clasped 
on a polysine slide (Menzel GmbH, Braunschweig, Germany). By centrifuging for
5 minutes at 688 rpm, the sediment was pressed onto the slide, creating a
10monolayer arrangement of all cells within a 12 mm diameter area. The liquid 
based preparation slides were Papanicolaou-stained.
To quantify the quality of the cells, we scored the morphology of the 
cells into 3 categories: poor, not optimal, and good. In the case of poor 
morphology, no diagnosis could be made. In the case of suboptimal 
morphology, it was hard but possible to make a diagnosis. As for good 
morphology cases, a diagnosis was easy to make.
The cellularity was also divided in 3 groups: poor (<6 epithelial cell 
clusters), moderate (6-10 epithelial cell clusters), and rich (>10 epithelial cell 
clusters). The presence of more than 6 epithelial cell clusters was required for 
adequate classification.
According to international guidelines for FNA cytology, the core wash 
and touch imprint cytological findings were categorized as follows: benign, 
atypical favouring benign, atypical, suspicious for carcinoma, malignant, or 
inadequate (Table 1). On CNB histological diagnosis, we considered carcinoma, 
suspicious for carcinoma, and ductal carcinoma in situ (DCIS) as positive for
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carcinoma. "Not representative" and "no material" were put in the 
unsatisfactory category.
Ta b l e  1. Ex p l a n a t iv e  t e r m in o l o g y  o f  c o r e  w a s h  a n d
TOUCH im p r in t  CYTOLOGY DIAGNOSIS CATEGORIES
Core wash/touch imprint
diagnosis Positive/ Negative Adequacy
Inadequate - Inadequate
Benign Negative Adequate
Atypia favouring benign - Adequate
Atypia - Adequate
Suspicious for carcinoma Positive Adequate
Malignant Positive Adequate
Two experienced observers read the CNB histology and the core wash 
and touch imprint slides in a blinded fashion. The results of the core wash and 
touch imprint cytology were correlated with the CNB diagnosis.
Sensitivity was defined as the proportion of positive and suspicious core 
wash or touch imprint cytology cases in malignant lesions (which include DCIS, 
carcinoma, and suspicious for carcinoma) on CNB histology. Specificity was 
defined as the number of negative core wash or touch imprint cytology cases 
divided by the number of positive and negative cytology specimens with 
subsequent benign histology on CNB. Unsatisfactory cases were left out of the 
calculations.
RESULTS
The CNBs were histologically diagnosed as carcinoma (n=17), DCIS (n=1), 
suspicious for carcinoma (n=2), atypical stroma/phylloides tumour (n=2), 
benign (n=7), and not representative/normal breast tissue (n=1). The benign 
category (n=7) comprised fibroadenoma (n=1), fibroadenoma/fibrotic breast 
tissue (n=2), fibrotic breast tissue (n=3), and sclerosing adenosis (n=1).
The core wash specimens corresponding to the 20 malignant CNBs 
were cytologically diagnosed as malignant in 15 cases (75%), suspicious in 4 
cases (20%), and atypia favoring benign in 1 case (5%) (Table 2). The atypia case 
on core wash was suggestive of carcinoma on CNB.
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CORRESPONDING CORE NEEDLE BIOPSY HISTOLOGY
Ta b l e  2. C o r r e la t io n  o f  d ia g n o s e s  o f  c o r e  w a sh  c y t o lo g y  a n d
Core needle biopsy diagnosis
Cytological Positive for Phylloides Benign Unsatisfactory
diagnosis carcinoma
Carcinoma 15 - - -
Suspicious 4 - - -
Atypia - - - -
Atypia favouring 1 2 6 -
benign
Unsatisfactory - - 1 1
Total 20 2 7 1
All atypical cases diagnosed in core wash cytology were atypia 
favouring benign. The phylloides tumours were diagnosed as atypia on core 
wash with the remark of stromal atypia. The sclerosing adenosis case was 
diagnosed as atypia on core wash. The fibroadenoma as found by CNB showed 
atypia consistent with fibroadenoma on core wash cytology. In 2 cases, it was 
not possible to differentiate between fibroadenoma and fibrotic breast tissue 
on CNB. The corresponding core wash specimens revealed 1 unsatisfactory and
1 atypical diagnosis. Fibrotic breast tissue on CNB (n=3) was once diagnosed as 
unsatisfactory and twice as atypical on core wash. The sensitivity was 95% and 
the specificity was 100%.
The touch imprint specimens corresponding to the 20 histologically 
diagnosed carcinomas comprised 15 carcinomas (75%), 3 suspicious (15%), 1 
atypia favouring benign (5%), and 1 unsatisfactory diagnosis (5%) (Table 3). All 
atypia seen in touch imprint cytology was atypia favouring benign. The 
phylloides tumours were also diagnosed as stromal atypia. The CNB diagnosis 
of sclerosing adenosis showed atypia on touch imprint cytology. The 
fibroadenoma had an atypical diagnosis on touch imprint cytology, whereas the
2 "fibroadenoma/sclerosing adenosis" cases were diagnosed as unsatisfactory 
by touch imprint cytology. The cases in which "fibrotic tissue" was found by 
CNB was, touch imprint cytology diagnoses were unsatisfactory (n=1) and 
atypical (n=2). Normal breast tissue on CNB showed atypia on touch imprint 
cytology. The sensitivity was 95% and the specificity was 100%.
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Ta b l e  3. C o r r e l a t io n  o f  d ia g n o s e s  o f  t o u c h  im p r in t  c y t o l o g y  a n d
CORRESPONDING CORE NEEDLE BIOPSY HISTOLOGY
Core Needle Biopsy Histology
Cytological Positive for Phylloides Benign Unsatisfactory
diagnosis carcinoma
Carcinoma 15 - - -
Suspicious 3 - - -
Atypia - - - -
Atypia favouring 1 2 4 1
benign
Unsatisfactory 1 - 3 -
Total 20 2 7 1
Core wash and touch imprint cytology showed almost the same results 
in cellularity. It was poor in 2 core wash cases (7%) and in 3 touch imprint cases 
(10%), moderate in 3 core wash cases (10%) and in 2 touch imprint cases (7%). 
Twenty-five cases (83%) showed a rich cellularity in both core wash and touch 
imprint techniques.
The morphology was poor in 2 core wash cases (7%) and in 4 touch 
imprint cases (13%). Although not optimal, a diagnosis could be made in 2 core 
wash cases (7%) and in 17 touch imprint cases (57%). The morphology was 
good in 26 core wash cases (86%) and in 9 touch imprint cases (30%) (Table 4).
Ta b l e  4. m o r p h o l o g y  Q u a l it y  in  c o r e  w a s h  a n d  t o u c h  im p r in t  c y t o l o g y
Quality Core Wash Touch Imprint
Poor 2 4
Moderate 2 17
Good 26 9
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Discussion
In the initial diagnostic workup, CNB yields more essential information about 
the tumour. However, an evaluation of the tissue sample requires more than 
24 hours of processing. A rapid diagnostic method to cytologically analyze the 
CNB can offer a diagnosis in 1 hour. Only for the price of a touch imprint or core 
wash specimen derived from a CNB, the clinician will be informed about the 
nature of the breast lesion and he will be able to plan further treatment the 
same day.
By using a modified processing technique for obtaining cytology from 
CNB, sensitivity and specificity for both core wash and touch imprint were 95 
and 100%, respectively. The unsatisfactory rate was 6.6% in the core wash and 
13.3% in the touch imprint cytology. In contrast to the literature, the malignant 
tumours were never unsatisfactory in our study.5-7
The diagnostics accuracies of touch imprint and core wash cytology are 
conflicting in the literature. Some authors reported a sensitivity and specificity 
of 85% and 98%, respectively, in their clinical study with core wash cytology, 
using a 16-gauge core needle.5 They had an unsatisfactory rate of 7% and 
regarded the core wash technique as useful for immediate diagnosis. Others 
reported a sensitivity of 89% and a specificity of 72% of core wash cytology. The 
unsatisfactory rate was 42%.6 A quarter of these unsatisfactory core wash 
results had a malignant diagnosis on CNB. The procedure was slightly different 
and they used an 18-gauge core needle. The study was done in a clinical 
setting. They concluded that the core wash technique was not useful for quick 
cytological diagnosis on CNB. A sensitivity and specificity of 100% each was 
seen in a study using an 11-gauge core needle.2
Our results can compete with these studies. However, we are aware 
that about 67% of the lesions in our study were malignant. We even did not 
have to worry about patients' discomfort. Yet, to resemble a clinical setting, we 
took only 2 or 3 CNBs from each breast lesion. The studies performed in the 
clinic had the advantage of ultrasound-guided CNBs. In our study, no 
ultrasound guiding or other imaging techniques were used. The nonpalpable 
lesions were biopsied randomly.
Touch imprint cytology of the CNB has a more widespread use than the 
core wash technique. Some authors use it for evaluation of the quality of the 
CNB only.8 Others use the technique to investigate the possibility of needle 
tract seeding.11 Still, touch imprint is mostly used for providing a preliminary
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diagnosis. The sensitivity ranged from 74%-95%, whereas specificity ranged 
from 97%-100%.1-4'7'9
As in the literature, we also had problems in cytologically classifying the 
benign lesions.1 Possibly, this is caused by the characteristics of these lesions. In 
benign tumours the cohesiveness of the tissue and cells is much higher than in 
malignant lesions.7,11 In our study, the histologically benign diagnosis on touch 
imprint and core wash cytology was noticed as benign or atypia favouring 
benign.
Our study showed slight differences between core wash and touch 
imprint in figures. The unsatisfactory rates were 6.6% and 13.3%, respectively. 
Core wash cytology was unsatisfactory in 1 benign and 1 unsatisfactory CNB. 
Touch imprint cytology was unsatisfactory in 3 benign CNB cases and 1 
suspicious CNB case. However, we are aware that we biopsied a small number 
of lesions.
The better cytological results in both the core wash and the touch 
imprint cytology in our laboratory could probably be attributed to the fact the 
CNB is collected in RPMI medium. The RPMI medium is used for the culture of 
normal and neoplastic human leukocytes. It has demonstrated wide 
applicability for supporting growth in many types of cultured cells. Therefore, it 
is a good medium in which to preserve the loosened cells optimally. This is in 
contrast to saline, which causes swelling of the cells and often leads to bursting 
of the cells.5,11
The better morphology seen in core wash (Table 4) is probably because 
of the finding that the cell material is worked up in a standardized procedure 
that collects all cells in the fluid and that is not operator-dependent.10 The 
quality of the touch imprint cytology is highly dependent on the manual skills of 
the person performing the biopsy and making the touch imprint slides.
Another known advantage of core wash cytology is the microscopic 
evaluation. The cells are pressed in a monolayer arrangement within a 12 mm 
diameter area, whereas the microscopic screenings area with touch imprint 
cytology is the whole slide.
All these arguments turned the scale, in our practice, in choosing the 
core wash procedure at expense of touch imprint.
In conclusion, according to our findings the modified core wash 
procedure can provide a reliable preliminary indication of the CNB results. This
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information is valuable for same-day patient counseling and management 
planning.
References
1. Sneige N, Tulbah A. Accuracy of cytologic diagnoses made from touch imprints of image- 
guided needle biopsy specimens of nonpalpable breast abnormalities. Diagn Cytopathol 
2000; 23: 29-34
2. Fotou M, Oikonomou V, Zagouri F, et al. Imprint cytology on microcalcifications excised by 
vacuum-assisted breast biopsy: a rapid preliminary diagnosis. World J Surg Oncol 2007; 5: 
40
3. Kass R, Henry-Tillman RS, Nurko J, et al. Touch preparation of breast core needle specimens 
is a new method for same day diagnosis. Am J Surg 2003; 186: 737-42
4. Klevesath MB, Fodwin RJ, Bannon R, Munthali L, Coveney E. Touch imprint cytology of core 
needle biopsy specimens: a useful method for immediate reporting of symptomatic breast 
lesions. Eur J Surg Oncol 2005; 31: 490-4
5. Lankford KV, Kluskens L, Dowlatshahi K, Reddy VB, Gattuso P. Utilization of core wash 
material in the diagnosis of breast lesions by stereotactic needle biopsy. Cancer. 1998; 84: 
98-100
6. Uematsu T, Kasami M. Core wash cytology of breast lesions by ultrasonographically guided 
core needle biopsy. Breast Cancer Res Treat 2008; 109: 251-3
7. Farshid G, Pieterse S. Core imprint cytology of screen-detected breast lesions is predictive 
of the histologic results. Cancer 2006; 108: 150-6
8. Green RS, Mathew S. The contribution of cytologic imprints of stereotactically guided core 
needle biopsies of the breast in the management of patients with mammographic 
abnormalities. Breast J 2001; 7: 214-8
9. Jacobs TW, Silverman JF, Schroeder B, Raza S, Baum JK, Schnitt SJ. Accuracy of touch 
imprint cytology of image-directed breast core needle biopsies. Acta Cytol 1999; 43: 169-74
10. Khalbuss WE, Kauff ND, Chuang L, Melamed MR. SpinThin, a simple, inexpensive technique 
for preparation of thin-layer cervical cytology from liquid-based specimens: data on 791 
cases. Cancer 2000; 90: 135-42
11. Uematsu T. Kasami, M. Risk of needle tract seeding of breast cancer: cytological results 
derived from core wash material. Breast Cancer Res Treat 2008; 110: 51-5
122
Chapter 8
Chapter 8
Journal of Bone and Joint Surgery, American Volume 
2009; 91 Suppl 3: 21-6
B. Kooistra, B. Dijkman, T Einhorn, M. Bhandari
125
Chapter 9
Ch
ap
te
r 
9
A b str a c t
A case series is a descriptive study that follows a group of patients who have a 
similar diagnosis or who are undergoing the same procedure over a certain 
period of time. As there is no experimental protocol or control for allocation of 
patients to treatment, surgeons and patients decide on whether or not 
treatment is given, making the clinical sample representative of a common 
clinical population. Results of case series can generate hypotheses that are 
useful in designing further studies, including randomized controlled trials. 
However, no causal inferences should be made from case series regarding the 
efficacy of the investigated treatment. This article will provide principles for the 
design, analysis, and reporting of case series, illustrated by examples from the 
orthopaedic surgical literature.
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Introduction
In clinical research, studies can be classified into descriptive and analytic 
studies. Descriptive studies are always observational studies and describe 
general disease characteristics related to person, place, and time. They include 
cross-sectional studies, surveillance studies, ecological correlational studies, 
case reports, and case series.1 Analytic studies test a hypothesis about a causal 
relation between exposure and outcome.2 They can be observational, such as 
case-control and cohort studies, or controlled, such as the randomized 
controlled trial. In the randomized controlled trial, the intervention or 
treatment is randomly assigned by the researcher, while in observational 
studies, the surgeon and/or the patient decide on which treatment is given, as 
happens in routine care.
The results of randomized controlled trials are considered the highest 
level of evidence because randomization controls for prognostic factors 
between two comparison groups, thereby minimizing the role of confounding 
bias and optimizing the internal validity. In the hierarchy of evidence, 
randomized controlled trials (Level I) are followed by cohort studies (Level II), 
case-control studies (Level III), case series (Level IV), and expert opinion (Level 
V).2
Even though a randomized controlled trial carries the highest level of 
evidence, for technical or ethical reasons, it is not an appropriate design for all 
clinical questions.2-4 For example, in fracture-healing research, it would be 
unethical to randomize patients with grossly contaminated open tibial shaft 
fractures to either early or delayed treatment. In these situations, 
observational studies are the best alternative to study the efficacy and safety of 
a certain intervention.
Cohort studies, case-control studies, and case series are all types of 
observational studies. Cohort and case-control studies differ from case series in 
that they make use of a comparison group in the analysis of the treatment 
effect on the outcomes. Case series belong to a group of descriptive studies 
that do not test the hypothesis of treatment efficacy.4 A case series follows a 
group of patients who have a similar diagnosis or who are undergoing the same 
procedure over a certain period of time.
Although case series have methodological limitations with regard to 
making causal inferences about the relation between treatment and outcome, 
they can be helpful in generating a hypothesis that can be tested in further
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analytic studies.2 This article will discuss the main purposes and the major 
strengths and limitations of a case series. Principles are provided for its design, 
analysis, and report.
When to consider a  case series?
Despite its negligible role in assessing treatment efficacy, a case series is 
suitable for a more cautious description of interventions in several settings. 
First, case series serve as a means of initially reporting on novel diagnostic or 
therapeutic strategies, particularly when the option of waiting for comparative 
evidence is considered unacceptable. Second, patient registries can be a tool 
for summarizing the outcomes in a certain patient category (for example, all 
patients with tibial fractures).4
The primary purpose of a case series should be the generation of 
hypotheses that subsequently can be tested in studies of greater 
methodological rigor. Put simply, a case series can be seen as a screening tool 
for sensible hypotheses that are worthy of further examination. Treatment 
safety and diagnostic accuracy are the principal outcomes that can be assessed 
fairly and reliably in a case series. In the assessment of either outcome, no 
control group is necessary and long-term follow-up can be obtained readily, 
especially in a retrospective design. Information regarding the characterization 
of disease patterns in terms of natural history, recovery, and prognostic factors 
may help a researcher determine the sample size, relevant covariates, and 
length of follow-up that should be used in a subsequent randomized controlled 
trial.5 Rather than being an antecedent of more valid research, case series may 
also be an alternative or a valuable adjunct.4,6
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STRENGTHS AND LIMITATIONS OF A CASE SERIES
As with all study designs, case series have strengths and limitations (Table 1).
Table 1. Strengths and limitations of a  case-series design
Strengths High external validity
No interference in treatment 
decision process 
Wide range of patients 
Inexpensive
Study conduct takes little time 
Limitations Lack of comparison group
Data collection often incomplete 
Susceptible to bias 
Selection bias 
Measurement bias
Strengths
In all observational studies, including case series, the study investigators do not 
control which intervention(s) the research participant receives. The advantage 
of this approach over a randomized controlled trial is that the study results are 
closer to those obtained in routine clinical practice and may therefore be 
considered more relevant.5,7 A higher relevance (or external validity) means 
that the results can be better applied to clinical practice in other centers. 
Another advantage of not interfering in the treatment decision is that the 
surgeons are not forced to perform an operation with which they are less 
experienced.
The external validity is also high in a case series that includes a diverse 
range of patients. By including patients with different characteristics and co­
interventions, the study sample is more likely to be representative of the 
population of interest. In a randomized controlled trial, however, relatively 
stringent inclusion criteria and selection of only those patients who wish to 
participate decrease the extent to which the results can be applied to common 
clinical practice.8,9
In contrast with randomized controlled trials, case series do not include 
a comparison group, nor is any form of randomization employed. The case
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series is therefore a relatively efficient and cost-saving design. In a case series, 
the decision about the treatment regimen remains with the surgeon and the 
patient. This is an obvious advantage when ethical considerations prohibit the 
randomization of a patient to a non-treatment group or to a treatment that 
would be inconsistent with common standards of orthopaedic practice (e.g., a 
placebo-treatment group).
Limitations
The primary limitation of a case series is its lack of a comparison (control) 
group. A control group is a group of patients who share all of the characteristics 
of the patients of the treatment group except that they do not receive the 
treatment. When a study lacks a control group, no causal inferences should be 
made about the relationship between the treatment and the outcomes, since it 
is impossible to determine whether the outcomes are attributable to the 
treatment effect or to other patient characteristics. As a result, hypotheses can 
only be made about apparent relationships.
A case series is often based on retrospective observation of patient 
data. Conducting a case series prospectively (i.e., the hypothesis precedes data 
collection) or retrospectively (vice versa) makes a difference as to the extent of 
selection and measurement bias encapsulated in the observations. In contrast 
to the method of operation of a randomized controlled trial, rigorously 
developed protocols and a dedicated single investigator (for example, a 
research nurse) are absent in a retrospective design, which may decrease the 
completeness of inclusion, data collection, and patient follow-up. Additionally, 
data are not measured in a standardized way, thereby increasing the 
measurement bias. Further, the researcher is dependent on whatever 
outcomes have been measured in the course of routine care and cannot always 
select a suitable and valid outcome measure as is possible in a prospective 
design.7
Similar to other observational study designs, case series are prone to 
bias. Selection bias occurs when follow-up data are less likely to be collected 
from patients with a better or worse outcome. For example, when the only 
subjects included in a study are those who are available for a follow-up of at 
least six months, patients who died or changed hospitals before six months are 
not included. These patients are likely to have had worse outcomes than the 
ones who survived, so the selection of patients is therefore biased.
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Measurement bias can arise when different methods of outcome 
measurement are used in a study. Compared with case series, measurement 
bias might be more likely to occur in case-control and cohort studies, because 
the difference between the treatment and control groups makes it more likely 
for investigators to gather information in different ways.
Selection and measurement bias should theoretically occur as much in 
case series as in randomized controlled trials, because randomized controlled 
trials only control for confounding bias.7 Confounding bias occurs in the 
presence of confounders, that is, factors that distort the true relationship of the 
study variable of interest by virtue of also being related to the outcome of 
interest.10 Confounding bias is not present in case series for the simple reason 
that there is no control group. However, because the protocols associated with 
randomized controlled trials are typically better developed and of higher 
quality than those of case series with regard to methods to control for bias, 
selection and measurement bias may be less common in randomized controlled 
trials.
Criteria for a  good case series
Specific guidelines for planning, conducting, and reporting a case series are 
presented below.1,4,5,7 We recommend reporting on how each of these 
guidelines was implemented when writing a paper on a case series.11
Design
As with other study designs, the study question should be focused and 
appropriate for a case series. Specifically, the question should not be whether 
the investigated treatment is more effective or safer than another treatment. 
The study question should list (1) its study population, (2) the intervention, and 
(3) the primary outcome.
The case definition should mention inclusion and exclusion criteria, 
which should be based on widely used, preferably validated definitions. If 
authors use their own criteria, definition and justification are necessary to 
enable the reader to compare the studied population with his or her own 
patients. A consecutive inclusion of patients optimizes external validity. It may 
be tempting to include patients seen over a large period of time to increase 
sample size. However, the use of a short inclusion period minimizes known and
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unknown changes over time in co-interventions, prognosis, and even in the 
intervention under study.
A detailed description of the intervention and the co-intervention 
should be stated. This will ensure repeatability of the study by other 
investigators. It is very important to thoroughly describe co-interventions (for 
example, postoperative mobilization and physical therapy), as these are not 
always standardized among study centers as is frequently implied by vague 
statements that patients received ''standardized operative or postoperative 
care.'' Additionally, indications for the studied treatment should be explained. 
This will primarily determine the consistency of the patient group.
The most important outcomes in care are those that measure patient 
satisfaction, relief of symptoms, and a feeling of well-being. An example is the 
Short Form-36 questionnaire, which not only measures physical function but 
also mental well-being.12 Including only clinical measurements would not 
represent the subjective nature of patient care. Further, outcomes 
measurements should be valid and reliable. Validity refers to the degree to 
which the data measure what they were intended to measure. An example of a 
valid measure is the Western Ontario and McMaster Universities (WOMAC) 
Osteoarthritis Index, which correlates well with earlier established instruments 
of pain, stiffness, and physical function.13 Reliability refers to the extent to 
which repeated measurements of a stable phenomenon get similar results. The 
general impression of radiographic healing of tibial fractures is an example of a 
measurement with a high interobserver agreement.14
The blinding of outcome assessors is ideal in every kind of research 
design and can be implemented quite usefully in case-series studies (e.g., by 
having some investigators collect data only on outcome and others collect data 
only on patient characteristics). This prevents the investigators' measurements 
from being influenced (intentionally or unintentionally) by their personal 
treatment preference.
The method of data acquisition (telephone interview, clinical 
measurement, or chart review) should be addressed in the study report for the 
sake of repeatability and the appraisal of measurement bias. A further criterion 
of a well-measured outcome is the minimal length of follow-up. Sufficient time 
should be given for complications to develop and be recorded. For example, a 
maximal follow-up time of six months in a study of health-related quality of life 
after a tibial fracture would underestimate the patients' eventual health status,
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since patients continue to improve for up to a year, and sometimes longer, 
after the occurrence of a fracture.
Analysis
As the design of a case series is descriptive, only descriptive statistics should be 
used.15 That is, no comparative tests yielding P values should be done. By 
describing summary statistics, the author errs on the conservative side of 
speculation and avoids misleading his or her colleagues with fancy probability 
statistics.
Reporting
As case series have many methodological limitations, their findings should be 
described. First, a statement of the external validity of the obtained data should 
be given. This includes (1) patient characteristics and (2) completeness of 
follow-up. Additionally, the presence of chance and the presence, direction, 
and magnitude of bias should be acknowledged. Authors who only emphasize 
the resemblance to routine clinical practice greatly mislead their audience by 
withholding from them information on internal validity.
Patients may differ according to prognostic variables, such as age, 
etiology, and disease severity among geographical regions. This may complicate 
comparisons with other reports or explain discrepancies. For example, a 
relatively greater contribution of blunt trauma to all observed severe injuries in 
Europe may explain why the most predictive trauma score differs from that 
which can be found in North American studies.16 The follow-up rates and 
reasons for loss to follow-up should be stated. Completeness of follow-up 
varies considerably among similar case series,9 making it difficult for readers to 
compare them. Therefore, authors should be cautious when interpreting their 
own results in relation to results of apparently similar case series.
Most importantly, no absolute conclusions on the studied treatment 
should be stated. As mentioned before, the lack of a comparison group 
prohibits any hypothesis from being tested. Valid conclusions basically repeat 
the descriptive study findings, for example, ''our patients treated by treatment 
X showed good outcome Y after Z months of follow-up.'' Stating that 
''treatment X is better than treatment Y'' or even that ''treatment X is 
effective'' would be invalid. Inferring such a finding could lead a reader to use 
treatment X in the care of a patient, a decision that would seem to be evidence-
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based but that in reality is not and could lead to an unfavourable outcome.
Example 1: a  case series followed by research with higher level of evidence
Extramedullary fixation with a sliding hip screw has shown good clinical results 
in the treatment of pertrochanteric fractures. However, because of some 
reported complications, the intramedullary gamma nail, which theoretically has 
biomechanical advantages over a sliding hip screw, was developed.17-19
Chevalley and Gamba presented a case series of sixty-three patients 
who were treated for a pertrochanteric hip fracture with a gamma nail.20 Data 
for this study were collected prospectively, and patients were followed until 
the end of treatment for an average of 7.2 months. The quality of reduction 
was classified, on the basis of the radiographic fracture gap, as good in thirty- 
eight patients, acceptable in nineteen patients, and unsatisfactory in six 
patients. On the average, full weight-bearing was allowed by the twenty-fourth 
day after the procedure, and fracture consolidation was seen radiographically 
at an average of 3.8 months. In their discussion, the authors state their belief 
that use of the gamma nail avoids delays in full weight-bearing, shortens the 
procedure to treat unstable intertrochanteric fractures, and diminishes the risk 
of nonunion.
Several strengths are recognized in the design of this case series. First, 
the prospective nature of the study made it more likely that the data that were 
collected would be complete. Also, consecutive patients were included in this 
series. Selection bias was limited because all patients who received treatment 
with gamma nails in the observed period were included in the study. The 
authors justly did not overstep the goal of a case series, as their goal was to 
present their results with gamma nailing. However, they did not describe their 
main outcomes of interest in their methods section and did not describe the 
criteria that were used to assess the outcomes. Because patients were followed 
until the end of treatment, this study is complete with regard to the report for 
potential complications associated with the treatment. However, no definition 
of the end of treatment was given by the investigators. The quality of reduction 
was assessed on the basis of classification of fracture-gap size as determined by 
the investigators. The authors did not justify this decision; however, they did 
define the categories. The postoperative results are therefore easily 
interpreted by readers who may not be familiar with this type of classification.
No causal inferences are made, as the authors do not claim that gamma
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nails are superior to sliding hip-screw systems in general and include the words 
''in our experience'' in their conclusion. Also, results from other series are 
mentioned in the conclusion, but the authors acknowledge that comparison 
with these series would not be appropriate.
Because a lack of consensus exists among observational studies 
regarding the optimal operative treatment of pertrochanteric fractures, further 
studies with a higher level of evidence were needed. Several randomized 
controlled trials were performed, comparing gamma-nail fixation with sliding 
hip screw fixation, and a recent meta-analysis summarized the evidence from 
these trials.21 The primary conclusion from this meta-analysis was that there 
was no advantage of gamma nail fixation over sliding hip-screw fixation with 
regard to mortality, nonunion, and complications. As a result, surgeons are now 
better prepared to make an evidence-based decision on the treatment of 
pertrochanteric fractures.
Example 2: treatment evaluation by functional outcome
Agreement exists on the need for operative treatment of tibial avulsion 
fractures of the posterior cruciate ligament, but not on the optimal surgical 
approach.22,23 Nicandri et al. recently presented a retrospective case series on 
patients who underwent a modified open posterior approach.24 Their purpose 
was to explore long-term functional status following this new procedure, 
including clinical (Musculoskeletal Function Assessment questionnaire, 
posterior drawer test, and knee range of motion) and radiographic (fracture- 
healing) outcomes.
In their introduction, the authors stated that an open procedure was 
indicated for some patients with posterior cruciate ligament avulsion, but they 
did not specify their inclusion criteria. As a result, trauma surgeons are unable 
to appreciate the clinical relevance.
The operative procedure and the postoperative treatment were very 
extensively described, and the clinical outcomes were all validated (except for 
the knee range of motion, which was measured with use of the commonly used 
goniometer). In contrast, no definition of radiographic healing was given. While 
there is controversy regarding the best method of monitoring radiographic 
healing,25 at least one accepted method should have been used.
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In this case series, the external validity is compromised because of the 
retrospective study design. From an already small sample, eight of eighteen 
patients were eliminated because of missing data.
The average musculoskeletal functional assessment score was 14, 
which is favourable. Two patients had grade-II laxity, and eight patients had 
grade-I laxity, which is favourable as well.
Only the P values of tests comparing the range of motion of the 
affected and the contralateral knees were presented, rather than raw data on 
affected knee range of motion. Since the sample size is very small, no 
significant differences could be detected, falsely suggesting that knee functions 
were intact.
In their discussion, the authors used their data to recommend the use 
of early postoperative mobilization. Although the authors mentioned the 
limitations of their case series, they concluded that their operative technique 
''results in good clinical, radiographic and functional outcomes.'' Although the 
clinical results are believable, it is not clear to which type of patients they apply. 
In addition, a substantial number of patients who underwent the procedure 
were excluded. Therefore, and because no control group was used, the 
authors' conclusion that the outcomes were the result of their surgical 
approach is invalid.
Example 3: a  case series designed to assess the safety of an intervention
Operative fixation of displaced supracondylar humeral fractures in children is 
performed to maintain anatomical reduction and to minimize the complication 
rate associated with nonoperative management. The best approach to 
Gartland26 type-II fractures remains controversial.
Skaggs et al. conducted a case series in which the purpose was to 
determine the complication rate, both surgical and anesthetic, of the operative 
treatment (closed reduction and percutaneous pinning) of type-II 
supracondylar fractures in children.27 Only patients with complete medical 
records and a minimum follow-up of six weeks were included. Data were 
acquired from a review of radiographs and clinical notes, and patients were 
classified as excellent, good, fair, or poor on the basis of the criteria described 
by Flynn et al.28 According to these criteria, 181 patients had excellent results, 
six had good results, and two had fair results. There were no surgical or 
anesthetic complications noted in this series.
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The primary limitation of this case series was the short follow-up 
period. This case series only used a minimum of six weeks of follow-up, which 
would be far too short a time for the occurrence of some surgical complications 
(such as nonunion) that were assigned as outcomes in this series.
Furthermore, the authors were not consistent in stating the purpose of 
their study. While they emphasized determination of the complication rate in 
their introduction and discussion, their overall recommendations also 
contained suggestions about the efficacy of the treatment (''satisfactory 
outcome''). Also, selection bias might be present, since only patients with 
complete medical records and a minimum of six weeks of follow-up were 
included.
In the methods section, the authors provided a detailed description of 
the data that were collected and they provided a reference for the Flynn 
classification system. As in all case series, the type of treatment was chosen by 
the surgeon, and, as a result, different pin configurations were used for 
fixation. These different configurations were properly presented in a table, 
which makes it easy for the readers to judge if this series is applicable to their 
own practice.
The authors reported on the results of another series of similar 
fractures in children who were treated without pinning, and they used this 
group as a control group to conclude that initial operative treatment in their 
series led to a higher chance of satisfactory outcome without an increased risk 
of complications. However, results from different case series cannot be 
compared, and such conclusions, as in this example, cannot be properly drawn.
suMMARY
Although a case series is lower than a randomized controlled trial in the 
hierarchy of evidence, it could be useful when use of a randomized controlled 
trial is not appropriate or possible. Even though no causal inferences can be 
made, a case series is a good way to generate new hypotheses about treatment 
efficacy and to assess information about the safety and diagnostic accuracy of a 
treatment. Also, the external validity of a case series often exceeds that of a 
randomized controlled trial. However, keeping the methodological limitations 
of a case series in mind, one should be careful in applying its conclusions to 
clinical practice before more evidence is obtained from randomized trials. The 
ideal case series would have a prospective design, would contain a clear
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definition of its population, the intervention, the outcomes, and the amount of 
follow-up, and would not make any causal inferences about the treatment 
effect. When designed and conducted in the right way, a case series can be a 
sensible alternative to studies with higher levels of evidence, with the 
additional advantage of saving a lot of time and money.
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Introduction
A rapid, same-day diagnosis is beneficial to patients presenting with a breast 
lesion. Despite obvious advantages of a tissue diagnosis by core needle biopsy 
(CNB), only cytological modalities (fine needle aspiration (FNA), nipple 
discharge (ND) cytology, touch imprint (TI) cytology and core wash (CW) 
cytology) allow for rapid microscopic assessment of tumour material. As such, 
only a conclusive and accurate cytological diagnosis can result in a correct 
diagnosis of either benign disease or malignancy to be delivered on the day of 
initial consultation.
Specifically, when concordant with clinical and/or imaging results, a 
'benign' cytological (C2) diagnosis reduces anxiety in patients with truly benign 
disease, whereas a 'malignant' diagnosis (C5) ensures a short-as-possible period 
of insecurity in patients with truly malignant disease. Accordingly, in this thesis 
we defined a conclusive cytological diagnosis as C2 in patients with benign 
disease on follow-up and as C5 in patients with breast cancer on follow-up.
Yet, limited observed conclusiveness rates of FNA and ND cytology have 
called their clinical use into question, as repeated biopsies or diagnostic 
excisions are needed in cases of inconclusive cytological results. Acknowledging 
the benefit of the same-day diagnosis principle, TI and CW cytology techniques 
that derive cytological specimens from CNBs have been developed recently.
This thesis evaluates conclusiveness rates of the abovementioned 
cytological modalities (mainly FNA), determinants of a conclusive diagnosis, and 
the consequences of inconclusive diagnoses for diagnostic and surgical 
therapeutic work-up. Here, a summary is presented based on the initial 
questions underlying this research.
Discussion of the aims
In chapter 1 the comparative accuracies and unique features of cytology and 
CNB for diagnosing breast lesions are reviewed. In 6 published prospective 
studies of patients having had both FNA and CNB, conclusiveness rates were 
higher for CNB in benign lesions (3 studies) as well as malignant lesions (3 
studies). A further drawback to FNA relative to CNB is that differentiating ductal 
carcinoma in situ (DCIS) from invasive carcinoma is not possible when 
examining aspirates. However, as same-day diagnosis is preferable for reasons 
stated above, FNA could sensibly be used in conjunction with CNB for lesions 
likely to have a conclusive FNA diagnosis (e.g., solid lesions measuring 2-4 cm in
142
diameter). Alternatively, TI or CW cytology may provide a preliminary diagnosis.
A conclusive non-operative diagnosis is useful to the patient because it 
provides the patient with clarity about the nature of her breast lesion and the 
advisable management. Additionally, it influences the surgical approach if the 
lesion is planned to be removed. For example, a lesion with a malignant 
preoperative diagnosis will be excised more extensively than a lesion with a less 
suspicious diagnosis. This is the subject of the first study of this thesis.
1. Does a conclusive preoperative diagnosis by FNA reduce the number of 
operative procedures needed for complete breast conserving therapy for 
breast cancer? How does this compare to a conclusive CNB diagnosis?
In chapter 2 the impact of conclusiveness and type (FNA vs. CNB) of 
preoperative pathology diagnoses on margin involvement of the initial excision 
and on re-excisions in breast cancer patients treated by lumpectomy is 
estimated. We found a conclusive preoperative diagnosis by FNA or CNB to be 
the strongest predictor of an involved margin of the initial excision (adjusted 
odds ratio (OR) 0.2) among other preoperative clinical and mammographic 
parameters (adjusted ORs ranging 0.8-1.2). A similar figure was found for the 
association with re-excisions. FNA and CNB had similar rates of an involved 
margin of the initial excision and re-excision.
With many 'static' factors (e.g., tumour size, mammographic 
appearance, etc) having been investigated before in relation to lumpectomy 
margins, this was the first study to directly focus on the effect of definitiveness 
of preoperative diagnoses by FNA and CNB in a comprehensive population of 
breast cancer patients. Our observation stresses the importance of obtaining 
conclusive breast biopsies prior to local excision, not only in the light of 
accurate preoperative work-up, but also with respect to efficient surgical 
management of malignant lesions amenable to breast conservation. Moreover, 
it augments the importance of diagnostic conclusiveness as the end point in 
further studies in this thesis.
Including both FNAs and CNBs in this study may be regarded as a 
limitation. Yet, the effects of conclusively malignant diagnoses (B5 and C5) on 
margin involvement and re-excision rates were similar for FNA and CNB groups. 
Consequently, we can be confident that the current results are well applicable 
to centres adhering only to either FNA or CNB.
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2. How often does FNA yield a conclusive diagnosis and can FNA 
conclusiveness be predicted from simple clinical and radiologic parameters?
In chapter 3 we assessed the conclusiveness of FNA diagnoses in a large group 
of histologically confirmed patients with benign and malignant breast disease. 
Furthermore, we identified factors that increase the likelihood of obtaining a 
conclusive diagnosis, allowing to more appropriately selecting patients to 
undergo FNA.
Strikingly, only 46% (95% confidence interval (95% CI), 42%-50%) of 
histologically benign lesions were diagnosed conclusively (C2) by FNA, whereas 
82% (95% CI, 80%-83%) of breast cancers had a conclusive preoperative 
diagnosis (C5). Tumour size from 2.0 to 2.9 cm was the only variable known 
before the FNA procedure that increased the probability of a conclusive 
diagnosis. The observation that tumours measuring >3 cm were comparatively 
less likely to have a conclusive diagnosis could be related to necrotic debris and 
desmoplastic tissue being present in larger tumours more frequently. FNA 
conclusiveness was also influenced by the pathologist examining the aspirate. 
Further parameters (patient age, palpable tumour, mammographic aspect of 
the lesion, and ultrasound guidance of the FNA procedure) were unhelpful in 
predicting a conclusive diagnosis.
In this study FNA conclusiveness may have been underestimated as 
patients with benign lesions were likely to be excised only when diagnosed 
inconclusively by FNA. Still, patients likely to have benign breast disease do not 
optimally profit from the potential of FNA to obtain a same-day diagnosis, as 
results are often inconclusive. As such, breast FNA has to be utilized selectively 
in the routine work-up of breast lesions. In suspicious lesions of large size, FNA 
may be used to obtain a quick confirmation of malignancy.
3. Does laboratory preparation of a monolayer preparation result in more 
conclusive FNA diagnosis than conventionally smearing the aspirate?
Chapter 4 involves a historical comparison of FNAs prepared for examination by 
conventional smearing (CS) or by a monolayer preparation (MP) using the 
Hettich cytocentrifuge. For CS, aspirators smear the aspirate directly onto one 
or more slides, whereas for MP, the aspirate is centrifuged, creating a 
monolayer arrangement of all aspirated cells on a single slide.
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Cytomorphologically, the latter technique results in higher cellularity and 
disturbing background material, such as necrotic debris, is removed. 
Additionally, MP lacks air drying artefacts and cells are not destroyed during 
the preparation process.
Our study confirmed that FNAs in the MP group were indeed more 
likely to have a conclusive diagnosis (crude OR=1.9). This effect remained when 
adjusting for the fact that substantially more FNA were ultrasound-guided in 
the MP group (adjusted OR=1.7). Moreover, the beneficial effect of MP was 
more pronounced in malignant than in benign lesions.
The 14% absolute risk reduction for an inconclusive diagnosis noted 
following MP introduction in the laboratory under study implies that 1 in 7 
patients potentially benefits from FNA being prepared by MP instead of by CS. 
Patients with malignant disease will benefit most, as is rational when 
considering that necrotic debris, which is frequently present in aspirates of 
malignant lesions, is removed by the MP. As such, breast centres adhering to 
cytological same-day diagnosis work-up may benefit from switching to MP of 
FNA.
4. Should an inconclusive FNA diagnosis be followed by a repeated FNA or by 
a CNB in order to obtain a conclusive non-operative diagnosis?
Chapter 5 examines the optimal diagnostic strategy in the relatively frequent 
case where FNA yields an inconclusive diagnosis. As a repeated FNA may still 
provide a conclusive diagnosis within one day, some centres advocate this 
work-up, whereas others perform an instant CNB following an inconclusive 
diagnosis.
When looking at patients with an indeterminate primary FNA who 
subsequently had either a repeated FNA or a CNB, substantially more patients 
in the CNB group had an improvement in the conclusiveness of their diagnosis 
following the second procedure. This superiority was not due to differences in 
tumour size, palpability, or ultrasound-guidance of the biopsies. However, it is 
difficult to aspirate cellular material by FNA from desmoplastic tumours, which 
are likely to be overrepresented in this study group. In contrast, CNB removes 
small tissue fragments from the tumour, possibly resulting in a higher likelihood 
of representative biopsy of malignant cells.
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Yet, irrespective of the possible explanation of our observation, we can 
recommend to use CNB in patients in whom a conclusive diagnosis by primary 
FNA cannot be obtained.
5. How often is ND cytology helpful in diagnosing patients presenting with 
unilateral ND?
In chapter 6 the usefulness of ND cytology in the work-up of patients 
presenting with unilateral discharge is discussed. Such patients often have one 
or more abnormalities at psychical examination, imaging or needle biopsy, but 
the ND itself is traditionally smeared and examined cytologically. Although ND 
cytology is known to exhibit inferior diagnostic accuracy compared to other 
modalities, it is considered to contribute to the diagnostic process in some 
instances and, as such, to be useful overall.
In a series of histologically confirmed patients that had cytology 
examination of their unilateral ND, we found that the major limitation to this 
modality was its inability to detect carcinomas. In fact, examining the 
macroscopic ND colour (when regarding red discharge as positive for 
carcinoma) was substantially more accurate than microscopic examination. 
Most importantly, only 1 of the 36 malignancies and 2 of the 127 benign lesions 
were detected solely by ND cytology.
Because of this low observed complementary value for diagnosing 
patients with unilateral ND, the use of ND cytology should be reconsidered 
carefully.
6. What is the accuracy of FNA in male patients with breast pathology?
Chapter 7 evaluates the diagnostic accuracy of FNA in male patients presenting 
with a breast lump. With gynecomastia representing the most frequent breast 
lesion in men, FNA may yield atypical diagnoses more often in this population 
than in women.
In a histologically confirmed series of 85 aspirated lesions we found 
FNA conclusiveness to be moderate in malignant lesions (75%; 95% CI, 51%- 
99%) and low in benign lesions (55%; 95% CI, 43%-67%). Yet, when only 
analyzing adequate samples, these parameters were much higher and 
comparable to recent studies that only analyzed adequate aspirates as well.
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Importantly, no malignancies were encountered in the follow-up of inadequate 
FNAs and only 4 of 44 gynecomastia cases were falsely atypical or suspicious on 
FNA.
Therefore, we concluded that FNA is a useful modality in the initial 
diagnosis of breast lesions in male patients.
7. Are CW and TI cytology of CNB specimens accurate means of providing a 
preliminary, same-day diagnosis of breast pathology?
In chapter 8 two relatively novel techniques, TI and CW cytology, which derive 
cytological specimens from CNBs are explored regarding their diagnostic 
accuracies (in casu, their correlations with the CNB diagnosis). CW cytology was 
prepared by a novel, modified procedure involving a cytocentrifuge and 
creating a monolayer preparation. The CNBs were performed by a cytological 
technician and a pathologist, directly on a surgical specimen in the laboratory. 
When applying the criteria as in other studies in this thesis, CW cytology had a 
conclusiveness of 75% (95% CI, 54%-96%) and 89% (95% CI, 63%-100%) in 
malignant and benign lesions, respectively. The conclusiveness of TI cytology 
was similar in malignant lesions but lower in benign lesions (67% (95% CI, 28%- 
100%)). However, these estimates are highly imprecise due to a low sample size 
(n=30).
While this study indicates that CW and TI cytology may be promising 
cytological techniques providing the potential of a same-day diagnosis, 
pathologists at the institution of investigation experience less marked 
cytopathological images when compared to fine needle aspirates. Nevertheless, 
CNBs were not performed by radiologists and were not done under image 
guidance in this study. This may have resulted in an underestimation of the 
conclusiveness of CW and TI cytology. Whether CW cytology can replace FNA 
because of non-inferior diagnostic accuracy has been investigated in a recently 
finished prospective trial of CW cytology of CNBs in vivo, the results of which 
will be published soon.
8. Methodological strengths and limitations of retrospective research designs.
Chapter 9 mainly deals with the methodological caveats of retrospective, non­
controlled research designs as used in most of the studies in this thesis.
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Although representing daily practice well, observational research does 
not allow for causal inferences to be made based on associations of two 
parameters. Yet, when two correlated matters follow each other in time (e.g, a 
conclusive FNA diagnosis relatively frequently followed by tumour-free margins 
of an initial excision in case of breast cancer), a causal relationship is more likely 
to exist. Still, non-recorded and/or unknown confounding variables can distort 
the observed association in non-controlled research. Therefore, in most studies 
of this thesis we employed multivariate analysis to minimize this risk.1
Additionally, during retrospective data collection eligible cases and 
relevant data may be missed due to inadequate registration of these data at 
the time that the patient was seen. When substantial, this selection may result 
in biased study results. Yet, the Dutch national pathology database (PALGA), 
which provided the basis of inclusion in the present studies, is highly systematic 
using standard coding for each examined pathology specimen.2 As such, gross 
selection bias is unlikely in the patients groups under study, but association 
estimates from our studies should not be considered as optimally precise.
Conclusions
A cytological diagnosis of breast lesions remains to carry the unique advantage 
of a patient-centered same-day diagnosis. Therefore, when keeping its 
limitations in mind, a cytological diagnosis by either fine needle aspiration or by 
core needle biopsy-derived cytology can greatly contribute to the timely work­
up of these cases.
The imperative need for preoperative histological information has 
prompted laboratory techniques which derive cytological material from core 
needle biopsies. Therefore, future prospective studies are vital to assess the 
accuracies of these relatively novel modalities.
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Inleiding
De diagnostiek bij vrouwen met een afwijking in de borst omvat meer dan één 
test die aangeeft of er wel of geen sprake is van borstkanker. Naast een 
lichamelijk onderzoek en radiologische diagnostiek (met name mammografie 
en echografie) heeft de chirurg microscopisch onderzoek van de tumor tot zijn 
of haar beschikking voordat hij besluit de afwijkingen al of niet chirurgisch te 
verwijderen. Het tumormateriaal dat hiervoor nodig is kan worden verkregen 
door een dunnenaaldbiopsie (Engels: fine needle aspiration (FNA)) of een 
dikkenaaldbiopsie (Engels: core needle biopsy (CNB)). Zowel FNA als CNB 
worden hier aangeduid als 'naaldbiopten'. Dit proefschrift bevat studies over 
de bijdrage van deze naaldbiopten, met name van FNA, aan de diagnostiek van 
patiënten met een afwijking in de borst.
Naaldbiopten
Bij FNA worden cellen met een dunne naald uit de tumor opgezogen. Het 
product hiervan is een zogenaamd cytologisch preparaat ('preparaat van 
cellen') waarin de patholoog onder andere aan de specifieke vorm van de 
individuele cellen onder de microscoop kan zien of de gebiopteerde afwijking 
waarschijnlijk borstkanker betreft. Het voordeel van cytologie is dat het 
preparaat zeer snel (binnen een half uur) kan worden gemaakt in het 
laboratorium. Hierdoor kan in minder dan 1 uur na de biopsie een diagnose 
worden medegedeeld aan de patiënt.
Bij CNB is de naald waarmee wordt geprikt dikker, waardoor een pijpje 
weefsel uit de borstafwijking kan worden verkregen. Het product hiervan is een 
histologisch preparaat ('weefselstukje') waarin niet alleen de individuele cellen, 
maar ook de ligging van de cellen ten opzichte van elkaar en ten opzichte van 
het goedaardige omgevende borstweefsel kan worden beoordeeld. Op grond 
van een aantal histologische eigenschappen van een tumor kan worden 
vastgesteld of deze kwaadaardig is en dus de potentie heeft om uit te zaaien. 
Mocht dit laatste zo zijn, dan zal ook de oksel moeten worden nagekeken op 
uitzaaiingen in de lymfeklieren. In het geval van een kwaadaardige tumor geeft 
een CNB dus nuttige aanvullende informatie t.o.v. cytologie. Een nadeel van de 
CNB is echter dat het vaak 2-3 dagen duurt voordat er een definitieve diagnose 
op het preparaat kan worden afgegeven. Er zijn tegenwoordig overigens ook 
technieken beschikbaar die binnen circa 3 uur een microscopisch preparaat kan
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aanleveren, echter niet op elk moment van de dag. De vaak gewenste 
aanvullende technieken vereisen ook veel meer tijd.
Een combinatie van cytologie en histologie uit één biopt is een relatief 
nieuwe ontwikkeling. Hierbij wordt een CNB afgenomen, maar worden de 
verkregen stukjes weefsel gewassen (core wash (CW) cytologie) of tegen een 
objectglaasje gedrukt (touch imprint (TI) cytologie). De buitenste cellaag blijft in 
het spoelvocht of op het glaasje achter. Daarmee wordt dan ook een 
cytologisch preparaat vervaardigd.
Naast een voelbare tumor of een afwijking die wordt gezien op een 
screeningsmammogram, presenteren vrouwen met borstpathologie zich in een 
minderheid van de gevallen met tepelvloed. De borstafwijking die dit vocht 
produceert laat hierin soms ook cellen los, zodat het tepelvocht cytologisch kan 
worden beoordeeld.
De diagnose
Zowel cytologische als histologische preparaten krijgen uiteindelijk een 
diagnose uit een gradueel spectrum: 'goedaardig', 'atypisch', 'verdacht voor 
kwaadaardigheid' of 'kwaadaardig'. Daarnaast kan het preparaat niet de juiste 
of niet voldoende cellen of weefsels bevatten zodat de uitslag als 'inadequaat' 
moet worden geduid. Dit kan bijvoorbeeld komen door het missen van de 
afwijking tijdens het aanprikken, zodat slechts cellen uit de omgeving worden 
verkregen.
Sneldiagnostiek bij patiënten met een afwijking in de borst, waarbij op 
de dag van het eerste bezoek een diagnose wordt gegeven, heeft psychologisch 
en logistiek voordeel. Vrouwen met een goedaardige diagnose kunnen snel 
worden gerustgesteld. Voor degenen met een kwaadaardige afwijking wordt de 
periode van het wachten op de diagnose, die als zeer stressvol wordt ervaren, 
verkort. Een definitieve diagnose van een borstafwijking bestaat uit de 
gezamenlijke bevindingen van het lichamelijk-, radiologisch- en pathologisch 
onderzoek, ook wel de 'triple diagnostiek' genoemd. Zo'n 'snelle' definitieve 
diagnose kan alleen geleverd worden d.m.v. cytologische diagnostiek. Dit is 
uiteraard alleen mogelijk als de patholoog een stellige diagnose van ofwel 
borstkanker ofwel goedaardigheid kan geven en deze cytologische diagnose in 
overeenkomst is met de bevindingen van het lichamelijke en het 
mammografische onderzoek.
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Een eenduidige en correcte cytologische diagnose is dus een 
voorwaarde voor een succesvolle ééndagsdiagnose voor patiënten met een 
borstafwijking. Van een conclusieve diagnose is sprake bij patiënten met een 
'kwaadaardige' preoperatieve diagnose die na operatie borstkanker blijken te 
hebben en bij patiënten met een 'goedaardige' preoperatieve diagnose die na 
operatie een goedaardige afwijking hadden. Helaas lukt dit niet altijd. De 
patholoog kan op basis van de cytologie of histologie niet altijd met zekerheid 
zeggen of het een goedaardige of kwaadaardige afwijking betreft. De diagnose 
is dan niet conclusief en moet er extra onderzoek worden ingezet om de 
preoperatieve diagnose eenduidig te krijgen. De 'conclusiviteit' van een 
naaldbiopsie is het percentage gevallen waarin deze een conclusieve diagnose 
tot gevolg heeft.
Dit proefschrift
De onderzoeken die in het kader van dit proefschrift zijn verricht, kijken naar de 
conclusiviteit van bovengenoemde cytologische diagnostische methodes (met 
name FNA), patiëntgebonden factoren die de kans op een conclusieve diagnose 
verhogen en de consequenties van niet-conclusieve diagnoses voor het 
diagnostisch traject en de chirurgische behandeling. Hieronder wordt een 
samenvatting gegeven van het proefschrift, uitgaande van de 
onderzoeksvragen die ten grondslag liggen aan de verschillende studies.
Beschouwing van de doelstellingen
In hoofdstuk 1 worden de diagnostische nauwkeurigheid en de unieke 
eigenschappen van cytologie en CNB met elkaar vergeleken op basis van 
bestaande literatuur hierover. In zes gepubliceerde studies met patiënten die 
zowel een FNA als CNB van dezelfde afwijking ondergingen, was de 
conclusiviteit hoger voor CNB in zowel goedaardige afwijkingen (in drie studies) 
als kwaadaardige afwijkingen (drie studies). Toch lijkt er nog een plaats te zijn 
voor FNA, maar dan alleen voor afwijkingen die vooraf een grotere kans 
hebben op een conclusieve diagnose met FNA, zoals solide kwaadaardige 
tumoren van twee tot vier cm groot. Als een alternatief kunnen TI of CW 
cytologie een dergelijke voorlopige diagnose geven.
Theoretisch is een conclusieve preoperatieve diagnose zinvol omdat het 
de patiënt duidelijkheid geeft over de aard van de borstafwijking. De chirurg is 
echter ook gebaat bij een conclusieve diagnose, omdat het hem/haar helpt te
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bepalen hoe de afwijking moet worden weggehaald. Een afwijking waarvan van 
tevoren bekend is dat het kwaadaardig is, zal ruimer worden weggehaald dan 
een afwijking met een minder verdachte preoperatieve diagnose. Dit is het 
onderwerp van de eerste studie in dit proefschrift.
1. Beperkt een conclusieve preoperatieve diagnose verkregen met FNA het 
aantal operaties dat nodig is voor complete verwijdering van borstkanker in 
het kader van een borstsparende behandeling? Hoe verhoudt zich dit tot een 
conclusieve CNB?
Een probleem in geval van een borstsparende behandeling is dat nogal eens 
een tweede maal moet worden geopereerd om de tumor in zijn geheel 
verwijderen, omdat blijkt dat de snijvlakken niet vrij van tumor zijn. Dit kan 
bijvoorbeeld komen doordat de chirurg voor de eerste operatie niet goed 
geïnformeerd was over de tumor. Het kan namelijk zijn dat het niet zeker was 
of de afwijking kwaadaardig was en dat daarom niet ruim genoeg om de tumor 
heen is gesneden. Er kan dan microscopisch tumorweefsel achterblijven. De 
patholoog bekijkt het verwijderde weefsel onder de microscoop en ziet dan 
tumorvelden of -cellen in de rand van het verwijderde weefsel. Er moet dus een 
tweede operatie plaatsvinden om de tumor ruim, dat wil zeggen met een rand 
normaal weefsel eromheen te verwijderen.
In hoofdstuk 2 wordt gekeken naar de invloed van de conclusiviteit en 
het type (FNA versus CNB) van preoperatieve naaldbiopten op microscopische 
snijranden en heroperaties bij borstkankerpatiënten die borstsparend zijn 
behandeld. Het bleek dat een conclusieve preoperatieve diagnose door FNA of 
CNB de kans op snijranden met tumor en een tweede operatie sterk 
verminderden. Het maakte daarbij niet uit of de diagnose met FNA of met CNB 
was gesteld.
Andere preoperatieve factoren hebben uiteraard ook invloed op de 
kans dat de afwijking er in één keer wordt uitgehaald (zoals de grootte en de 
groeiwijze van de tumor), maar deze zijn veelal niet te beïnvloeden. 
Concluderend onderstreept deze studie het belang tot een conclusieve 
diagnose te komen voordat men overgaat tot een operatie. In geval van een 
niet-conclusieve preoperatieve diagnose zal men dus opnieuw een naaldbiopsie 
moeten doen om alsnog een conclusieve uitslag te verkrijgen.
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2. Hoe vaak is FNA conclusief en kan vooraf worden voorspeld bij welke 
patiënten de kans hierop het grootst is?
In hoofdstuk 3 wordt de conclusiviteit van FNA onderzocht bij een grote groep 
patiënten met goedaardige en kwaadaardige afwijkingen. Verder werd er 
gekeken naar factoren die de kans dat een FNA een conclusieve diagnose zal 
opleveren vergroten en dus kunnen dienen om te bepalen bij welke patiënten 
een dergelijke dunnenaaldbiopsie zinvol zal zijn.
In slechts 46% van de goedaardige afwijkingen was de FNA conclusief 
('goedaardig'), terwijl in 82% van de kwaadaardige tumoren FNA een 
conclusieve ('kwaadaardige') diagnose leverde. Een tumorgrootte van 2.0 tot 
2.9 cm was de enige vooraf bekende factor die de kans op een conclusieve 
diagnose vergrootte. Men zou verwachten dat de conclusiviteit verder 
toeneemt bij nóg grotere tumoren omdat er vaker 'raak' wordt geprikt. Onze 
observatie dat dit niet het geval is, kan worden verklaard door reacties van 
weefselverval en verbindweefseling in grotere tumoren, waarvan de 
bloedvoorziening slechter is. Weefselsterfte (necrose) en bindweefselvorming 
zijn microscopisch lastig eenduidig te interpreteren. Conclusiviteit werd ook 
bepaald door de patholoog die het materiaal interpreteerde, maar niet door 
andere factoren die voorafgaand aan de dunnenaaldbiopsie bekend waren 
(leeftijd van de patiënt, of de tumor voelbaar was, het aspect van de tumor op 
het mammogram en of de biopsie onder beeldgeleiding door een echo 
gebeurde).
Gezien het feit dat FNA weinig conclusief was in goedaardige 
afwijkingen, lijkt het gerechtvaardigd om FNA alleen te reserveren voor 
patiënten bij wie borstkanker wordt vermoed, en dan vooral degenen met de 
grotere tumoren. Deze patiënten hebben namelijk het meeste kans op een 
snelle diagnose.
3. vergroot een dunnelaagpreparaat de kans op een conclusieve FNA 
diagnose vergeleken met een conventionele uitstrijk?
In hoofdstuk 4 worden twee manieren om een cytologisch preparaat van een 
FNA te maken, die na elkaar werden gebruikt in een periode van 16 jaar, 
vergeleken op conclusiviteit. Traditioneel werden de opgezogen cellen direct op 
één of meer objectglaasjes uitgestreken. In een latere tijdsperiode werd het
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opgezogen materiaal in een conserveringsvloeistof gedaan en later 
gecentrifugeerd, waarna alle cellen in één laag op één objectglaasje werden 
aangebracht ('dunnelaagcytologie'). Deze techniek geeft microscopisch gezien 
een hogere dichtheid van cellen en minder (storend) achtergrondmateriaal. 
Verder worden de cellen niet 'kapotgesmeerd' tijdens het maken van een 
dunnelaagpreparaat.
Onze studie bevestigde dat dunnelaagpreparaten vaker een conclusieve 
diagnose gaven dan de vroeger uitgevoerde uitstrijkpreparaten (respectievelijk, 
73% versus 59%). Dit was in het bijzonder zo bij dunnenaaldbiopten van 
kwaadaardige tumoren. Dit laatste lijkt logisch omdat er in kwaadaardige 
tumoren weefselsterfte (necrose) aanwezig kan zijn. Het afgestorven weefsel 
wordt dan ook opgezogen tijdens de biopsie. Bij een dunnelaagpreparaat wordt 
deze necrose door centrifugeren grotendeels verwijderd, wat de microscopisch 
interpretatie waarschijnlijk gemakkelijker maakt.
Verdere voordelen van een dunnelaagpreparaat t.o.v. de conventionele 
uitstrijk zijn dat de opgezogen cellen op een kleiner oppervlak op het 
objectglaasje belanden, waardoor ze dichter op elkaar komen te liggen, en dat 
de oorspronkelijke vorm van de cellen beter behouden blijft. Dit maakt de 
microsopische beoordeling gemakkelijker.
Klinieken die waarde hechten aan sneldiagnostiek kunnen hun service 
dus verbeteren door over te stappen op de dunnelaagcytologie techniek.
4. Moet een inconclusieve FNA gevolgd worden door een tweede FNA of door 
een CNB om in tweede instantie een conclusieve preoperatieve diagnose te 
verkrijgen?
In hoofdstuk 5 wordt onderzocht wat de beste strategie is het geval van een 
niet-conclusieve FNA. Omdat het herhalen van een FNA alsnog een diagnose 
binnen één dag kan opleveren, zijn er centra die dit doen. Andere kiezen dan 
echter direct voor een CNB.
Voor deze studie is een selectie gemaakt van patiënten met een eerste 
FNA die niet-conclusief was, gevolgd door ofwel een tweede FNA ofwel een 
CNB. Het bleek dat het substantieel vaker lukte om een meer conclusieve 
diagnose te verkrijgen wanneer het tweede naaldbiopt een CNB was.
Het is waarschijnlijk dat de patiëntengroep in deze studie een selectie is 
van degenen met tumoren die moeilijker cellen loslaten om op te zuigen, zoals
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tumoren met verbindweefseling. Het lijkt dus logisch dat het herhalen van een 
FNA relatief onsuccesvol zal zijn. Een CNB zuigt echter geen cellen op, maar 
'hapt' c.q. snijdt stukjes weefsel uit de tumor weg. De tumorcellen die in de 
verbindweefseling "gevangen" zitten komen dan dus vaker mee in het biopt en 
de diagnose zal vaker conclusief zijn.
Echter ongeacht de verklaring van onze observatie kunnen we op grond 
van deze studie aanbevelen om direct een CNB te doen bij patiënten met een 
niet-conclusieve FNA diagnose.
5. Hoe vaak helpt tepelvochtcytologie ons verder in de diagnostiek van 
patiënten met eenzijdige tepelvloed?
In hoofdstuk 6 wordt het nut van tepelvochtcytologie in het diagnostische 
traject van patiënten met eenzijdige tepelvloed onderzocht. Dergelijke 
patiënten hebben daarbij vaak een of meer afwijkingen bij lichamelijk 
onderzoek, beeldvormend onderzoek of naaldbiopsie. Toch wordt het 
tepelvocht zelf vaak ook cytologisch beoordeeld om de uitslag te laten 
meewegen in de diagnostiek.
Op grond van onze onderzoeksresultaten van patiënten met een 
uiteindelijke weefseldiagnose verkregen door een CNB of een chirurgische 
biopsie bleek dat de belangrijkste beperking van tepelvochtcytologie was dat 
het de patiënten die echt borstkanker bleken te hebben zelden detecteerde. 
Het bleek verder dat men de diagnose beter kon voorspellen door met het 
blote oog naar de kleur van het vocht te kijken (waarbij bloederig vocht als een 
teken van kanker wordt beschouwd en alle andere kleuren als teken van een 
goedaardige afwijking). Tepelvochtcytologie bleek van weinig toegevoegde 
waarde: slechts 1 van de 36 kwaadaardige afwijkingen en 2 van de 127 
goedaardige afwijkingen werden enkel door tepelvochtcytologie als zodanig 
gedetecteerd.
Gezien deze lage unieke bijdrage aan de diagnostiek van eenzijdig 
tepelvocht moet het gebruik van tepelvochtcytologie dus ernstig worden 
heroverwogen.
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6. Hoe nauwkeurig is FNA bij mannen met een afwijking in de borst?
Ook mannen hebben enig borstklierweefsel en ook hierin kunnen goedaardige 
en kwaadaardige zwellingen ontstaan. Ongeveer 1% van de patiënten met 
borstafwijkingen is man met als meest voorkomende afwijking de 
gynaecomastie, een ontwikkeling van borstklierweefsel. Er moet echter ook 
rekening worden gehouden met borstkanker, zeker op oudere leeftijd en in 
families waarin genmutaties (BRCA1 en BRCA2) voor borstkanker voorkomen. 
In hoofdstuk 7 beschrijven we de diagnostische nauwkeurigheid van FNA bij 
mannen met een massa in de borst.
Het bleek dat de conclusiviteit van FNA middelmatig was in 
kwaadaardige tumoren (75%) en laag was in goedaardige (55%). Dit kwam 
grotendeels doordat er veel 'inadequate' diagnoses waren: er waren te weinig 
of geen cellen uit de massa opgezogen. Wanneer deze diagnoses niet werden 
meegerekend, bleek de conclusiviteit van FNA veel hoger en vergelijkbaar met 
die in recente publicaties. Van belang was bovendien dat bij de patiënten met 
een inadequate diagnose later nooit borstkanker is gevonden. Daarom 
concludeerden wij dat FNA een nuttige eerste stap is in de diagnostiek van 
borstzwellingen bij de man.
7. Geven CW en TI cytologie van dikkenaaldbiopten een nauwkeurige 
voorlopige diagnose?
In hoofdstuk 8 worden twee cytologische technieken bekeken waarbij 
cytologische preparaten van een CNB werden vervaardigd m.b.v. een door ons 
laboratorium ontwikkelde gemodificeerde CW techniek en de TI 
cytologietechniek. Zo werd dus bij elke patiënt met één biopt zowel een (snelle) 
cytologische als een histologische diagnose gesteld. Er werd weer gekeken naar 
de conclusiviteit van beide cytologische technieken, afgemeten aan de uitslag 
van de CNB waarvan zij werden afgeleid. Het betrof een laboratorium studie. 
De CNB's werden niet afgenomen bij patiënten vóór de operatie, maar op het 
borstweefsel dat was verwijderd tijdens een operatie. Vervolgens werden TI 
preparaten door het weefsel uit een CNB uit te strijken op een objectglaasje en 
werden CW preparaten vervaardigd d.m.v. de dunnelaagcytologie techniek.
CW cytologie was conclusief in 75% van de kwaadaardige en in 89% van 
de goedaardige tumoren. De conclusiviteit van TI cytologie was vergelijkbaar in
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de kwaadaardige afwijkingen maar lager (69%) in de goedaardige afwijkingen. 
Deze percentages zijn echter grof geschat omdat er slechts 30 tumoren werden 
gebiopteerd.
Toch lijken CW en TI cytologie veelbelovend in hun potentie om tot een 
conclusieve diagnose op dezelfde dag te komen. Gezien het feit dat de CW 
cytologie een dunnelaagtechniek betreft met de reeds eerder gemelde 
voordelen, wordt de voorkeur gegeven aan de CW cytologie. Het ware nut van 
de CW techniek moet echter nog bewezen worden in onderzoeken bij vrouwen 
van wie de afwijking nog in de borst zit. Wij hebben inmiddels een dergelijke 
studie afgerond waarvan de resultaten op korte termijn zullen worden 
gepubliceerd.
8. Wetenschappelijke sterke en zwakke eigenschappen van een 
retrospectieve onderzoeksopzet.
In hoofdstuk 9 worden de wetenschappelijke valkuilen van retrospectief 
('terugkijkend') onderzoek besproken. Bij een dergelijk onderzoek zijn de 
gegevens die nodig zijn om de onderzoeksvraag te beantwoorden reeds 
genoteerd, maar niet doelbewust verzameld, voordat de onderzoeksvraag werd 
gesteld. De benodigde gegevens worden dus achteraf opgezocht uit 
patiëntendossiers, ziekenhuisregistraties of databanken.
De meeste studies in dit proefschrift hadden een retrospectieve opzet. 
Hoewel bij een dergelijke opzet de verzamelde gegevens de dagelijkse praktijk 
goed weerspiegelen, blijft het onderzoek niet meer dan een observatie. Dit 
betekent dat er formeel geen oorzakelijk verband tussen twee gerelateerde 
fenomenen kan worden geclaimd (zie ook het dilemma van de kip en het ei). 
Een dergelijk verband wordt echter wel waarschijnlijker als het ene fenomeen 
het andere volgt in de tijd (bijvoorbeeld het verband tussen een conclusieve 
FNA diagnose en tumorvrije snijranden van de eerste operatie voor 
borstkanker).
Verder kan een geobserveerd verband tussen twee zaken ook tot stand 
komen doordat er een derde fenomeen in het spel is dat een verband heeft 
met beide andere. Een voorbeeld is het verband tussen het vlaggen van een 
grensrechter en het juichen van het publiek in een voetbalstadion. Het zou 
vreemd zijn te concluderen dat het publiek uitzinnig wordt van het heffen van 
een vlag door de grensrechter. In werkelijkheid is het gescoorde doelpunt wat
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voor het gejuich zorgt. Om dit soort valkuilen zoveel mogelijk te vermijden 
werden in veel van de studies in dit proefschrift 'multivariate analyses' 
gebruikt,1 die als het ware rekening houden met mogelijk vertekenende 
factoren.
Een andere belangrijke beperking van retrospectief onderzoek is dat er 
bij het verzamelen van onderzoeksgegevens geschikte patiënten en andere 
relevante gegevens worden gemist door incomplete registratie van 
patiëntgegevens op het moment dat de patiënt werd gezien. Wanneer dit vaak 
het geval is, kan dit tot vertekende resultaten leiden. De landelijke 
pathologiedatabase (PALGA) waaruit de patiënten voor onze onderzoeken 
werden geselecteerd en de meeste gegevens werden gehaald, is erg 
systematisch.2 Daardoor zullen er geen grote vertekeningen van onze 
observaties zijn opgetreden. Gezien de bovengenoemde beperkingen van 
retrospectief onderzoek zullen de geobserveerde verbanden uit onze studies 
echter niet optimaal precies zijn.
Conclusies
Een cytologische diagnose van borstafwijkingen blijft het unieke voordeel 
houden dat de diagnose op de dag van het eerste bezoek aan het ziekenhuis 
kan worden gegeven. Daarom kan, wanneer de beperking ervan in acht worden 
genomen, een cytologische diagnose door dunnenaaldbiopsie of 
dikkenaaldbiopsie-afgeleide cytologie (core wash en touch imprint cytologie) 
een goede bijdrage leveren aan het diagnostische snel-traject bij patiënten met 
een borstafwijking.
De toenemende behoefte aan histologische informatie vóór de operatie 
heeft tot gevolgd gehad dat er de laatste jaren technieken zijn ontwikkeld die 
cytologische preparaten van dikkenaaldbiopten vervaardigen. Er zal verder 
onderzoek nodig zijn om de exacte waarde van deze technieken te bepalen.
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Het leven van een proefschrift begint niet zoals dat van de mens: de 
conceptiefase duurt vrij lang (jaren), de teraardekoming juist kort (hoogstens 
een paar weken). Daarnaast werken er veel meer dan twee personen mee aan 
het tot stand komen ervan. Deze mensen wil ik hier bedanken.
Dr. Luc Strobbe, mijn co-promotor en mentor. Luc, bedankt voor jouw 
onvoorwaardelijke enthousiasme: "je hebt d'r zin in" altijd. Eigenlijk is het niet 
te geloven hoeveel uren aan tijd en Joules aan energie jij in dit project hebt 
zitten: een totaal aan kilowatturen waar veel Nuon-mannetjes van opschrikken. 
Ik heb steeds gemerkt dat je je relativerend en bescheiden opstelt en dat maakt 
onderzoek met jou heel ongedwongen. Met je betrouwbare uitstraling ben je 
een geweldig voorbeeld voor me geweest. Dat je wiener-melange-chocolade- 
zwarte koffie-mix (ik vergeet ongetwijfeld belangrijke ingrediënten) nog lang de 
Canada-mok mag vullen!
Drs. Carla Wauters, begeleider-vanaf-het-begin en eigenlijk ook co-promotor. 
Carla, ontzettend bedankt voor het altijd maar weer kritisch doornemen van de 
teksten, getallen en tabellen. Ik vond het een eer dat je zoveel tijd voor het 
onderzoek vrijmaakte in je multi-functie op de pathologieafdeling. Je 
enthousiasme heeft ons onderzoek snel vooruit geholpen en het is mooi dat 
hieruit binnenkort ook jouw proefschrift geboren zal worden!
Prof. dr. Theo Wobbes, mijn promotor die lang niet wist dat hij de promotor 
zou worden toen hij het project goedkeurde (ik zelf wist dat trouwens ook 
niet). Professor Wobbes, wij ontmoetten elkaar voor het eerst in de snijzaal 
tijdens de 2e onderwijsmaand van de geneeskundeopleiding. Niet veel later heb 
ik een dag bij u meegekeken op de operatiekamer en uiteindelijk lijkt me dit 
project toch wel het hoogtepunt! Bedankt voor het vertrouwen dat het 
onderzoek tot een goed einde zou komen en voor de begeleiding van het 
promotietraject.
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Prof. dr. Hans de Wilt, prof. dr. Emiel Rutgers en prof. dr. Pieter Wesseling, 
samen de manuscriptcommissie van dit proefschrift vormend. Hartelijk dank 
voor het lezen en beoordelen van het manuscript.
Dick Verbeek, Roel Besseling, Marco Beers en Ronald van den Kieboom, 
laboranten van de Afdeling Pathologie van het CWZ en laatste strohalmen bij 
technische problemen. Bedankt voor jullie technische hulp met 
computercodes!
Drs. Andries Werre, ontwerper/monteur van mijn onderbeen en degene die mij 
op dit onderzoek bracht. Andries, je weet dat ik je enorm waardeer om wat je 
voor me hebt betekend en het is leuk dat dit onderzoek uiteindelijk ook via jou 
is gelopen. Bedankt!
Dr. Marco Bol, kamergenoot tijdens de cruciale maanden. Het oeverloze 
gedicteer van wat je zag onder de microscoop, heeft me door de eveneens 
eindeloze excelbestanden heen geholpen. Het strategisch optimaal opgestelde 
plastic plantje was een gouden vondst, net als het Bruce Springsteen-concert! 
Bedankt voor je adviezen rondom het promoveren.
Taco en Ingrid, mijn ouders. Bedankt voor jullie interesse en steun voor mijn 
doen en laten tijdens dit project!
Stijn en Michiel, mannen, bedankt voor jullie paranimfschap en de eindeloze 
uren belangeloze tekstcorrectie. Een paranimf, dat ben je voor het leven, dus 
maak gebruik van jullie nieuwe status en geniet van de privileges die het 
paranimfschap jullie brengt!
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Bauke Willem Kooistra werd in 1985 geboren in een Nijmeegs academisch 
ziekenhuis, nog geen flauw benul hebbend dat je er ook kon studeren, laat 
staan promoveren. Op 15-jarige leeftijd werd zijn onderbeen overreden, 
waarna een intensieve tijd volgde waarin hij als patiënt kennismaakte met de 
chirurgie. In 2004 behaalde hij cum laude het gymnasiumdiploma aan het 
Stedelijk Gymnasium te Nijmegen.
Geïnspireerd door zijn ziekenhuisverblijf begon hij in 2004 met de 
studie geneeskunde aan de Radboud Universiteit Nijmegen, waarbij hij het 
propedeusediploma ook cum laude behaalde. Tijdens zijn studietijd was hij 
actief als amateur-cabaretier bij het Medisch Studenten Cabaret van de 
Medische Faculteit Nijmegen en als lid van cabaretgroep Solo a trios en de 
geluidsman. Voor het begin van zijn co-schappen verrichte hij gedurende 6 
maanden het onderzoek dat tot dit proefschrift heeft geleid in het Canisius 
Wilhelmina Ziekenhuis in Nijmegen (begeleiding: dr. Luc J.A. Strobbe, afdeling 
Heelkunde). Daarna deed hij 6 maanden onderzoek naar o.a. radiografische 
beoordeling van fractuurgenezing aan de McMaster University in Hamilton, 
Ontario, Canada (begeleiding: dr. Mohit Bhandari, afdeling Orthopedie). Ook dit 
leidde tot verscheidene publicaties.
Momenteel is hij bezig met de co-schappen. Zijn vrije tijd besteedt hij 
aan zijn vriendin/vrienden, feesten, drummen, reizen, squashen en timmeren. 
Hij woont in een goedgemutst studentenhuis, wat paradoxaal genoeg wordt 
beheerd door een alternatief geneescentrum. Na zijn arts-examen wil hij zich 
graag specialiseren in een chirurgisch vak.
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